Pediatric Rosacea

Article Type
Changed
Thu, 01/10/2019 - 13:31
Display Headline
Pediatric Rosacea

Rosacea is a chronic skin disease characterized by flushing, erythema, telangiectasia, papules, and pustules in the central face region.1 It most often affects middle-aged women (age range, 30–50 years).2 Rosacea is rare in the pediatric population, especially before puberty.3 There are 3 subtypes of pediatric rosacea: vascular, papulopustular, and ocular. Phymatous/rhinophymatous rosacea is only seen in the adult population.3 Recommendations for the management of pediatric rosacea heavily rely on data from retrospective chart reviews and case series.

Etiology of Pediatric Rosacea

Rosacea is thought to be a consequence of vasomotor instability in both adults and children. A family history of rosacea is sometimes reported in patients with pediatric rosacea.4 Patients often are sensitive to heat, sunlight, topical corticosteroids, spicy foods, hot liquids, and certain soaps and cleansers.1,3,4 In a review of the literature by Vemuri et al,5 the various reported triggers of rosacea include harsh climates that damage the blood vessels and dermal connective tissue, defects in the endothelium and dermal matrix, perivascular inflammation, orally ingested chemicals, changes in the flora of the hair follicles, excessive antimicrobial peptides, and the presence of free radicals. Overall, it is unclear which of these factors are triggers of pediatric rosacea.

The molecular basis of rosacea has been elucidated. It is well known that rosacea patients have higher levels of cathelicidins in the facial skin. Furthermore, they appear to have different processed forms of cathelicidin peptides compared to adults without rosacea, possibly due to changes in posttranslational processing.6 One such peptide, cathelicidin LL-37, also has been implicated in atopic dermatitis7 and psoriasis.8 Its role in rosacea appears to be multifaceted. Cathelicidin LL-37 helps to attract neutrophils, monocytes, and T lymphocytes, and also has antimicrobial properties; therefore, it plays a role in both the innate and adaptive immune systems.9 Cathelicidin LL-37 also has been implicated in inducing angiogenesis10 and suppressing dermal fibroblasts.11

Muto et al12 found that there is an increased number of mast cells in the dermis of patients with rosacea. Mast cells contribute to vasodilation, angiogenesis, and the recruitment of other inflammatory cells.12 Importantly, human mast cells are a source of cathelicidins including cathelicidin LL-37; these proteins play a vital role in the antimicrobial capabilities of mast cells.13

Clinical Presentation and Comorbidities

Vascular rosacea presents with characteristic flushing and erythema, which lasts more than a few minutes as compared to physiologic erythema,1 and sometimes telangiectasia is seen.3 The cheeks, chin, and nasolabial folds are most commonly involved.2 In papulopustular rosacea, papules and pustules are seen overlying the erythema.1,3 Open and closed comedones also have been documented in case reports but are not commonly seen.2 Pediatric rosacea often begins with flushing of the face and then progresses to the development of papules and pustules.4

Ocular rosacea can occur with or without cutaneous findings. In a retrospective study of 20 pediatric patients (aged 1–15 years), 11 (55%) patients had both ocular and cutaneous rosacea, 3 (15%) only had ocular symptoms, and 6 (30%) only had cutaneous symptoms. The most common form of rosacea in this study was papulopustular rosacea.14 Ocular symptoms often are bilateral15 and can include blepharitis, conjunctival injection, recurrent chalazion, conjunctivitis,2 and less commonly corneal ulceration and scarring.16 Patients also may report photophobia or a foreign body sensation.17 Importantly, ocular symptoms often precede the cutaneous symptoms and can delay the diagnosis of rosacea,14,16,18 as these symptoms often are misdiagnosed as viral or bacterial infections.15 Fortunately, ocular disease responds well to treatment if diagnosed early.

Weston and Morelli19 conducted a retrospective study of 106 children (46 males; 60 females) 13 years and younger with steroid rosacea; 29 children were younger than 3 years. A family history of rosacea was present in 20% of participants, and prior use of class 7 steroids was reported in 54%, whereas only 3% had used class 1 topical steroids. Ninety-eight participants had perinasal involvement, 94 had perioral involvement, and 44 had periorbital involvement of the lower eyelids.19

Rosacea fulminans (also known as pyoderma faciale) is a rare acute-onset eruption typically found in young women in their 20s and 30s.20 Rosacea fulminans is characterized by papules, pustules, nodules, cysts, draining sinuses, communicating sinus tracts, and less commonly comedones.20,21 The skin can appear erythematous, cyanotic, or dull red.21 Most of the lesions are found on the face, particularly on the forehead, cheeks, nose, and chin,21 but lesions on the chest and back have been documented in adult patients.20 In an examination of prior case series, most patients were otherwise healthy. There are case reports documenting rosacea fulminans in teenagers,20 but the youngest patient recorded was an otherwise healthy 3-year-old girl who developed a sudden onset of erythematous papules, pustules, cysts, and purulent discharging sinuses on the cheeks that spread to the chin, perioral, and paranasal areas.21

 

 

Differential Diagnosis

Rosacea is rare in children, so other papulopustular disorders must be ruled out, including acne vulgaris, periorificial/perioral dermatitis, sarcoidosis, systemic lupus erythematosus, steroid-induced rosacea, ataxia telangiectasia, and demodicosis.

Acne vulgaris commonly presents in older adolescents and teenagers with open and closed comedones, inflammatory papules, and pustules.2 Intense facial flushing and telangiectasia usually is not seen.

In perioral dermatitis, skin lesions often are clustered around the mouth, nose, and eyes. Typically there are no telangiectases or ocular complications.3 Facial flushing and telangiectases are uncommon, except in steroid-induced perioral dermatitis.2

The cutaneous findings of sarcoidosis include red-brown papules on the face and lips, and patients also may have ocular involvement such as uveitis and iritis.3 However, there are typically other systemic findings such as pulmonary symptoms, weight loss, fatigue, lethargy, fever, and erythema nodosum.2,3 Chest radiograph findings (eg, bilateral hilar lym-phadenopathy), ophthalmologic examination, and laboratory data (eg, elevated alkaline phosphate and/or elevated angiotensin-converting enzyme) can help confirm or rule out the diagnosis of sarcoidosis.2,3

Unlike systemic lupus erythematosus, patients with rosacea will have involvement of sun-protected areas of the skin. Patients with systemic lupus erythematosus typically report arthralgia and severe photosensitivity and will have elevated antinuclear antibody titers. Skin biopsies and immunofluorescence can help confirm the diagnosis.3 Importantly, some patients with rosacea will have a positive lupus band test.22,23

Steroid-induced rosacea typically occurs 2 weeks after discontinuing therapy with topical fluorinated glucocorticosteroids.24 Children present with monomorphic papules, pustules, and telangiectases4 on the eyelids and lateral face as opposed to the central face regions.24

Ataxia telangiectasia can present with telangiectases, skin atrophy, café au lait spots, and premature graying.25 A 15-year-old adolescent girl with ataxia telangiectasia presented with granulomatous acne rosacea that improved after 4 weeks of treatment with isotretinoin 0.5 mg/kg daily. The lesions cleared almost completely after 5 months.25

Demodicosis is a disorder of the pilosebaceous units caused by the human Demodex mite.26 It typically involves the periorificial regions in adults and the elderly population. Patients can present with fine, white-yellow, scaly changes of the sebaceous hair follicles, with minimal erythema and inflammation. Papules and pustules also can be present.26

Diagnosis and Histopathology

Because rosacea is rare in children, it is important to thoroughly evaluate other possible diagnoses. The diagnosis of pediatric rosacea is clinical and biopsies are rarely performed. Laboratory tests such as cultures generally are not useful.

Marks and Harcourt-Webster27 reviewed the biopsies of 108 adult patients with rosacea. The biopsies of patients with predominantly erythema and telangiectasia showed evidence of vascular dilatation with a perivascular infiltrate composed predominantly of lymphocytes and 39 specimens that were compared to controls showed more solar elastosis. Biopsies of papular rosacea contained inflammatory infiltrates in the upper and mid dermis composed primarily of lymphocytes and histiocytes. In some patients, neutrophils, plasma cells, and giant cells also were observed. Hair follicle abnormalities were present in 20% of the biopsies, with 19% showing evidence of the Demodex mite. Vascular dilatation also was common. Overall, common findings included lymphohistiocytic infiltrates around the blood vessels of the upper dermis, dilated vessels, edema, elastosis, and disorganization of connective tissue in the upper dermis.

Helm et al28 reviewed histopathologic patterns from 53 patients with granulomatous rosacea. Findings included a mixed lymphohistiocytic infiltrate (predominantly lymphocytic in 40% of patients and predominantly histiocytic with occasional giant cells in 34% of patients), epithelioid granulomas (11% of patients), and epithelioid granulomas with caseation necrosis (11% of patients).

The histopathology of rosacea fulminans is characterized by dense perivascular and periadnexal infiltrates composed of granulocytes, eosinophils, and epithelioid granulomas, as well as panniculitis.20

Treatment and Clinical Outcomes

Certain lifestyle recommendations are integral components of disease management, including avoidance of triggers such as extreme temperatures, hot drinks, spicy food, and topical agents that could be irritating (especially topical corticosteroids).29 Patients should be advised to use daily sunscreen containing physical blockers such as titanium dioxide or zinc oxide. Teenagers should avoid the use of cosmetics and makeup, especially products containing sodium lauryl sulfate, menthol, and camphor. Daily use of emollients can help some patients.29

There are both topical and systemic therapies available for pediatric rosacea; however, most of the data are based on the use of these treatments in the adult population. Patients with mild to moderate disease often can be managed using topical agents. Metronidazole (0.75% cream, 1% gel, or 0.75% lotion) has been studied extensively in adult patients, and when used once daily for 12 weeks, it has been able to control moderate to severe disease.30,31 In one study conducted in adult patients, topical metronidazole was able to maintain remission in adults who had previously been treated with a combination of oral tetracycline and metronidazole gel.31 Sodium sulfacetamide 10%–sulfur 5% (cleanser or lotion) has been successful in adult patients and often is used in combination with other therapies such as topical metronidazole.32-34 Azelaic acid cream 20%,35 benzoyl peroxide (wash or gel),29 topical clindamycin,36 topical erythromycin,29,37 tacrolimus ointment 0.1%,38 and tretinoin cream also have been studied in adults.3,39 Several of these topical agents can cause irritation on application (eg, metronidazole, sulfur-based agents, azelaic acid, benzoyl peroxide, erythromycin, tretinoin).3

 

 

The use of systemic treatments in pediatric patients is heavily based on case reports and case series.2,14,16,40 Therapies have included tetracycline (500 mg twice daily tapered to 250 mg daily),29 minocycline (50–100 mg twice daily), doxycycline (50–100 mg twice daily or 4 times daily), erythromycin (30–50 mg/kg daily), clarithromycin (15 mg/kg twice daily for 4 weeks and then daily for 4 weeks), and azithromycin (5–10 mg/kg daily).3 Tetracycline antibiotics should not be used in children 8 years or younger.

In a case series by Drolet and Paller,2 an 11-year-old girl was treated with tetracycline 500 mg (later tapered to 250 mg daily) and metronidazole gel 0.75%, both used twice daily. Previously, she had not responded to topical steroids, tretinoin cream 0.05%, benzoyl peroxide 5%, or systemic prednisone. After 6 weeks of treatment, the pustules and chalazion had resolved and she had only minimal erythema of the skin and conjunctiva. Sixteen months after the start of treatment, a regimen of tetracycline 250 mg daily and metronidazole gel resulted in disease clearance on the face.2

A 9-year-old girl with concurrent systemic lupus erythematosus was treated with tetracycline 250 mg and topical erythromycin 2%, both used twice daily.2 After 4 weeks her face was clear. Four months later she developed new telangiectases and topical erythromycin was replaced with topical metronidazole. Eventually the dose of tetracycline was reduced to 250 mg daily.2

An 11-year-old boy with likely granulomatous rosacea was treated with erythromycin 250 mg 4 times daily, alclometasone dipropionate cream 0.05% twice daily, and topical clindamycin twice daily.2 Marked improvement was noticed after 3 weeks of treatment. Metronidazole gel 0.75% was added and 3 months later the patient’s face was clear, without evidence of scarring. The dose of erythromycin was later reduced to 500 mg daily, and eventually the patient experienced clearance with the use of metronidazole gel daily.2

In another case series, 4 female patients (age range, 4–12 years) were treated with systemic erythromycin 20 mg/kg daily (ocular involvement only) or doxycycline 2.2 mg/kg daily used in two 12-year-old patients with ocular and cutaneous involvement for at least 12 months. All 4 patients showed considerable improvement within 1 month and remained free of disease throughout a mean follow-up period of 25.5 months.40

As evidenced by these case reports, there is a wide array of treatments that have been used for pediatric rosacea. Although there are no formal evidence-based guidelines, there are certain considerations that must be taken into account when choosing treatment plans. Doxycycline and minocycline are known to cause less gastrointestinal upset than tetracycline with similar efficacy.41 Importantly, the tetracyclines are contraindicated in children younger than 9 years, as they can cause teeth staining and possibly affect skeletal growth.3,4 When used in older children (age range, 9–12 years), patients must be advised not to take their medication with calcium or antacids.3 Clarithromycin and azithromycin tend to have fewer gastrointestinal side effects than erythromycin. Erythromycin and other macrolides can be used in children of all ages and in patients who are allergic to tetracyclines.3

Children with mild ocular symptoms often can control their disease with bacitracin and topical ocular antibiotics such as erythromycin.2,15 For patients who require systemic antibiotics, various tetracyclines and macrolides have been used with success.2,14-16,40

Adults with rosacea fulminans can require treatment with isotretinoin, oral antibiotics, and topical or even systemic corticosteroids.42 The 3-year-old girl with rosacea fulminans initially was treated with oral erythromycin (250 mg 4 times daily), oral prednisolone (0.5 mg/kg daily tapered over 2 weeks), fluocinolone acetonide cream 0.025%, and warm compresses with only moderate improvement.21 She was then started on oral isotretinoin (0.75 mg/kg daily) and within 4 weeks marked improvement was noted. After 8 weeks, the lesions had disappeared completely with only a few pitted scars remaining. Isotretinoin was continued for 24 weeks. One year after completion of treatment, she was still disease free.21

Weston and Morelli19 recommended the following treatment regimen for children with steroid rosacea: abrupt cessation of topical steroid use (as opposed to gradual withdrawal) and initiation of oral erythromycin stearate (30 mg/kg daily) in 2 daily doses for 4 weeks. Children who were unable to tolerate erythromycin (n=6) were told to use topical clindamycin phosphate twice daily for 4 weeks. Within 3 weeks 22% of patients had resolution, while 86% had resolution within 4 weeks. All of the patients cleared within 8 weeks. Importantly, there was no significant difference in duration of time until clearance between children who used the oral antibiotic or topical antibiotic.19

Conclusion

We know that the skin of rosacea patients contains higher levels of cathelicidins, which have been implicated in amplifying and contributing to the inflammatory response in several ways. Mast cells, which are a source of cathelicidins, also are increased in the skin of these patients. Children can present with vascular rosacea (characterized by flushing, erythema, and/or telangiectasia), papulopustular rosacea, or ocular rosacea. Common ocular symptoms include blepharitis, conjunctivitis, and recurrent chalazion. It is important to refer pediatric rosacea patients with ocular symptoms to an ophthalmologist to prevent ocular sequelae.

 

 

Rosacea is a clinical diagnosis but biopsy can be performed to rule out other diagnoses. Treatment consists of lifestyle modifications such as avoiding known triggers and the use of topical and/or oral agents. Common topical therapies include metronidazole and erythromycin. Systemic antibiotics include tetracycline, doxycycline, minocycline, azithromycin, and erythromycin. Some children are able to taper systemic agents and maintain disease control with topical therapy, while others may need to continue a low-dose antibiotic. Although flares can be controlled within weeks to months, rosacea is a chronic disorder and childhood rosacea tends to persist into adulthood.

References
  1. Crawford GH, Pelle MT, James WD. Rosacea: i. etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51:327-341; quiz 342-324.
  2. Drolet B, Paller AS. Childhood rosacea. Pediatr Dermatol. 1992;9:22-26.
  3. Kroshinsky D, Glick SA. Pediatric rosacea. Dermatol Ther. 2006;19:196-201.
  4. Lacz NL, Schwartz RA. Rosacea in the pediatric population. Cutis. 2004;74:99-103.
  5. Vemuri RC, Gundamaraju R, Sekaran SD, et al. Major pathophysiological correlations of rosacea: a complete clinical appraisal. Int J Med Sci. 2015;12:387-396.
  6. Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007;13:975-980.
  7. Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med. 2002;347:1151-1160.
  8. Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007;449:564-569.
  9. De Y, Chen Q, Schmidt AP, et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med. 2000;192:1069-1074.
  10. Koczulla R, von Degenfeld G, Kupatt C, et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest. 2003;111:1665-1672.
  11. Park HJ, Cho DH, Kim HJ, et al. Collagen synthesis is suppressed in dermal fibroblasts by the human antimicrobial peptide LL-37. J Invest Dermatol. 2009;129:843-850.
  12. Muto Y, Wang Z, Vanderberghe M, et al. Mast cells are key mediators of cathelicidin-initiated skin inflammation in rosacea. J Invest Dermatol. 2014;134:2728-2736.
  13. Di Nardo A, Vitiello A, Gallo RL. Cutting edge: mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J Immunol. 2003;170:2274-2278.
  14. Leoni S, Mesplie N, Aitali F, et al. Metronidazole: alternative treatment for ocular and cutaneous rosacea in the pediatric population [in French]. J Fr Ophthalmol. 2011;34:703-710.
  15. Nazir SA, Murphy S, Siatkowski RM, et al. Ocular rosacea in childhood. Am J Ophthalmol. 2004;137:138-144.
  16. Miguel AI, Salgado MB, Lisboa MS, et al. Pediatric ocular rosacea: 2 cases. Eur J Ophthalmol. 2012;22:664-666.
  17. Stone DU, Chodosh J. Ocular rosacea: an update on pathogenesis and therapy. Curr Opin Ophthalmol. 2004;15:499-502.
  18. Mavrakanas N, Schutz JS, Dosso AA. Pediatric ocular rosacea [published online March 22, 2010]. J Pediatr Ophthalmol Strabismus. 2010;47:117-120.
  19. Weston WL, Morelli JG. Steroid rosacea in prepubertal children. Arch Pediatr Adolesc Med. 2000;154:62-64.
  20. Plewig G, Jansen T, Kligman AM. Pyoderma faciale. a review and report of 20 additional cases: is it rosacea? Arch Dermatol. 1992;128:1611-1617.
  21. Firooz A, Firoozabadi MR, Dowlati Y. Rosacea fulminans (pyoderma faciale): successful treatment of a 3-year-old girl with oral isotretinoin. Int J Dermatol. 2001;40:203-205.
  22. Baart de la Faille H, Baart de la F-K. Immunofluorescent studies of the skin in rosacea. Dermatologica. 1969;139:49-54.
  23. Wilkin JK. Rosacea. Int J Dermatol. 1983;22:393-400.
  24. Franco HL, Weston WL. Steroid rosacea in children. Pediatrics. 1979;64:36-38.
  25. Cantarutti N, Claps A, Angelino G, et al. Multi-drugs resistant acne rosacea in a child affected by ataxia-telangiectasia: successful treatment with isotretinoin. Ital J Pediatr. 2015;41:23.
  26. Chen W, Plewig G. Human demodicosis: revisit and a proposed classification. Br J Dermatol. 2014;170:1219-1225.
  27. Marks R, Harcourt-Webster J. Histopathology of rosacea. Arch Dermatol. 1969;100:683-691.
  28. Helm KF, Menz J, Gibson LE, et al. A clinical and histopathologic study of granulomatous rosacea. J Am Acad Dermatol. 1991;25(6, pt 1):1038-1043.
  29. Pelle MT, Crawford GH, James WD. Rosacea: II. therapy. J Am Acad Dermatol. 2004;51:499-512; quiz 513-494.
  30. Dahl MV, Jarratt M, Kaplan D, et al. Once-daily topical metronidazole cream formulations in the treatment of the papules and pustules of rosacea. J Am Acad Dermatol. 2001;45:723-730.
  31. Dahl MV, Katz HI, Krueger GG, et al. Topical metronidazole maintains remissions of rosacea. Arch Dermatol. 1998;134:679-683.
  32. Trumbore MW, Goldstein JA, Gurge RM. Treatment of papulopustular rosacea with sodium sulfacetamide 10%/sulfur 5% emollient foam. J Drugs Dermatol. 2009;8:299-304.
  33. Del Rosso JQ. Evaluating the role of topical therapies in the management of rosacea: focus on combination sodium sulfacetamide and sulfur formulations. Cutis. 2004;73(1 suppl):29-33.
  34. Del Rosso JQ. A status report on the medical management of rosacea: focus on topical therapies. Cutis. 2002;70:271-275.
  35. Maddin S. A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. J Am Acad Dermatol. 1999;40(6, pt 1):961-965.
  36. Wilkin JK, DeWitt S. Treatment of rosacea: topical clindamycin versus oral tetracycline. Int J Dermatol. 1993;32:65-67.
  37. Mills OH Jr, Kligman AM. Letter: topically applied erythromycin in rosacea. Arch Dermatol. 1976;112:553-554.
  38. Hengge UR. Off-label indications for topical tacrolimus [in German]. Hautarzt. 2013;64:752-756.
  39. Ertl GA, Levine N, Kligman AM. A comparison of the efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea. Arch Dermatol. 1994;130:319-324.
  40. Cetinkaya A, Akova YA. Pediatric ocular acne rosacea: long-term treatment with systemic antibiotics. Am J Ophthalmol. 2006;142:816-821.
  41. Maibach H. Second-generation tetracyclines, a dermatologic overview: clinical uses and pharmacology. Cutis. 1991;48:411-417.
  42. Jansen T, Plewig G, Kligman AM. Diagnosis and treatment of rosacea fulminans. Dermatology. 1994;188:251-254.
Article PDF
Author and Disclosure Information

Ms. Kellen is from the Department of Dermatology, Mount Sinai Hospital, New York, New York. Dr. Silverberg is from Mount Sinai St. Luke’s-Roosevelt Hospital and Beth Israel Medical Centers of the Icahn School of Medicine at Mount Sinai, New York.

The authors report no conflict of interest.

Correspondence: Nanette B. Silverberg, MD, 1090 Amsterdam Ave, Ste 11B, New York, NY 10025 ([email protected]).

Issue
Cutis - 98(1)
Publications
Page Number
49-53
Legacy Keywords
Rosacea, pediatric, children
Sections
Author and Disclosure Information

Ms. Kellen is from the Department of Dermatology, Mount Sinai Hospital, New York, New York. Dr. Silverberg is from Mount Sinai St. Luke’s-Roosevelt Hospital and Beth Israel Medical Centers of the Icahn School of Medicine at Mount Sinai, New York.

The authors report no conflict of interest.

Correspondence: Nanette B. Silverberg, MD, 1090 Amsterdam Ave, Ste 11B, New York, NY 10025 ([email protected]).

Author and Disclosure Information

Ms. Kellen is from the Department of Dermatology, Mount Sinai Hospital, New York, New York. Dr. Silverberg is from Mount Sinai St. Luke’s-Roosevelt Hospital and Beth Israel Medical Centers of the Icahn School of Medicine at Mount Sinai, New York.

The authors report no conflict of interest.

Correspondence: Nanette B. Silverberg, MD, 1090 Amsterdam Ave, Ste 11B, New York, NY 10025 ([email protected]).

Article PDF
Article PDF

Rosacea is a chronic skin disease characterized by flushing, erythema, telangiectasia, papules, and pustules in the central face region.1 It most often affects middle-aged women (age range, 30–50 years).2 Rosacea is rare in the pediatric population, especially before puberty.3 There are 3 subtypes of pediatric rosacea: vascular, papulopustular, and ocular. Phymatous/rhinophymatous rosacea is only seen in the adult population.3 Recommendations for the management of pediatric rosacea heavily rely on data from retrospective chart reviews and case series.

Etiology of Pediatric Rosacea

Rosacea is thought to be a consequence of vasomotor instability in both adults and children. A family history of rosacea is sometimes reported in patients with pediatric rosacea.4 Patients often are sensitive to heat, sunlight, topical corticosteroids, spicy foods, hot liquids, and certain soaps and cleansers.1,3,4 In a review of the literature by Vemuri et al,5 the various reported triggers of rosacea include harsh climates that damage the blood vessels and dermal connective tissue, defects in the endothelium and dermal matrix, perivascular inflammation, orally ingested chemicals, changes in the flora of the hair follicles, excessive antimicrobial peptides, and the presence of free radicals. Overall, it is unclear which of these factors are triggers of pediatric rosacea.

The molecular basis of rosacea has been elucidated. It is well known that rosacea patients have higher levels of cathelicidins in the facial skin. Furthermore, they appear to have different processed forms of cathelicidin peptides compared to adults without rosacea, possibly due to changes in posttranslational processing.6 One such peptide, cathelicidin LL-37, also has been implicated in atopic dermatitis7 and psoriasis.8 Its role in rosacea appears to be multifaceted. Cathelicidin LL-37 helps to attract neutrophils, monocytes, and T lymphocytes, and also has antimicrobial properties; therefore, it plays a role in both the innate and adaptive immune systems.9 Cathelicidin LL-37 also has been implicated in inducing angiogenesis10 and suppressing dermal fibroblasts.11

Muto et al12 found that there is an increased number of mast cells in the dermis of patients with rosacea. Mast cells contribute to vasodilation, angiogenesis, and the recruitment of other inflammatory cells.12 Importantly, human mast cells are a source of cathelicidins including cathelicidin LL-37; these proteins play a vital role in the antimicrobial capabilities of mast cells.13

Clinical Presentation and Comorbidities

Vascular rosacea presents with characteristic flushing and erythema, which lasts more than a few minutes as compared to physiologic erythema,1 and sometimes telangiectasia is seen.3 The cheeks, chin, and nasolabial folds are most commonly involved.2 In papulopustular rosacea, papules and pustules are seen overlying the erythema.1,3 Open and closed comedones also have been documented in case reports but are not commonly seen.2 Pediatric rosacea often begins with flushing of the face and then progresses to the development of papules and pustules.4

Ocular rosacea can occur with or without cutaneous findings. In a retrospective study of 20 pediatric patients (aged 1–15 years), 11 (55%) patients had both ocular and cutaneous rosacea, 3 (15%) only had ocular symptoms, and 6 (30%) only had cutaneous symptoms. The most common form of rosacea in this study was papulopustular rosacea.14 Ocular symptoms often are bilateral15 and can include blepharitis, conjunctival injection, recurrent chalazion, conjunctivitis,2 and less commonly corneal ulceration and scarring.16 Patients also may report photophobia or a foreign body sensation.17 Importantly, ocular symptoms often precede the cutaneous symptoms and can delay the diagnosis of rosacea,14,16,18 as these symptoms often are misdiagnosed as viral or bacterial infections.15 Fortunately, ocular disease responds well to treatment if diagnosed early.

Weston and Morelli19 conducted a retrospective study of 106 children (46 males; 60 females) 13 years and younger with steroid rosacea; 29 children were younger than 3 years. A family history of rosacea was present in 20% of participants, and prior use of class 7 steroids was reported in 54%, whereas only 3% had used class 1 topical steroids. Ninety-eight participants had perinasal involvement, 94 had perioral involvement, and 44 had periorbital involvement of the lower eyelids.19

Rosacea fulminans (also known as pyoderma faciale) is a rare acute-onset eruption typically found in young women in their 20s and 30s.20 Rosacea fulminans is characterized by papules, pustules, nodules, cysts, draining sinuses, communicating sinus tracts, and less commonly comedones.20,21 The skin can appear erythematous, cyanotic, or dull red.21 Most of the lesions are found on the face, particularly on the forehead, cheeks, nose, and chin,21 but lesions on the chest and back have been documented in adult patients.20 In an examination of prior case series, most patients were otherwise healthy. There are case reports documenting rosacea fulminans in teenagers,20 but the youngest patient recorded was an otherwise healthy 3-year-old girl who developed a sudden onset of erythematous papules, pustules, cysts, and purulent discharging sinuses on the cheeks that spread to the chin, perioral, and paranasal areas.21

 

 

Differential Diagnosis

Rosacea is rare in children, so other papulopustular disorders must be ruled out, including acne vulgaris, periorificial/perioral dermatitis, sarcoidosis, systemic lupus erythematosus, steroid-induced rosacea, ataxia telangiectasia, and demodicosis.

Acne vulgaris commonly presents in older adolescents and teenagers with open and closed comedones, inflammatory papules, and pustules.2 Intense facial flushing and telangiectasia usually is not seen.

In perioral dermatitis, skin lesions often are clustered around the mouth, nose, and eyes. Typically there are no telangiectases or ocular complications.3 Facial flushing and telangiectases are uncommon, except in steroid-induced perioral dermatitis.2

The cutaneous findings of sarcoidosis include red-brown papules on the face and lips, and patients also may have ocular involvement such as uveitis and iritis.3 However, there are typically other systemic findings such as pulmonary symptoms, weight loss, fatigue, lethargy, fever, and erythema nodosum.2,3 Chest radiograph findings (eg, bilateral hilar lym-phadenopathy), ophthalmologic examination, and laboratory data (eg, elevated alkaline phosphate and/or elevated angiotensin-converting enzyme) can help confirm or rule out the diagnosis of sarcoidosis.2,3

Unlike systemic lupus erythematosus, patients with rosacea will have involvement of sun-protected areas of the skin. Patients with systemic lupus erythematosus typically report arthralgia and severe photosensitivity and will have elevated antinuclear antibody titers. Skin biopsies and immunofluorescence can help confirm the diagnosis.3 Importantly, some patients with rosacea will have a positive lupus band test.22,23

Steroid-induced rosacea typically occurs 2 weeks after discontinuing therapy with topical fluorinated glucocorticosteroids.24 Children present with monomorphic papules, pustules, and telangiectases4 on the eyelids and lateral face as opposed to the central face regions.24

Ataxia telangiectasia can present with telangiectases, skin atrophy, café au lait spots, and premature graying.25 A 15-year-old adolescent girl with ataxia telangiectasia presented with granulomatous acne rosacea that improved after 4 weeks of treatment with isotretinoin 0.5 mg/kg daily. The lesions cleared almost completely after 5 months.25

Demodicosis is a disorder of the pilosebaceous units caused by the human Demodex mite.26 It typically involves the periorificial regions in adults and the elderly population. Patients can present with fine, white-yellow, scaly changes of the sebaceous hair follicles, with minimal erythema and inflammation. Papules and pustules also can be present.26

Diagnosis and Histopathology

Because rosacea is rare in children, it is important to thoroughly evaluate other possible diagnoses. The diagnosis of pediatric rosacea is clinical and biopsies are rarely performed. Laboratory tests such as cultures generally are not useful.

Marks and Harcourt-Webster27 reviewed the biopsies of 108 adult patients with rosacea. The biopsies of patients with predominantly erythema and telangiectasia showed evidence of vascular dilatation with a perivascular infiltrate composed predominantly of lymphocytes and 39 specimens that were compared to controls showed more solar elastosis. Biopsies of papular rosacea contained inflammatory infiltrates in the upper and mid dermis composed primarily of lymphocytes and histiocytes. In some patients, neutrophils, plasma cells, and giant cells also were observed. Hair follicle abnormalities were present in 20% of the biopsies, with 19% showing evidence of the Demodex mite. Vascular dilatation also was common. Overall, common findings included lymphohistiocytic infiltrates around the blood vessels of the upper dermis, dilated vessels, edema, elastosis, and disorganization of connective tissue in the upper dermis.

Helm et al28 reviewed histopathologic patterns from 53 patients with granulomatous rosacea. Findings included a mixed lymphohistiocytic infiltrate (predominantly lymphocytic in 40% of patients and predominantly histiocytic with occasional giant cells in 34% of patients), epithelioid granulomas (11% of patients), and epithelioid granulomas with caseation necrosis (11% of patients).

The histopathology of rosacea fulminans is characterized by dense perivascular and periadnexal infiltrates composed of granulocytes, eosinophils, and epithelioid granulomas, as well as panniculitis.20

Treatment and Clinical Outcomes

Certain lifestyle recommendations are integral components of disease management, including avoidance of triggers such as extreme temperatures, hot drinks, spicy food, and topical agents that could be irritating (especially topical corticosteroids).29 Patients should be advised to use daily sunscreen containing physical blockers such as titanium dioxide or zinc oxide. Teenagers should avoid the use of cosmetics and makeup, especially products containing sodium lauryl sulfate, menthol, and camphor. Daily use of emollients can help some patients.29

There are both topical and systemic therapies available for pediatric rosacea; however, most of the data are based on the use of these treatments in the adult population. Patients with mild to moderate disease often can be managed using topical agents. Metronidazole (0.75% cream, 1% gel, or 0.75% lotion) has been studied extensively in adult patients, and when used once daily for 12 weeks, it has been able to control moderate to severe disease.30,31 In one study conducted in adult patients, topical metronidazole was able to maintain remission in adults who had previously been treated with a combination of oral tetracycline and metronidazole gel.31 Sodium sulfacetamide 10%–sulfur 5% (cleanser or lotion) has been successful in adult patients and often is used in combination with other therapies such as topical metronidazole.32-34 Azelaic acid cream 20%,35 benzoyl peroxide (wash or gel),29 topical clindamycin,36 topical erythromycin,29,37 tacrolimus ointment 0.1%,38 and tretinoin cream also have been studied in adults.3,39 Several of these topical agents can cause irritation on application (eg, metronidazole, sulfur-based agents, azelaic acid, benzoyl peroxide, erythromycin, tretinoin).3

 

 

The use of systemic treatments in pediatric patients is heavily based on case reports and case series.2,14,16,40 Therapies have included tetracycline (500 mg twice daily tapered to 250 mg daily),29 minocycline (50–100 mg twice daily), doxycycline (50–100 mg twice daily or 4 times daily), erythromycin (30–50 mg/kg daily), clarithromycin (15 mg/kg twice daily for 4 weeks and then daily for 4 weeks), and azithromycin (5–10 mg/kg daily).3 Tetracycline antibiotics should not be used in children 8 years or younger.

In a case series by Drolet and Paller,2 an 11-year-old girl was treated with tetracycline 500 mg (later tapered to 250 mg daily) and metronidazole gel 0.75%, both used twice daily. Previously, she had not responded to topical steroids, tretinoin cream 0.05%, benzoyl peroxide 5%, or systemic prednisone. After 6 weeks of treatment, the pustules and chalazion had resolved and she had only minimal erythema of the skin and conjunctiva. Sixteen months after the start of treatment, a regimen of tetracycline 250 mg daily and metronidazole gel resulted in disease clearance on the face.2

A 9-year-old girl with concurrent systemic lupus erythematosus was treated with tetracycline 250 mg and topical erythromycin 2%, both used twice daily.2 After 4 weeks her face was clear. Four months later she developed new telangiectases and topical erythromycin was replaced with topical metronidazole. Eventually the dose of tetracycline was reduced to 250 mg daily.2

An 11-year-old boy with likely granulomatous rosacea was treated with erythromycin 250 mg 4 times daily, alclometasone dipropionate cream 0.05% twice daily, and topical clindamycin twice daily.2 Marked improvement was noticed after 3 weeks of treatment. Metronidazole gel 0.75% was added and 3 months later the patient’s face was clear, without evidence of scarring. The dose of erythromycin was later reduced to 500 mg daily, and eventually the patient experienced clearance with the use of metronidazole gel daily.2

In another case series, 4 female patients (age range, 4–12 years) were treated with systemic erythromycin 20 mg/kg daily (ocular involvement only) or doxycycline 2.2 mg/kg daily used in two 12-year-old patients with ocular and cutaneous involvement for at least 12 months. All 4 patients showed considerable improvement within 1 month and remained free of disease throughout a mean follow-up period of 25.5 months.40

As evidenced by these case reports, there is a wide array of treatments that have been used for pediatric rosacea. Although there are no formal evidence-based guidelines, there are certain considerations that must be taken into account when choosing treatment plans. Doxycycline and minocycline are known to cause less gastrointestinal upset than tetracycline with similar efficacy.41 Importantly, the tetracyclines are contraindicated in children younger than 9 years, as they can cause teeth staining and possibly affect skeletal growth.3,4 When used in older children (age range, 9–12 years), patients must be advised not to take their medication with calcium or antacids.3 Clarithromycin and azithromycin tend to have fewer gastrointestinal side effects than erythromycin. Erythromycin and other macrolides can be used in children of all ages and in patients who are allergic to tetracyclines.3

Children with mild ocular symptoms often can control their disease with bacitracin and topical ocular antibiotics such as erythromycin.2,15 For patients who require systemic antibiotics, various tetracyclines and macrolides have been used with success.2,14-16,40

Adults with rosacea fulminans can require treatment with isotretinoin, oral antibiotics, and topical or even systemic corticosteroids.42 The 3-year-old girl with rosacea fulminans initially was treated with oral erythromycin (250 mg 4 times daily), oral prednisolone (0.5 mg/kg daily tapered over 2 weeks), fluocinolone acetonide cream 0.025%, and warm compresses with only moderate improvement.21 She was then started on oral isotretinoin (0.75 mg/kg daily) and within 4 weeks marked improvement was noted. After 8 weeks, the lesions had disappeared completely with only a few pitted scars remaining. Isotretinoin was continued for 24 weeks. One year after completion of treatment, she was still disease free.21

Weston and Morelli19 recommended the following treatment regimen for children with steroid rosacea: abrupt cessation of topical steroid use (as opposed to gradual withdrawal) and initiation of oral erythromycin stearate (30 mg/kg daily) in 2 daily doses for 4 weeks. Children who were unable to tolerate erythromycin (n=6) were told to use topical clindamycin phosphate twice daily for 4 weeks. Within 3 weeks 22% of patients had resolution, while 86% had resolution within 4 weeks. All of the patients cleared within 8 weeks. Importantly, there was no significant difference in duration of time until clearance between children who used the oral antibiotic or topical antibiotic.19

Conclusion

We know that the skin of rosacea patients contains higher levels of cathelicidins, which have been implicated in amplifying and contributing to the inflammatory response in several ways. Mast cells, which are a source of cathelicidins, also are increased in the skin of these patients. Children can present with vascular rosacea (characterized by flushing, erythema, and/or telangiectasia), papulopustular rosacea, or ocular rosacea. Common ocular symptoms include blepharitis, conjunctivitis, and recurrent chalazion. It is important to refer pediatric rosacea patients with ocular symptoms to an ophthalmologist to prevent ocular sequelae.

 

 

Rosacea is a clinical diagnosis but biopsy can be performed to rule out other diagnoses. Treatment consists of lifestyle modifications such as avoiding known triggers and the use of topical and/or oral agents. Common topical therapies include metronidazole and erythromycin. Systemic antibiotics include tetracycline, doxycycline, minocycline, azithromycin, and erythromycin. Some children are able to taper systemic agents and maintain disease control with topical therapy, while others may need to continue a low-dose antibiotic. Although flares can be controlled within weeks to months, rosacea is a chronic disorder and childhood rosacea tends to persist into adulthood.

Rosacea is a chronic skin disease characterized by flushing, erythema, telangiectasia, papules, and pustules in the central face region.1 It most often affects middle-aged women (age range, 30–50 years).2 Rosacea is rare in the pediatric population, especially before puberty.3 There are 3 subtypes of pediatric rosacea: vascular, papulopustular, and ocular. Phymatous/rhinophymatous rosacea is only seen in the adult population.3 Recommendations for the management of pediatric rosacea heavily rely on data from retrospective chart reviews and case series.

Etiology of Pediatric Rosacea

Rosacea is thought to be a consequence of vasomotor instability in both adults and children. A family history of rosacea is sometimes reported in patients with pediatric rosacea.4 Patients often are sensitive to heat, sunlight, topical corticosteroids, spicy foods, hot liquids, and certain soaps and cleansers.1,3,4 In a review of the literature by Vemuri et al,5 the various reported triggers of rosacea include harsh climates that damage the blood vessels and dermal connective tissue, defects in the endothelium and dermal matrix, perivascular inflammation, orally ingested chemicals, changes in the flora of the hair follicles, excessive antimicrobial peptides, and the presence of free radicals. Overall, it is unclear which of these factors are triggers of pediatric rosacea.

The molecular basis of rosacea has been elucidated. It is well known that rosacea patients have higher levels of cathelicidins in the facial skin. Furthermore, they appear to have different processed forms of cathelicidin peptides compared to adults without rosacea, possibly due to changes in posttranslational processing.6 One such peptide, cathelicidin LL-37, also has been implicated in atopic dermatitis7 and psoriasis.8 Its role in rosacea appears to be multifaceted. Cathelicidin LL-37 helps to attract neutrophils, monocytes, and T lymphocytes, and also has antimicrobial properties; therefore, it plays a role in both the innate and adaptive immune systems.9 Cathelicidin LL-37 also has been implicated in inducing angiogenesis10 and suppressing dermal fibroblasts.11

Muto et al12 found that there is an increased number of mast cells in the dermis of patients with rosacea. Mast cells contribute to vasodilation, angiogenesis, and the recruitment of other inflammatory cells.12 Importantly, human mast cells are a source of cathelicidins including cathelicidin LL-37; these proteins play a vital role in the antimicrobial capabilities of mast cells.13

Clinical Presentation and Comorbidities

Vascular rosacea presents with characteristic flushing and erythema, which lasts more than a few minutes as compared to physiologic erythema,1 and sometimes telangiectasia is seen.3 The cheeks, chin, and nasolabial folds are most commonly involved.2 In papulopustular rosacea, papules and pustules are seen overlying the erythema.1,3 Open and closed comedones also have been documented in case reports but are not commonly seen.2 Pediatric rosacea often begins with flushing of the face and then progresses to the development of papules and pustules.4

Ocular rosacea can occur with or without cutaneous findings. In a retrospective study of 20 pediatric patients (aged 1–15 years), 11 (55%) patients had both ocular and cutaneous rosacea, 3 (15%) only had ocular symptoms, and 6 (30%) only had cutaneous symptoms. The most common form of rosacea in this study was papulopustular rosacea.14 Ocular symptoms often are bilateral15 and can include blepharitis, conjunctival injection, recurrent chalazion, conjunctivitis,2 and less commonly corneal ulceration and scarring.16 Patients also may report photophobia or a foreign body sensation.17 Importantly, ocular symptoms often precede the cutaneous symptoms and can delay the diagnosis of rosacea,14,16,18 as these symptoms often are misdiagnosed as viral or bacterial infections.15 Fortunately, ocular disease responds well to treatment if diagnosed early.

Weston and Morelli19 conducted a retrospective study of 106 children (46 males; 60 females) 13 years and younger with steroid rosacea; 29 children were younger than 3 years. A family history of rosacea was present in 20% of participants, and prior use of class 7 steroids was reported in 54%, whereas only 3% had used class 1 topical steroids. Ninety-eight participants had perinasal involvement, 94 had perioral involvement, and 44 had periorbital involvement of the lower eyelids.19

Rosacea fulminans (also known as pyoderma faciale) is a rare acute-onset eruption typically found in young women in their 20s and 30s.20 Rosacea fulminans is characterized by papules, pustules, nodules, cysts, draining sinuses, communicating sinus tracts, and less commonly comedones.20,21 The skin can appear erythematous, cyanotic, or dull red.21 Most of the lesions are found on the face, particularly on the forehead, cheeks, nose, and chin,21 but lesions on the chest and back have been documented in adult patients.20 In an examination of prior case series, most patients were otherwise healthy. There are case reports documenting rosacea fulminans in teenagers,20 but the youngest patient recorded was an otherwise healthy 3-year-old girl who developed a sudden onset of erythematous papules, pustules, cysts, and purulent discharging sinuses on the cheeks that spread to the chin, perioral, and paranasal areas.21

 

 

Differential Diagnosis

Rosacea is rare in children, so other papulopustular disorders must be ruled out, including acne vulgaris, periorificial/perioral dermatitis, sarcoidosis, systemic lupus erythematosus, steroid-induced rosacea, ataxia telangiectasia, and demodicosis.

Acne vulgaris commonly presents in older adolescents and teenagers with open and closed comedones, inflammatory papules, and pustules.2 Intense facial flushing and telangiectasia usually is not seen.

In perioral dermatitis, skin lesions often are clustered around the mouth, nose, and eyes. Typically there are no telangiectases or ocular complications.3 Facial flushing and telangiectases are uncommon, except in steroid-induced perioral dermatitis.2

The cutaneous findings of sarcoidosis include red-brown papules on the face and lips, and patients also may have ocular involvement such as uveitis and iritis.3 However, there are typically other systemic findings such as pulmonary symptoms, weight loss, fatigue, lethargy, fever, and erythema nodosum.2,3 Chest radiograph findings (eg, bilateral hilar lym-phadenopathy), ophthalmologic examination, and laboratory data (eg, elevated alkaline phosphate and/or elevated angiotensin-converting enzyme) can help confirm or rule out the diagnosis of sarcoidosis.2,3

Unlike systemic lupus erythematosus, patients with rosacea will have involvement of sun-protected areas of the skin. Patients with systemic lupus erythematosus typically report arthralgia and severe photosensitivity and will have elevated antinuclear antibody titers. Skin biopsies and immunofluorescence can help confirm the diagnosis.3 Importantly, some patients with rosacea will have a positive lupus band test.22,23

Steroid-induced rosacea typically occurs 2 weeks after discontinuing therapy with topical fluorinated glucocorticosteroids.24 Children present with monomorphic papules, pustules, and telangiectases4 on the eyelids and lateral face as opposed to the central face regions.24

Ataxia telangiectasia can present with telangiectases, skin atrophy, café au lait spots, and premature graying.25 A 15-year-old adolescent girl with ataxia telangiectasia presented with granulomatous acne rosacea that improved after 4 weeks of treatment with isotretinoin 0.5 mg/kg daily. The lesions cleared almost completely after 5 months.25

Demodicosis is a disorder of the pilosebaceous units caused by the human Demodex mite.26 It typically involves the periorificial regions in adults and the elderly population. Patients can present with fine, white-yellow, scaly changes of the sebaceous hair follicles, with minimal erythema and inflammation. Papules and pustules also can be present.26

Diagnosis and Histopathology

Because rosacea is rare in children, it is important to thoroughly evaluate other possible diagnoses. The diagnosis of pediatric rosacea is clinical and biopsies are rarely performed. Laboratory tests such as cultures generally are not useful.

Marks and Harcourt-Webster27 reviewed the biopsies of 108 adult patients with rosacea. The biopsies of patients with predominantly erythema and telangiectasia showed evidence of vascular dilatation with a perivascular infiltrate composed predominantly of lymphocytes and 39 specimens that were compared to controls showed more solar elastosis. Biopsies of papular rosacea contained inflammatory infiltrates in the upper and mid dermis composed primarily of lymphocytes and histiocytes. In some patients, neutrophils, plasma cells, and giant cells also were observed. Hair follicle abnormalities were present in 20% of the biopsies, with 19% showing evidence of the Demodex mite. Vascular dilatation also was common. Overall, common findings included lymphohistiocytic infiltrates around the blood vessels of the upper dermis, dilated vessels, edema, elastosis, and disorganization of connective tissue in the upper dermis.

Helm et al28 reviewed histopathologic patterns from 53 patients with granulomatous rosacea. Findings included a mixed lymphohistiocytic infiltrate (predominantly lymphocytic in 40% of patients and predominantly histiocytic with occasional giant cells in 34% of patients), epithelioid granulomas (11% of patients), and epithelioid granulomas with caseation necrosis (11% of patients).

The histopathology of rosacea fulminans is characterized by dense perivascular and periadnexal infiltrates composed of granulocytes, eosinophils, and epithelioid granulomas, as well as panniculitis.20

Treatment and Clinical Outcomes

Certain lifestyle recommendations are integral components of disease management, including avoidance of triggers such as extreme temperatures, hot drinks, spicy food, and topical agents that could be irritating (especially topical corticosteroids).29 Patients should be advised to use daily sunscreen containing physical blockers such as titanium dioxide or zinc oxide. Teenagers should avoid the use of cosmetics and makeup, especially products containing sodium lauryl sulfate, menthol, and camphor. Daily use of emollients can help some patients.29

There are both topical and systemic therapies available for pediatric rosacea; however, most of the data are based on the use of these treatments in the adult population. Patients with mild to moderate disease often can be managed using topical agents. Metronidazole (0.75% cream, 1% gel, or 0.75% lotion) has been studied extensively in adult patients, and when used once daily for 12 weeks, it has been able to control moderate to severe disease.30,31 In one study conducted in adult patients, topical metronidazole was able to maintain remission in adults who had previously been treated with a combination of oral tetracycline and metronidazole gel.31 Sodium sulfacetamide 10%–sulfur 5% (cleanser or lotion) has been successful in adult patients and often is used in combination with other therapies such as topical metronidazole.32-34 Azelaic acid cream 20%,35 benzoyl peroxide (wash or gel),29 topical clindamycin,36 topical erythromycin,29,37 tacrolimus ointment 0.1%,38 and tretinoin cream also have been studied in adults.3,39 Several of these topical agents can cause irritation on application (eg, metronidazole, sulfur-based agents, azelaic acid, benzoyl peroxide, erythromycin, tretinoin).3

 

 

The use of systemic treatments in pediatric patients is heavily based on case reports and case series.2,14,16,40 Therapies have included tetracycline (500 mg twice daily tapered to 250 mg daily),29 minocycline (50–100 mg twice daily), doxycycline (50–100 mg twice daily or 4 times daily), erythromycin (30–50 mg/kg daily), clarithromycin (15 mg/kg twice daily for 4 weeks and then daily for 4 weeks), and azithromycin (5–10 mg/kg daily).3 Tetracycline antibiotics should not be used in children 8 years or younger.

In a case series by Drolet and Paller,2 an 11-year-old girl was treated with tetracycline 500 mg (later tapered to 250 mg daily) and metronidazole gel 0.75%, both used twice daily. Previously, she had not responded to topical steroids, tretinoin cream 0.05%, benzoyl peroxide 5%, or systemic prednisone. After 6 weeks of treatment, the pustules and chalazion had resolved and she had only minimal erythema of the skin and conjunctiva. Sixteen months after the start of treatment, a regimen of tetracycline 250 mg daily and metronidazole gel resulted in disease clearance on the face.2

A 9-year-old girl with concurrent systemic lupus erythematosus was treated with tetracycline 250 mg and topical erythromycin 2%, both used twice daily.2 After 4 weeks her face was clear. Four months later she developed new telangiectases and topical erythromycin was replaced with topical metronidazole. Eventually the dose of tetracycline was reduced to 250 mg daily.2

An 11-year-old boy with likely granulomatous rosacea was treated with erythromycin 250 mg 4 times daily, alclometasone dipropionate cream 0.05% twice daily, and topical clindamycin twice daily.2 Marked improvement was noticed after 3 weeks of treatment. Metronidazole gel 0.75% was added and 3 months later the patient’s face was clear, without evidence of scarring. The dose of erythromycin was later reduced to 500 mg daily, and eventually the patient experienced clearance with the use of metronidazole gel daily.2

In another case series, 4 female patients (age range, 4–12 years) were treated with systemic erythromycin 20 mg/kg daily (ocular involvement only) or doxycycline 2.2 mg/kg daily used in two 12-year-old patients with ocular and cutaneous involvement for at least 12 months. All 4 patients showed considerable improvement within 1 month and remained free of disease throughout a mean follow-up period of 25.5 months.40

As evidenced by these case reports, there is a wide array of treatments that have been used for pediatric rosacea. Although there are no formal evidence-based guidelines, there are certain considerations that must be taken into account when choosing treatment plans. Doxycycline and minocycline are known to cause less gastrointestinal upset than tetracycline with similar efficacy.41 Importantly, the tetracyclines are contraindicated in children younger than 9 years, as they can cause teeth staining and possibly affect skeletal growth.3,4 When used in older children (age range, 9–12 years), patients must be advised not to take their medication with calcium or antacids.3 Clarithromycin and azithromycin tend to have fewer gastrointestinal side effects than erythromycin. Erythromycin and other macrolides can be used in children of all ages and in patients who are allergic to tetracyclines.3

Children with mild ocular symptoms often can control their disease with bacitracin and topical ocular antibiotics such as erythromycin.2,15 For patients who require systemic antibiotics, various tetracyclines and macrolides have been used with success.2,14-16,40

Adults with rosacea fulminans can require treatment with isotretinoin, oral antibiotics, and topical or even systemic corticosteroids.42 The 3-year-old girl with rosacea fulminans initially was treated with oral erythromycin (250 mg 4 times daily), oral prednisolone (0.5 mg/kg daily tapered over 2 weeks), fluocinolone acetonide cream 0.025%, and warm compresses with only moderate improvement.21 She was then started on oral isotretinoin (0.75 mg/kg daily) and within 4 weeks marked improvement was noted. After 8 weeks, the lesions had disappeared completely with only a few pitted scars remaining. Isotretinoin was continued for 24 weeks. One year after completion of treatment, she was still disease free.21

Weston and Morelli19 recommended the following treatment regimen for children with steroid rosacea: abrupt cessation of topical steroid use (as opposed to gradual withdrawal) and initiation of oral erythromycin stearate (30 mg/kg daily) in 2 daily doses for 4 weeks. Children who were unable to tolerate erythromycin (n=6) were told to use topical clindamycin phosphate twice daily for 4 weeks. Within 3 weeks 22% of patients had resolution, while 86% had resolution within 4 weeks. All of the patients cleared within 8 weeks. Importantly, there was no significant difference in duration of time until clearance between children who used the oral antibiotic or topical antibiotic.19

Conclusion

We know that the skin of rosacea patients contains higher levels of cathelicidins, which have been implicated in amplifying and contributing to the inflammatory response in several ways. Mast cells, which are a source of cathelicidins, also are increased in the skin of these patients. Children can present with vascular rosacea (characterized by flushing, erythema, and/or telangiectasia), papulopustular rosacea, or ocular rosacea. Common ocular symptoms include blepharitis, conjunctivitis, and recurrent chalazion. It is important to refer pediatric rosacea patients with ocular symptoms to an ophthalmologist to prevent ocular sequelae.

 

 

Rosacea is a clinical diagnosis but biopsy can be performed to rule out other diagnoses. Treatment consists of lifestyle modifications such as avoiding known triggers and the use of topical and/or oral agents. Common topical therapies include metronidazole and erythromycin. Systemic antibiotics include tetracycline, doxycycline, minocycline, azithromycin, and erythromycin. Some children are able to taper systemic agents and maintain disease control with topical therapy, while others may need to continue a low-dose antibiotic. Although flares can be controlled within weeks to months, rosacea is a chronic disorder and childhood rosacea tends to persist into adulthood.

References
  1. Crawford GH, Pelle MT, James WD. Rosacea: i. etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51:327-341; quiz 342-324.
  2. Drolet B, Paller AS. Childhood rosacea. Pediatr Dermatol. 1992;9:22-26.
  3. Kroshinsky D, Glick SA. Pediatric rosacea. Dermatol Ther. 2006;19:196-201.
  4. Lacz NL, Schwartz RA. Rosacea in the pediatric population. Cutis. 2004;74:99-103.
  5. Vemuri RC, Gundamaraju R, Sekaran SD, et al. Major pathophysiological correlations of rosacea: a complete clinical appraisal. Int J Med Sci. 2015;12:387-396.
  6. Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007;13:975-980.
  7. Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med. 2002;347:1151-1160.
  8. Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007;449:564-569.
  9. De Y, Chen Q, Schmidt AP, et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med. 2000;192:1069-1074.
  10. Koczulla R, von Degenfeld G, Kupatt C, et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest. 2003;111:1665-1672.
  11. Park HJ, Cho DH, Kim HJ, et al. Collagen synthesis is suppressed in dermal fibroblasts by the human antimicrobial peptide LL-37. J Invest Dermatol. 2009;129:843-850.
  12. Muto Y, Wang Z, Vanderberghe M, et al. Mast cells are key mediators of cathelicidin-initiated skin inflammation in rosacea. J Invest Dermatol. 2014;134:2728-2736.
  13. Di Nardo A, Vitiello A, Gallo RL. Cutting edge: mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J Immunol. 2003;170:2274-2278.
  14. Leoni S, Mesplie N, Aitali F, et al. Metronidazole: alternative treatment for ocular and cutaneous rosacea in the pediatric population [in French]. J Fr Ophthalmol. 2011;34:703-710.
  15. Nazir SA, Murphy S, Siatkowski RM, et al. Ocular rosacea in childhood. Am J Ophthalmol. 2004;137:138-144.
  16. Miguel AI, Salgado MB, Lisboa MS, et al. Pediatric ocular rosacea: 2 cases. Eur J Ophthalmol. 2012;22:664-666.
  17. Stone DU, Chodosh J. Ocular rosacea: an update on pathogenesis and therapy. Curr Opin Ophthalmol. 2004;15:499-502.
  18. Mavrakanas N, Schutz JS, Dosso AA. Pediatric ocular rosacea [published online March 22, 2010]. J Pediatr Ophthalmol Strabismus. 2010;47:117-120.
  19. Weston WL, Morelli JG. Steroid rosacea in prepubertal children. Arch Pediatr Adolesc Med. 2000;154:62-64.
  20. Plewig G, Jansen T, Kligman AM. Pyoderma faciale. a review and report of 20 additional cases: is it rosacea? Arch Dermatol. 1992;128:1611-1617.
  21. Firooz A, Firoozabadi MR, Dowlati Y. Rosacea fulminans (pyoderma faciale): successful treatment of a 3-year-old girl with oral isotretinoin. Int J Dermatol. 2001;40:203-205.
  22. Baart de la Faille H, Baart de la F-K. Immunofluorescent studies of the skin in rosacea. Dermatologica. 1969;139:49-54.
  23. Wilkin JK. Rosacea. Int J Dermatol. 1983;22:393-400.
  24. Franco HL, Weston WL. Steroid rosacea in children. Pediatrics. 1979;64:36-38.
  25. Cantarutti N, Claps A, Angelino G, et al. Multi-drugs resistant acne rosacea in a child affected by ataxia-telangiectasia: successful treatment with isotretinoin. Ital J Pediatr. 2015;41:23.
  26. Chen W, Plewig G. Human demodicosis: revisit and a proposed classification. Br J Dermatol. 2014;170:1219-1225.
  27. Marks R, Harcourt-Webster J. Histopathology of rosacea. Arch Dermatol. 1969;100:683-691.
  28. Helm KF, Menz J, Gibson LE, et al. A clinical and histopathologic study of granulomatous rosacea. J Am Acad Dermatol. 1991;25(6, pt 1):1038-1043.
  29. Pelle MT, Crawford GH, James WD. Rosacea: II. therapy. J Am Acad Dermatol. 2004;51:499-512; quiz 513-494.
  30. Dahl MV, Jarratt M, Kaplan D, et al. Once-daily topical metronidazole cream formulations in the treatment of the papules and pustules of rosacea. J Am Acad Dermatol. 2001;45:723-730.
  31. Dahl MV, Katz HI, Krueger GG, et al. Topical metronidazole maintains remissions of rosacea. Arch Dermatol. 1998;134:679-683.
  32. Trumbore MW, Goldstein JA, Gurge RM. Treatment of papulopustular rosacea with sodium sulfacetamide 10%/sulfur 5% emollient foam. J Drugs Dermatol. 2009;8:299-304.
  33. Del Rosso JQ. Evaluating the role of topical therapies in the management of rosacea: focus on combination sodium sulfacetamide and sulfur formulations. Cutis. 2004;73(1 suppl):29-33.
  34. Del Rosso JQ. A status report on the medical management of rosacea: focus on topical therapies. Cutis. 2002;70:271-275.
  35. Maddin S. A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. J Am Acad Dermatol. 1999;40(6, pt 1):961-965.
  36. Wilkin JK, DeWitt S. Treatment of rosacea: topical clindamycin versus oral tetracycline. Int J Dermatol. 1993;32:65-67.
  37. Mills OH Jr, Kligman AM. Letter: topically applied erythromycin in rosacea. Arch Dermatol. 1976;112:553-554.
  38. Hengge UR. Off-label indications for topical tacrolimus [in German]. Hautarzt. 2013;64:752-756.
  39. Ertl GA, Levine N, Kligman AM. A comparison of the efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea. Arch Dermatol. 1994;130:319-324.
  40. Cetinkaya A, Akova YA. Pediatric ocular acne rosacea: long-term treatment with systemic antibiotics. Am J Ophthalmol. 2006;142:816-821.
  41. Maibach H. Second-generation tetracyclines, a dermatologic overview: clinical uses and pharmacology. Cutis. 1991;48:411-417.
  42. Jansen T, Plewig G, Kligman AM. Diagnosis and treatment of rosacea fulminans. Dermatology. 1994;188:251-254.
References
  1. Crawford GH, Pelle MT, James WD. Rosacea: i. etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51:327-341; quiz 342-324.
  2. Drolet B, Paller AS. Childhood rosacea. Pediatr Dermatol. 1992;9:22-26.
  3. Kroshinsky D, Glick SA. Pediatric rosacea. Dermatol Ther. 2006;19:196-201.
  4. Lacz NL, Schwartz RA. Rosacea in the pediatric population. Cutis. 2004;74:99-103.
  5. Vemuri RC, Gundamaraju R, Sekaran SD, et al. Major pathophysiological correlations of rosacea: a complete clinical appraisal. Int J Med Sci. 2015;12:387-396.
  6. Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007;13:975-980.
  7. Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med. 2002;347:1151-1160.
  8. Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007;449:564-569.
  9. De Y, Chen Q, Schmidt AP, et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med. 2000;192:1069-1074.
  10. Koczulla R, von Degenfeld G, Kupatt C, et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest. 2003;111:1665-1672.
  11. Park HJ, Cho DH, Kim HJ, et al. Collagen synthesis is suppressed in dermal fibroblasts by the human antimicrobial peptide LL-37. J Invest Dermatol. 2009;129:843-850.
  12. Muto Y, Wang Z, Vanderberghe M, et al. Mast cells are key mediators of cathelicidin-initiated skin inflammation in rosacea. J Invest Dermatol. 2014;134:2728-2736.
  13. Di Nardo A, Vitiello A, Gallo RL. Cutting edge: mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J Immunol. 2003;170:2274-2278.
  14. Leoni S, Mesplie N, Aitali F, et al. Metronidazole: alternative treatment for ocular and cutaneous rosacea in the pediatric population [in French]. J Fr Ophthalmol. 2011;34:703-710.
  15. Nazir SA, Murphy S, Siatkowski RM, et al. Ocular rosacea in childhood. Am J Ophthalmol. 2004;137:138-144.
  16. Miguel AI, Salgado MB, Lisboa MS, et al. Pediatric ocular rosacea: 2 cases. Eur J Ophthalmol. 2012;22:664-666.
  17. Stone DU, Chodosh J. Ocular rosacea: an update on pathogenesis and therapy. Curr Opin Ophthalmol. 2004;15:499-502.
  18. Mavrakanas N, Schutz JS, Dosso AA. Pediatric ocular rosacea [published online March 22, 2010]. J Pediatr Ophthalmol Strabismus. 2010;47:117-120.
  19. Weston WL, Morelli JG. Steroid rosacea in prepubertal children. Arch Pediatr Adolesc Med. 2000;154:62-64.
  20. Plewig G, Jansen T, Kligman AM. Pyoderma faciale. a review and report of 20 additional cases: is it rosacea? Arch Dermatol. 1992;128:1611-1617.
  21. Firooz A, Firoozabadi MR, Dowlati Y. Rosacea fulminans (pyoderma faciale): successful treatment of a 3-year-old girl with oral isotretinoin. Int J Dermatol. 2001;40:203-205.
  22. Baart de la Faille H, Baart de la F-K. Immunofluorescent studies of the skin in rosacea. Dermatologica. 1969;139:49-54.
  23. Wilkin JK. Rosacea. Int J Dermatol. 1983;22:393-400.
  24. Franco HL, Weston WL. Steroid rosacea in children. Pediatrics. 1979;64:36-38.
  25. Cantarutti N, Claps A, Angelino G, et al. Multi-drugs resistant acne rosacea in a child affected by ataxia-telangiectasia: successful treatment with isotretinoin. Ital J Pediatr. 2015;41:23.
  26. Chen W, Plewig G. Human demodicosis: revisit and a proposed classification. Br J Dermatol. 2014;170:1219-1225.
  27. Marks R, Harcourt-Webster J. Histopathology of rosacea. Arch Dermatol. 1969;100:683-691.
  28. Helm KF, Menz J, Gibson LE, et al. A clinical and histopathologic study of granulomatous rosacea. J Am Acad Dermatol. 1991;25(6, pt 1):1038-1043.
  29. Pelle MT, Crawford GH, James WD. Rosacea: II. therapy. J Am Acad Dermatol. 2004;51:499-512; quiz 513-494.
  30. Dahl MV, Jarratt M, Kaplan D, et al. Once-daily topical metronidazole cream formulations in the treatment of the papules and pustules of rosacea. J Am Acad Dermatol. 2001;45:723-730.
  31. Dahl MV, Katz HI, Krueger GG, et al. Topical metronidazole maintains remissions of rosacea. Arch Dermatol. 1998;134:679-683.
  32. Trumbore MW, Goldstein JA, Gurge RM. Treatment of papulopustular rosacea with sodium sulfacetamide 10%/sulfur 5% emollient foam. J Drugs Dermatol. 2009;8:299-304.
  33. Del Rosso JQ. Evaluating the role of topical therapies in the management of rosacea: focus on combination sodium sulfacetamide and sulfur formulations. Cutis. 2004;73(1 suppl):29-33.
  34. Del Rosso JQ. A status report on the medical management of rosacea: focus on topical therapies. Cutis. 2002;70:271-275.
  35. Maddin S. A comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea. J Am Acad Dermatol. 1999;40(6, pt 1):961-965.
  36. Wilkin JK, DeWitt S. Treatment of rosacea: topical clindamycin versus oral tetracycline. Int J Dermatol. 1993;32:65-67.
  37. Mills OH Jr, Kligman AM. Letter: topically applied erythromycin in rosacea. Arch Dermatol. 1976;112:553-554.
  38. Hengge UR. Off-label indications for topical tacrolimus [in German]. Hautarzt. 2013;64:752-756.
  39. Ertl GA, Levine N, Kligman AM. A comparison of the efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea. Arch Dermatol. 1994;130:319-324.
  40. Cetinkaya A, Akova YA. Pediatric ocular acne rosacea: long-term treatment with systemic antibiotics. Am J Ophthalmol. 2006;142:816-821.
  41. Maibach H. Second-generation tetracyclines, a dermatologic overview: clinical uses and pharmacology. Cutis. 1991;48:411-417.
  42. Jansen T, Plewig G, Kligman AM. Diagnosis and treatment of rosacea fulminans. Dermatology. 1994;188:251-254.
Issue
Cutis - 98(1)
Issue
Cutis - 98(1)
Page Number
49-53
Page Number
49-53
Publications
Publications
Article Type
Display Headline
Pediatric Rosacea
Display Headline
Pediatric Rosacea
Legacy Keywords
Rosacea, pediatric, children
Legacy Keywords
Rosacea, pediatric, children
Sections
Inside the Article

Practice Points

  • Although rosacea is largely a diagnosis of adults, it also can begin in childhood and adolescence.
  • Ocular rosacea and papulopustular disease are common clinical findings in younger patients.
  • Usage of topical metronidazole and age-appropriate oral antibiotics are the mainstay of management.
Disallow All Ads
Article PDF Media

Case series describes melanoma-associated leukoderma presenting as atypical vitiligo

Article Type
Changed
Mon, 01/14/2019 - 09:40
Display Headline
Case series describes melanoma-associated leukoderma presenting as atypical vitiligo

Consider melanoma-associated leukoderma (MAL) as a possible diagnosis in patients presenting with atypical vitiligo-like skin depigmentation that is refractory to standard treatment, advised the authors of a series of seven such cases.

In a research letter published online in the British Journal of Dermatology, Dr. H.E. Teulings and colleagues from the department of dermatology and the Netherlands Institute for Pigment Disorders at the University of Amsterdam, presented a retrospective analysis of seven patients diagnosed with MAL from 2009-2014, who had been initially diagnosed with nonsegmental vitiligo.

The authors defined MAL as “depigmentation that developed within 1 year before the detection of a primary melanoma or within 3 years before the detection of melanoma metastases with an unknown primary tumour.”

The five women and two men were white and were older (aged 45 to 72 years). They had experienced a sudden onset of highly progressive hypo- and depigmentation, which the authors described as often consisting of “round, patchy, confetti-like lesions” measuring 4-5 mm in diameter; most were scattered symmetrically over the trunk, extremities, and/or face (Br J Dermatol. 2016 Jun 7. doi: 10.1111/bjd.14790).

The authors noted that this presentation was unlike typical vitiligo, “which is often bilaterally distributed in an acrofacial pattern, or scattered symmetrically over the entire body with a predilection for extensor surfaces with a relatively early onset in life and a slowly evolving disease course over time.”

The lesions were also generally resistant to topical steroids and UV phototherapy, and six of the seven patients had no family history of vitiligo. The patients were either diagnosed with a primary melanoma at first presentation or were later diagnosed with metastatic melanoma. The majority responded well to immunotherapy, although one patient died.

“In conclusion, although MAL only constitutes a small percentage of patients presenting with vitiligo-like depigmentation, awareness of this phenomenon and correct diagnosis of these patients is crucial to limit further melanoma treatment delay,” the authors wrote. “Many dermatologists are not aware of the diagnosis MAL and may easily diagnose and treat these patients as having nonsegmental vitiligo, thereby overlooking the underlying (metastatic) melanoma,” they added.

Dr. Teulings is supported by a grant from the Dutch Cancer Society. The authors had no conflicts of interest to declare.

References

Author and Disclosure Information

Publications
Topics
Legacy Keywords
melanoma-associated, leukoderma, atypical, vitiligo, MAL
Author and Disclosure Information

Author and Disclosure Information

Consider melanoma-associated leukoderma (MAL) as a possible diagnosis in patients presenting with atypical vitiligo-like skin depigmentation that is refractory to standard treatment, advised the authors of a series of seven such cases.

In a research letter published online in the British Journal of Dermatology, Dr. H.E. Teulings and colleagues from the department of dermatology and the Netherlands Institute for Pigment Disorders at the University of Amsterdam, presented a retrospective analysis of seven patients diagnosed with MAL from 2009-2014, who had been initially diagnosed with nonsegmental vitiligo.

The authors defined MAL as “depigmentation that developed within 1 year before the detection of a primary melanoma or within 3 years before the detection of melanoma metastases with an unknown primary tumour.”

The five women and two men were white and were older (aged 45 to 72 years). They had experienced a sudden onset of highly progressive hypo- and depigmentation, which the authors described as often consisting of “round, patchy, confetti-like lesions” measuring 4-5 mm in diameter; most were scattered symmetrically over the trunk, extremities, and/or face (Br J Dermatol. 2016 Jun 7. doi: 10.1111/bjd.14790).

The authors noted that this presentation was unlike typical vitiligo, “which is often bilaterally distributed in an acrofacial pattern, or scattered symmetrically over the entire body with a predilection for extensor surfaces with a relatively early onset in life and a slowly evolving disease course over time.”

The lesions were also generally resistant to topical steroids and UV phototherapy, and six of the seven patients had no family history of vitiligo. The patients were either diagnosed with a primary melanoma at first presentation or were later diagnosed with metastatic melanoma. The majority responded well to immunotherapy, although one patient died.

“In conclusion, although MAL only constitutes a small percentage of patients presenting with vitiligo-like depigmentation, awareness of this phenomenon and correct diagnosis of these patients is crucial to limit further melanoma treatment delay,” the authors wrote. “Many dermatologists are not aware of the diagnosis MAL and may easily diagnose and treat these patients as having nonsegmental vitiligo, thereby overlooking the underlying (metastatic) melanoma,” they added.

Dr. Teulings is supported by a grant from the Dutch Cancer Society. The authors had no conflicts of interest to declare.

Consider melanoma-associated leukoderma (MAL) as a possible diagnosis in patients presenting with atypical vitiligo-like skin depigmentation that is refractory to standard treatment, advised the authors of a series of seven such cases.

In a research letter published online in the British Journal of Dermatology, Dr. H.E. Teulings and colleagues from the department of dermatology and the Netherlands Institute for Pigment Disorders at the University of Amsterdam, presented a retrospective analysis of seven patients diagnosed with MAL from 2009-2014, who had been initially diagnosed with nonsegmental vitiligo.

The authors defined MAL as “depigmentation that developed within 1 year before the detection of a primary melanoma or within 3 years before the detection of melanoma metastases with an unknown primary tumour.”

The five women and two men were white and were older (aged 45 to 72 years). They had experienced a sudden onset of highly progressive hypo- and depigmentation, which the authors described as often consisting of “round, patchy, confetti-like lesions” measuring 4-5 mm in diameter; most were scattered symmetrically over the trunk, extremities, and/or face (Br J Dermatol. 2016 Jun 7. doi: 10.1111/bjd.14790).

The authors noted that this presentation was unlike typical vitiligo, “which is often bilaterally distributed in an acrofacial pattern, or scattered symmetrically over the entire body with a predilection for extensor surfaces with a relatively early onset in life and a slowly evolving disease course over time.”

The lesions were also generally resistant to topical steroids and UV phototherapy, and six of the seven patients had no family history of vitiligo. The patients were either diagnosed with a primary melanoma at first presentation or were later diagnosed with metastatic melanoma. The majority responded well to immunotherapy, although one patient died.

“In conclusion, although MAL only constitutes a small percentage of patients presenting with vitiligo-like depigmentation, awareness of this phenomenon and correct diagnosis of these patients is crucial to limit further melanoma treatment delay,” the authors wrote. “Many dermatologists are not aware of the diagnosis MAL and may easily diagnose and treat these patients as having nonsegmental vitiligo, thereby overlooking the underlying (metastatic) melanoma,” they added.

Dr. Teulings is supported by a grant from the Dutch Cancer Society. The authors had no conflicts of interest to declare.

References

References

Publications
Publications
Topics
Article Type
Display Headline
Case series describes melanoma-associated leukoderma presenting as atypical vitiligo
Display Headline
Case series describes melanoma-associated leukoderma presenting as atypical vitiligo
Legacy Keywords
melanoma-associated, leukoderma, atypical, vitiligo, MAL
Legacy Keywords
melanoma-associated, leukoderma, atypical, vitiligo, MAL
Article Source

FROM THE BRITISH JOURNAL OF DERMATOLOGY

PURLs Copyright

Inside the Article

Vitals

Key clinical point: Doctors should consider melanoma-associated leukoderma (MAL) as a possible diagnosis in patients presenting with atypical vitiligo-like depigmentation that is refractory to standard treatment.

Major finding: Seven patients with MAL, who were initially diagnosed with nonsegmental vitiligo, were older; had late onset, progressive symptoms; and had presentations that were not like typical vitiligo.

Data source: A retrospective case series of seven patients diagnosed with MAL at a tertiary vitiligo center.

Disclosures: One author was supported by a grant from the Dutch Cancer Society. No conflicts of interest were declared.

Below-knee angioplasty for limb salvage: Keep it simple

Article Type
Changed
Wed, 01/02/2019 - 09:37
Display Headline
Below-knee angioplasty for limb salvage: Keep it simple

PARIS – Below-the-knee plain balloon angioplasty is an effective strategy for limb-salvage in patients with critical limb ischemia who otherwise face the prospect of a major amputation, Ana P. Mollon, MD, said at the annual congress of the European Association of Percutaneous Cardiovascular Interventions.

Dr. Mollon of Posadas National Hospital in Buenos Aires, presented a retrospective series of 82 consecutive patients who underwent below-the-knee percutaneous angioplasty for critical limb ischemia with multivessel involvement. The amputation-free survival rate at a mean of 15.1 months of follow-up was 88%.

Bruce Jancin/Frontline Medical News
Dr. Ana P. Mollon

Sixty of the 82 patients had triple-artery involvement below the knee. The other 22 had two involved arteries. As is typical in patients with critical limb ischemia, comorbid conditions were common: Seventy-five patients had diabetes, 58 were hypertensive, and 48 were current smokers.

Of the 124 arteries treated by Dr. Mollon and coworkers, the posterior tibial artery was addressed in 41% of cases, the anterior tibial artery in 39%, and the peroneal artery in 18%. Two percent of patients received dilatation of plantar arch lesions.

Seventy percent of treated lesions were total occlusions, nearly half of which were more than 5 cm in length.

The treatment was plain balloon angioplasty in 78% of cases, drug-coated balloons in 12%, bare metal stenting in 7%, and drug-eluting stents in 3%. An antegrade approach was used in 95% of cases, and the remainder received a dual antegrade/retrograde approach.

Roughly 80% of patients were Rutherford category 5 or 6 before treatment. At 12 months post angioplasty, most patients were category 1 or 2, and about one-quarter were category 5 or 6.

Angioplasty was unsuccessful in restoring straight line flow in six patients.

All 10 patients who underwent a major amputation had triple-vessel involvement below the knee; in 9 of the 10, interventionalists were able to treat one of the three severely diseased arteries. Five of the 10 amputees had osteomyelitis.

Session chair Flavio Ribichini, MD, applauded Dr. Mollon and her Argentine colleagues for their predominant use of plain balloon angioplasty in this setting.

“I absolutely share your view on this. It’s the simplest and cheapest approach. The point is that you’re saving the foot now. It’s not that important what’s going to happen in 1 year. I don’t think it makes sense to use drug-coated balloons in this setting. It’s much more sensible to use a simple procedure and see how it goes,” said Dr. Ribichini, professor of cardiovascular medicine at the University of Verona (Italy).

Dr. Mollon said that several years ago her group briefly turned to the use of drug-coated balloons for below-the-knee limb salvage, but they soon switched back to plain balloon angioplasty because they didn’t see any advantage in patient outcomes with the more elaborate technology.

Discussant Benjamin Honton, MD, of the Pasteur Clinic in Toulouse, France, said, “We, too, have been disappointed with the drug-coated balloon, especially in the posterior tibial artery.”

Dr. Mollon reported having no financial conflicts.

[email protected]

References

Meeting/Event
Author and Disclosure Information

Publications
Topics
Legacy Keywords
critical limb ischemia, plain balloon angioplasty, amputation, peripheral artery disease
Sections
Author and Disclosure Information

Author and Disclosure Information

Meeting/Event
Meeting/Event

PARIS – Below-the-knee plain balloon angioplasty is an effective strategy for limb-salvage in patients with critical limb ischemia who otherwise face the prospect of a major amputation, Ana P. Mollon, MD, said at the annual congress of the European Association of Percutaneous Cardiovascular Interventions.

Dr. Mollon of Posadas National Hospital in Buenos Aires, presented a retrospective series of 82 consecutive patients who underwent below-the-knee percutaneous angioplasty for critical limb ischemia with multivessel involvement. The amputation-free survival rate at a mean of 15.1 months of follow-up was 88%.

Bruce Jancin/Frontline Medical News
Dr. Ana P. Mollon

Sixty of the 82 patients had triple-artery involvement below the knee. The other 22 had two involved arteries. As is typical in patients with critical limb ischemia, comorbid conditions were common: Seventy-five patients had diabetes, 58 were hypertensive, and 48 were current smokers.

Of the 124 arteries treated by Dr. Mollon and coworkers, the posterior tibial artery was addressed in 41% of cases, the anterior tibial artery in 39%, and the peroneal artery in 18%. Two percent of patients received dilatation of plantar arch lesions.

Seventy percent of treated lesions were total occlusions, nearly half of which were more than 5 cm in length.

The treatment was plain balloon angioplasty in 78% of cases, drug-coated balloons in 12%, bare metal stenting in 7%, and drug-eluting stents in 3%. An antegrade approach was used in 95% of cases, and the remainder received a dual antegrade/retrograde approach.

Roughly 80% of patients were Rutherford category 5 or 6 before treatment. At 12 months post angioplasty, most patients were category 1 or 2, and about one-quarter were category 5 or 6.

Angioplasty was unsuccessful in restoring straight line flow in six patients.

All 10 patients who underwent a major amputation had triple-vessel involvement below the knee; in 9 of the 10, interventionalists were able to treat one of the three severely diseased arteries. Five of the 10 amputees had osteomyelitis.

Session chair Flavio Ribichini, MD, applauded Dr. Mollon and her Argentine colleagues for their predominant use of plain balloon angioplasty in this setting.

“I absolutely share your view on this. It’s the simplest and cheapest approach. The point is that you’re saving the foot now. It’s not that important what’s going to happen in 1 year. I don’t think it makes sense to use drug-coated balloons in this setting. It’s much more sensible to use a simple procedure and see how it goes,” said Dr. Ribichini, professor of cardiovascular medicine at the University of Verona (Italy).

Dr. Mollon said that several years ago her group briefly turned to the use of drug-coated balloons for below-the-knee limb salvage, but they soon switched back to plain balloon angioplasty because they didn’t see any advantage in patient outcomes with the more elaborate technology.

Discussant Benjamin Honton, MD, of the Pasteur Clinic in Toulouse, France, said, “We, too, have been disappointed with the drug-coated balloon, especially in the posterior tibial artery.”

Dr. Mollon reported having no financial conflicts.

[email protected]

PARIS – Below-the-knee plain balloon angioplasty is an effective strategy for limb-salvage in patients with critical limb ischemia who otherwise face the prospect of a major amputation, Ana P. Mollon, MD, said at the annual congress of the European Association of Percutaneous Cardiovascular Interventions.

Dr. Mollon of Posadas National Hospital in Buenos Aires, presented a retrospective series of 82 consecutive patients who underwent below-the-knee percutaneous angioplasty for critical limb ischemia with multivessel involvement. The amputation-free survival rate at a mean of 15.1 months of follow-up was 88%.

Bruce Jancin/Frontline Medical News
Dr. Ana P. Mollon

Sixty of the 82 patients had triple-artery involvement below the knee. The other 22 had two involved arteries. As is typical in patients with critical limb ischemia, comorbid conditions were common: Seventy-five patients had diabetes, 58 were hypertensive, and 48 were current smokers.

Of the 124 arteries treated by Dr. Mollon and coworkers, the posterior tibial artery was addressed in 41% of cases, the anterior tibial artery in 39%, and the peroneal artery in 18%. Two percent of patients received dilatation of plantar arch lesions.

Seventy percent of treated lesions were total occlusions, nearly half of which were more than 5 cm in length.

The treatment was plain balloon angioplasty in 78% of cases, drug-coated balloons in 12%, bare metal stenting in 7%, and drug-eluting stents in 3%. An antegrade approach was used in 95% of cases, and the remainder received a dual antegrade/retrograde approach.

Roughly 80% of patients were Rutherford category 5 or 6 before treatment. At 12 months post angioplasty, most patients were category 1 or 2, and about one-quarter were category 5 or 6.

Angioplasty was unsuccessful in restoring straight line flow in six patients.

All 10 patients who underwent a major amputation had triple-vessel involvement below the knee; in 9 of the 10, interventionalists were able to treat one of the three severely diseased arteries. Five of the 10 amputees had osteomyelitis.

Session chair Flavio Ribichini, MD, applauded Dr. Mollon and her Argentine colleagues for their predominant use of plain balloon angioplasty in this setting.

“I absolutely share your view on this. It’s the simplest and cheapest approach. The point is that you’re saving the foot now. It’s not that important what’s going to happen in 1 year. I don’t think it makes sense to use drug-coated balloons in this setting. It’s much more sensible to use a simple procedure and see how it goes,” said Dr. Ribichini, professor of cardiovascular medicine at the University of Verona (Italy).

Dr. Mollon said that several years ago her group briefly turned to the use of drug-coated balloons for below-the-knee limb salvage, but they soon switched back to plain balloon angioplasty because they didn’t see any advantage in patient outcomes with the more elaborate technology.

Discussant Benjamin Honton, MD, of the Pasteur Clinic in Toulouse, France, said, “We, too, have been disappointed with the drug-coated balloon, especially in the posterior tibial artery.”

Dr. Mollon reported having no financial conflicts.

[email protected]

References

References

Publications
Publications
Topics
Article Type
Display Headline
Below-knee angioplasty for limb salvage: Keep it simple
Display Headline
Below-knee angioplasty for limb salvage: Keep it simple
Legacy Keywords
critical limb ischemia, plain balloon angioplasty, amputation, peripheral artery disease
Legacy Keywords
critical limb ischemia, plain balloon angioplasty, amputation, peripheral artery disease
Sections
Article Source

AT EUROPCR 2016

PURLs Copyright

Inside the Article

Vitals

Key clinical point: Experts agree that plain balloon angioplasty is the way to go for limb salvage in patients with critical limb ischemia.

Major finding: The amputation-free survival rate in a consecutive series of patients who underwent below-the-knee angioplasty for critical limb ischemia was 88% at a mean of 15.1 months of follow-up.

Data source: A retrospective case series comprising 82 consecutive patients.

Disclosures: The presenter reported having no financial conflicts.

Education, Networking Opportunities Inspire Arizona Hospitalist Vishal Verma, MD, to Start New SHM Chapter

Article Type
Changed
Tue, 02/04/2020 - 12:54
Display Headline
Education, Networking Opportunities Inspire Arizona Hospitalist Vishal Verma, MD, to Start New SHM Chapter

Editor’s note: As SHM celebrates the “Year of the Hospitalist,” we’re putting the spotlight on some of our most active members who are making substantial contributions to hospital medicine. You can get involved, too! Log on to www.hospitalmedicine.org/yoth for more information on how you can join the yearlong celebration and help SHM improve the care of hospitalized patients.

 

This month, The Hospitalist spotlights Vishal Verma, MD, medical director of the hospitalist program at 4C Medical Group in Scottsdale, Ariz. In addition to being an active SHM member and regular attendee at SHM meetings, Dr. Verma recently purchased a group membership for his hospitalist team. He also started an Arizona chapter of SHM, based on his positive experiences with SHM. He recently spoke with The Hospitalist to share his path to hospital medicine and his inspiration to expand the society’s reach in Arizona.

 

Question: How did you arrive at a career in hospital medicine?

 

 

Vishal Verma, MD, medical director of the hospitalist program at 4C Medical Group in Scottsdale, Ariz.

 

Answer: After finishing my medical school training at Kasturba Medical College in Manipal, India, I traveled to the United States to further my education and begin my internship and residency. I started my internship in internal medicine at a downtown Brooklyn, N.Y., hospital in 2006. Internship year, though often considered to be a hectic and laborious year, was when I learned for the first time how to care for hospitalized patients. I was chosen by the chief residents as intern of the month in my first month of training. This honor, and the experience of training in an inner-city hospital, further ignited my passion to practice medicine.

 

It was during my time as an intern and resident when I fully realized the critical role hospitalists play as the main coordinators of care and witnessed their influence on care outcomes. I later served as chief medical resident and was elected by my fellow residents as president of house staff. I was also elected as vice president of the Committee of Interns and Residents (CIR) and served on CIR’s National Executive Board, where I passionately advocated for my patients and fellow colleagues. Serving in various roles provided me with an in-depth knowledge of hospital medicine and helped me build it as my career.

 

Q: In your current role, how does your membership with SHM help you improve quality of patient care?

 

A: Our group consists of 14 hospitalists who serve in two community hospitals. Being a member of SHM for many years has been a rewarding experience as it keeps me informed about changes and advances in hospital medicine. Through the Journal of Hospital Medicine, regular webinars, and SHM conferences and annual meetings, SHM helps us enrich our knowledge base on quality, performance, patient experience, coding, practice management, acute and post-acute care, and other aspects of hospital medicine.

 

At our recent visit to HM16 in San Diego, a few members of our team attended sessions on post-acute care and value-based reimbursements. At the sessions, we learned of the importance of stressing quality and engaging sub-acute rehab facilities in meaningful ways so as to improve the quality of care in skilled nursing facilities and also help to decrease the length of stay from 30 days to closer to 15 days. 4C Medical Group has implemented many suggestions from these lectures and is in the process of transforming our post-acute-care teams.

 

I also serve as a member of the board of directors for 4C Medical Group, where my association with SHM has helped me give valuable input while we manage the care of over 20,000 patients in acute, sub-acute, and home-based teams as well as outpatient clinics. SHM provides its members with a platform to sharpen their leadership skills and enables members to build a strong network among fellow leaders, which helps us learn about and share best practices, which translates to better quality of care.

 

 

For example, a recent presentation by SHM member Dr. Jesse Theisen-Toupal on inpatient management of opioid use disorder was an eye-opener. Learning about harm-reduction strategies for opioid misuse during the presentation was very helpful to us, and we shared the suggestions with our hospitalist team.

 

Q: What inspired you to start an Arizona chapter in Scottsdale and purchase a group membership for your team?

 

A: At HM16, I met Debra Beach, manager of membership and outreach programs at SHM, and we discussed how our company can align with SHM and bring our hospitalists on board as members to provide them with a greater network of resources. I was surprised that Arizona did not have a dedicated SHM chapter. Phoenix, one of the U.S.’s largest metropolitan areas, has many large hospital systems employing and contracting thousands of hospitalists. I saw an opening for a great opportunity to take the lead on developing an SHM chapter in Arizona with the support of my 4C colleagues. After discussing this opportunity with other hospitalist groups in Arizona, we came to the conclusion that it would benefit not only our team at 4C but hospitalists statewide.

 

I am confident that the Arizona chapter of SHM will not only be successful but soon will be contributing nationally to the hospitalist movement. Moreover, SHM will help keep our members educated and informed about the upcoming changes as we transition to a pay-for-performance model of reimbursement and any other healthcare system changes still to come.

 

I believe in the famous Chinese proverb, “A journey of a thousand miles begins with a single step.” We have taken the first step in our hospitalist group, and without a doubt, SHM’s journey in the state of Arizona shall be a success story. All our members are excited with this new beginning.

 

Q: How do you see hospital medicine evolving over the next 20 years?

 

A: 2016 has already been designated as the “Year of the Hospitalist.” I will take it a step further and predict that the next decade will be a decade of hospital medicine. Inpatient care is transforming at a rapid pace, and we need a dedicated and well-trained stream of doctors who are specialists in managing hospitalized patients. Care of hospitalized patients was once fragmented and costly; now with hospitalists as captains of the ship, care can be delivered in more comprehensive, cost-effective ways with better quality and increased performance. The introduction of a separate specialist billing code for hospitalists by the CMS is a step in the right direction.

 

In the next few years, I would enjoy seeing a separate board for hospitalists with hospital medicine’s own specialty certification. The potential for hospital medicine’s continued growth is tremendous, and I look forward to being a part of its future. TH

 

 


 

Brett Radler is SHM’s communications specialist.

Issue
The Hospitalist - 2016(07)
Publications
Sections

Editor’s note: As SHM celebrates the “Year of the Hospitalist,” we’re putting the spotlight on some of our most active members who are making substantial contributions to hospital medicine. You can get involved, too! Log on to www.hospitalmedicine.org/yoth for more information on how you can join the yearlong celebration and help SHM improve the care of hospitalized patients.

 

This month, The Hospitalist spotlights Vishal Verma, MD, medical director of the hospitalist program at 4C Medical Group in Scottsdale, Ariz. In addition to being an active SHM member and regular attendee at SHM meetings, Dr. Verma recently purchased a group membership for his hospitalist team. He also started an Arizona chapter of SHM, based on his positive experiences with SHM. He recently spoke with The Hospitalist to share his path to hospital medicine and his inspiration to expand the society’s reach in Arizona.

 

Question: How did you arrive at a career in hospital medicine?

 

 

Vishal Verma, MD, medical director of the hospitalist program at 4C Medical Group in Scottsdale, Ariz.

 

Answer: After finishing my medical school training at Kasturba Medical College in Manipal, India, I traveled to the United States to further my education and begin my internship and residency. I started my internship in internal medicine at a downtown Brooklyn, N.Y., hospital in 2006. Internship year, though often considered to be a hectic and laborious year, was when I learned for the first time how to care for hospitalized patients. I was chosen by the chief residents as intern of the month in my first month of training. This honor, and the experience of training in an inner-city hospital, further ignited my passion to practice medicine.

 

It was during my time as an intern and resident when I fully realized the critical role hospitalists play as the main coordinators of care and witnessed their influence on care outcomes. I later served as chief medical resident and was elected by my fellow residents as president of house staff. I was also elected as vice president of the Committee of Interns and Residents (CIR) and served on CIR’s National Executive Board, where I passionately advocated for my patients and fellow colleagues. Serving in various roles provided me with an in-depth knowledge of hospital medicine and helped me build it as my career.

 

Q: In your current role, how does your membership with SHM help you improve quality of patient care?

 

A: Our group consists of 14 hospitalists who serve in two community hospitals. Being a member of SHM for many years has been a rewarding experience as it keeps me informed about changes and advances in hospital medicine. Through the Journal of Hospital Medicine, regular webinars, and SHM conferences and annual meetings, SHM helps us enrich our knowledge base on quality, performance, patient experience, coding, practice management, acute and post-acute care, and other aspects of hospital medicine.

 

At our recent visit to HM16 in San Diego, a few members of our team attended sessions on post-acute care and value-based reimbursements. At the sessions, we learned of the importance of stressing quality and engaging sub-acute rehab facilities in meaningful ways so as to improve the quality of care in skilled nursing facilities and also help to decrease the length of stay from 30 days to closer to 15 days. 4C Medical Group has implemented many suggestions from these lectures and is in the process of transforming our post-acute-care teams.

 

I also serve as a member of the board of directors for 4C Medical Group, where my association with SHM has helped me give valuable input while we manage the care of over 20,000 patients in acute, sub-acute, and home-based teams as well as outpatient clinics. SHM provides its members with a platform to sharpen their leadership skills and enables members to build a strong network among fellow leaders, which helps us learn about and share best practices, which translates to better quality of care.

 

 

For example, a recent presentation by SHM member Dr. Jesse Theisen-Toupal on inpatient management of opioid use disorder was an eye-opener. Learning about harm-reduction strategies for opioid misuse during the presentation was very helpful to us, and we shared the suggestions with our hospitalist team.

 

Q: What inspired you to start an Arizona chapter in Scottsdale and purchase a group membership for your team?

 

A: At HM16, I met Debra Beach, manager of membership and outreach programs at SHM, and we discussed how our company can align with SHM and bring our hospitalists on board as members to provide them with a greater network of resources. I was surprised that Arizona did not have a dedicated SHM chapter. Phoenix, one of the U.S.’s largest metropolitan areas, has many large hospital systems employing and contracting thousands of hospitalists. I saw an opening for a great opportunity to take the lead on developing an SHM chapter in Arizona with the support of my 4C colleagues. After discussing this opportunity with other hospitalist groups in Arizona, we came to the conclusion that it would benefit not only our team at 4C but hospitalists statewide.

 

I am confident that the Arizona chapter of SHM will not only be successful but soon will be contributing nationally to the hospitalist movement. Moreover, SHM will help keep our members educated and informed about the upcoming changes as we transition to a pay-for-performance model of reimbursement and any other healthcare system changes still to come.

 

I believe in the famous Chinese proverb, “A journey of a thousand miles begins with a single step.” We have taken the first step in our hospitalist group, and without a doubt, SHM’s journey in the state of Arizona shall be a success story. All our members are excited with this new beginning.

 

Q: How do you see hospital medicine evolving over the next 20 years?

 

A: 2016 has already been designated as the “Year of the Hospitalist.” I will take it a step further and predict that the next decade will be a decade of hospital medicine. Inpatient care is transforming at a rapid pace, and we need a dedicated and well-trained stream of doctors who are specialists in managing hospitalized patients. Care of hospitalized patients was once fragmented and costly; now with hospitalists as captains of the ship, care can be delivered in more comprehensive, cost-effective ways with better quality and increased performance. The introduction of a separate specialist billing code for hospitalists by the CMS is a step in the right direction.

 

In the next few years, I would enjoy seeing a separate board for hospitalists with hospital medicine’s own specialty certification. The potential for hospital medicine’s continued growth is tremendous, and I look forward to being a part of its future. TH

 

 


 

Brett Radler is SHM’s communications specialist.

Editor’s note: As SHM celebrates the “Year of the Hospitalist,” we’re putting the spotlight on some of our most active members who are making substantial contributions to hospital medicine. You can get involved, too! Log on to www.hospitalmedicine.org/yoth for more information on how you can join the yearlong celebration and help SHM improve the care of hospitalized patients.

 

This month, The Hospitalist spotlights Vishal Verma, MD, medical director of the hospitalist program at 4C Medical Group in Scottsdale, Ariz. In addition to being an active SHM member and regular attendee at SHM meetings, Dr. Verma recently purchased a group membership for his hospitalist team. He also started an Arizona chapter of SHM, based on his positive experiences with SHM. He recently spoke with The Hospitalist to share his path to hospital medicine and his inspiration to expand the society’s reach in Arizona.

 

Question: How did you arrive at a career in hospital medicine?

 

 

Vishal Verma, MD, medical director of the hospitalist program at 4C Medical Group in Scottsdale, Ariz.

 

Answer: After finishing my medical school training at Kasturba Medical College in Manipal, India, I traveled to the United States to further my education and begin my internship and residency. I started my internship in internal medicine at a downtown Brooklyn, N.Y., hospital in 2006. Internship year, though often considered to be a hectic and laborious year, was when I learned for the first time how to care for hospitalized patients. I was chosen by the chief residents as intern of the month in my first month of training. This honor, and the experience of training in an inner-city hospital, further ignited my passion to practice medicine.

 

It was during my time as an intern and resident when I fully realized the critical role hospitalists play as the main coordinators of care and witnessed their influence on care outcomes. I later served as chief medical resident and was elected by my fellow residents as president of house staff. I was also elected as vice president of the Committee of Interns and Residents (CIR) and served on CIR’s National Executive Board, where I passionately advocated for my patients and fellow colleagues. Serving in various roles provided me with an in-depth knowledge of hospital medicine and helped me build it as my career.

 

Q: In your current role, how does your membership with SHM help you improve quality of patient care?

 

A: Our group consists of 14 hospitalists who serve in two community hospitals. Being a member of SHM for many years has been a rewarding experience as it keeps me informed about changes and advances in hospital medicine. Through the Journal of Hospital Medicine, regular webinars, and SHM conferences and annual meetings, SHM helps us enrich our knowledge base on quality, performance, patient experience, coding, practice management, acute and post-acute care, and other aspects of hospital medicine.

 

At our recent visit to HM16 in San Diego, a few members of our team attended sessions on post-acute care and value-based reimbursements. At the sessions, we learned of the importance of stressing quality and engaging sub-acute rehab facilities in meaningful ways so as to improve the quality of care in skilled nursing facilities and also help to decrease the length of stay from 30 days to closer to 15 days. 4C Medical Group has implemented many suggestions from these lectures and is in the process of transforming our post-acute-care teams.

 

I also serve as a member of the board of directors for 4C Medical Group, where my association with SHM has helped me give valuable input while we manage the care of over 20,000 patients in acute, sub-acute, and home-based teams as well as outpatient clinics. SHM provides its members with a platform to sharpen their leadership skills and enables members to build a strong network among fellow leaders, which helps us learn about and share best practices, which translates to better quality of care.

 

 

For example, a recent presentation by SHM member Dr. Jesse Theisen-Toupal on inpatient management of opioid use disorder was an eye-opener. Learning about harm-reduction strategies for opioid misuse during the presentation was very helpful to us, and we shared the suggestions with our hospitalist team.

 

Q: What inspired you to start an Arizona chapter in Scottsdale and purchase a group membership for your team?

 

A: At HM16, I met Debra Beach, manager of membership and outreach programs at SHM, and we discussed how our company can align with SHM and bring our hospitalists on board as members to provide them with a greater network of resources. I was surprised that Arizona did not have a dedicated SHM chapter. Phoenix, one of the U.S.’s largest metropolitan areas, has many large hospital systems employing and contracting thousands of hospitalists. I saw an opening for a great opportunity to take the lead on developing an SHM chapter in Arizona with the support of my 4C colleagues. After discussing this opportunity with other hospitalist groups in Arizona, we came to the conclusion that it would benefit not only our team at 4C but hospitalists statewide.

 

I am confident that the Arizona chapter of SHM will not only be successful but soon will be contributing nationally to the hospitalist movement. Moreover, SHM will help keep our members educated and informed about the upcoming changes as we transition to a pay-for-performance model of reimbursement and any other healthcare system changes still to come.

 

I believe in the famous Chinese proverb, “A journey of a thousand miles begins with a single step.” We have taken the first step in our hospitalist group, and without a doubt, SHM’s journey in the state of Arizona shall be a success story. All our members are excited with this new beginning.

 

Q: How do you see hospital medicine evolving over the next 20 years?

 

A: 2016 has already been designated as the “Year of the Hospitalist.” I will take it a step further and predict that the next decade will be a decade of hospital medicine. Inpatient care is transforming at a rapid pace, and we need a dedicated and well-trained stream of doctors who are specialists in managing hospitalized patients. Care of hospitalized patients was once fragmented and costly; now with hospitalists as captains of the ship, care can be delivered in more comprehensive, cost-effective ways with better quality and increased performance. The introduction of a separate specialist billing code for hospitalists by the CMS is a step in the right direction.

 

In the next few years, I would enjoy seeing a separate board for hospitalists with hospital medicine’s own specialty certification. The potential for hospital medicine’s continued growth is tremendous, and I look forward to being a part of its future. TH

 

 


 

Brett Radler is SHM’s communications specialist.

Issue
The Hospitalist - 2016(07)
Issue
The Hospitalist - 2016(07)
Publications
Publications
Article Type
Display Headline
Education, Networking Opportunities Inspire Arizona Hospitalist Vishal Verma, MD, to Start New SHM Chapter
Display Headline
Education, Networking Opportunities Inspire Arizona Hospitalist Vishal Verma, MD, to Start New SHM Chapter
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Use ProPublica
Hide sidebar & use full width
render the right sidebar.

Get up to Speed on the Latest in Pediatric Hospital Medicine

Article Type
Changed
Fri, 09/14/2018 - 12:03
Display Headline
Get up to Speed on the Latest in Pediatric Hospital Medicine

Pediatric Hospital Medicine 2016 (PHM16), the premier educational conference for pediatric hospitalists and all clinicians involved in the care of hospitalized children, will be held July 28–31 at the Hyatt Regency Chicago. PHM16 will provide in-depth review and challenge participants in various areas, including clinical practice, medical education, quality improvement, and professional development. Time will also be dedicated to networking and meeting with leaders in the field.

Register, book your hotel, and see the full course schedule at www.phmmeeting.org.


Brett Radler is SHM’s communications coordinator.

Issue
The Hospitalist - 2016(07)
Publications
Topics
Sections

Pediatric Hospital Medicine 2016 (PHM16), the premier educational conference for pediatric hospitalists and all clinicians involved in the care of hospitalized children, will be held July 28–31 at the Hyatt Regency Chicago. PHM16 will provide in-depth review and challenge participants in various areas, including clinical practice, medical education, quality improvement, and professional development. Time will also be dedicated to networking and meeting with leaders in the field.

Register, book your hotel, and see the full course schedule at www.phmmeeting.org.


Brett Radler is SHM’s communications coordinator.

Pediatric Hospital Medicine 2016 (PHM16), the premier educational conference for pediatric hospitalists and all clinicians involved in the care of hospitalized children, will be held July 28–31 at the Hyatt Regency Chicago. PHM16 will provide in-depth review and challenge participants in various areas, including clinical practice, medical education, quality improvement, and professional development. Time will also be dedicated to networking and meeting with leaders in the field.

Register, book your hotel, and see the full course schedule at www.phmmeeting.org.


Brett Radler is SHM’s communications coordinator.

Issue
The Hospitalist - 2016(07)
Issue
The Hospitalist - 2016(07)
Publications
Publications
Topics
Article Type
Display Headline
Get up to Speed on the Latest in Pediatric Hospital Medicine
Display Headline
Get up to Speed on the Latest in Pediatric Hospital Medicine
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)

Team identifies potential therapeutic target for AML

Article Type
Changed
Tue, 07/05/2016 - 05:00
Display Headline
Team identifies potential therapeutic target for AML

Micrograph showing AML

New research suggests that E proteins and their antagonists, Id proteins, can play key roles in acute myeloid leukemia (AML).

The study showed that overexpression of the Id2 protein or knockdown of the E2-2 protein can suppress both mixed-lineage leukemia (MLL)-rearranged AML and t(8;21) AML.

These findings, published in Cancer Cell, suggest the Id2/E-protein axis may be a promising therapeutic target for AML.

“There is a particularly urgent need for new, targeted, drug-based therapies for AML, and with every discovery of what’s driving the cancer, we take a step closer to achieving that,” said study author Ricky Johnstone, PhD, of Peter MacCallum Cancer Centre in Melbourne, Victoria, Australia.

“What we found in this case was the suppression of Id2 protein plays an important, and previously unrecognized, role in allowing MLL re-arranged AML cancer cells to take hold and spread. Drugs that influence levels of this protein, or stop it being suppressed by the cancer, could provide a much-needed new avenue to combatting this disease.”

The researchers first found that Id2 regulates leukemia stem cell (LSC) potential. Specifically, low Id2 expression is associated with LSC enrichment, and Id2 overexpression hinders leukemia development.

Further investigation revealed that the fusion protein MLL-AF9 suppresses Id2 and activates E2-2 expression, while E2-2 depletion phenocopies Id2 overexpression in MLL-AF9-AML cells.

The team also found that Id2’s tumor-suppressive function is conserved in t(8;21) AML. And low expression of Id2 and its associated gene signature are associated with poor prognosis in patients with MLL-rearranged AML or t(8;21) AML.

Publications
Topics

Micrograph showing AML

New research suggests that E proteins and their antagonists, Id proteins, can play key roles in acute myeloid leukemia (AML).

The study showed that overexpression of the Id2 protein or knockdown of the E2-2 protein can suppress both mixed-lineage leukemia (MLL)-rearranged AML and t(8;21) AML.

These findings, published in Cancer Cell, suggest the Id2/E-protein axis may be a promising therapeutic target for AML.

“There is a particularly urgent need for new, targeted, drug-based therapies for AML, and with every discovery of what’s driving the cancer, we take a step closer to achieving that,” said study author Ricky Johnstone, PhD, of Peter MacCallum Cancer Centre in Melbourne, Victoria, Australia.

“What we found in this case was the suppression of Id2 protein plays an important, and previously unrecognized, role in allowing MLL re-arranged AML cancer cells to take hold and spread. Drugs that influence levels of this protein, or stop it being suppressed by the cancer, could provide a much-needed new avenue to combatting this disease.”

The researchers first found that Id2 regulates leukemia stem cell (LSC) potential. Specifically, low Id2 expression is associated with LSC enrichment, and Id2 overexpression hinders leukemia development.

Further investigation revealed that the fusion protein MLL-AF9 suppresses Id2 and activates E2-2 expression, while E2-2 depletion phenocopies Id2 overexpression in MLL-AF9-AML cells.

The team also found that Id2’s tumor-suppressive function is conserved in t(8;21) AML. And low expression of Id2 and its associated gene signature are associated with poor prognosis in patients with MLL-rearranged AML or t(8;21) AML.

Micrograph showing AML

New research suggests that E proteins and their antagonists, Id proteins, can play key roles in acute myeloid leukemia (AML).

The study showed that overexpression of the Id2 protein or knockdown of the E2-2 protein can suppress both mixed-lineage leukemia (MLL)-rearranged AML and t(8;21) AML.

These findings, published in Cancer Cell, suggest the Id2/E-protein axis may be a promising therapeutic target for AML.

“There is a particularly urgent need for new, targeted, drug-based therapies for AML, and with every discovery of what’s driving the cancer, we take a step closer to achieving that,” said study author Ricky Johnstone, PhD, of Peter MacCallum Cancer Centre in Melbourne, Victoria, Australia.

“What we found in this case was the suppression of Id2 protein plays an important, and previously unrecognized, role in allowing MLL re-arranged AML cancer cells to take hold and spread. Drugs that influence levels of this protein, or stop it being suppressed by the cancer, could provide a much-needed new avenue to combatting this disease.”

The researchers first found that Id2 regulates leukemia stem cell (LSC) potential. Specifically, low Id2 expression is associated with LSC enrichment, and Id2 overexpression hinders leukemia development.

Further investigation revealed that the fusion protein MLL-AF9 suppresses Id2 and activates E2-2 expression, while E2-2 depletion phenocopies Id2 overexpression in MLL-AF9-AML cells.

The team also found that Id2’s tumor-suppressive function is conserved in t(8;21) AML. And low expression of Id2 and its associated gene signature are associated with poor prognosis in patients with MLL-rearranged AML or t(8;21) AML.

Publications
Publications
Topics
Article Type
Display Headline
Team identifies potential therapeutic target for AML
Display Headline
Team identifies potential therapeutic target for AML
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica

Caregiver Partners in Care Transitions

Article Type
Changed
Mon, 01/02/2017 - 19:34
Display Headline
Family caregivers as partners in care transitions: The caregiver advise record and enable act

Under the national leadership of AARP, 42 states and territories have introduced the Caregiver Advise Record and Enable (CARE) Act, 32 have passed it, and the following 30 have enacted it into law: Arkansas, California, Colorado, Connecticut, District of Columbia, Illinois, Indiana, Louisiana, Maine, Maryland, Michigan, Minnesota, Mississippi, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, Utah, Virginia, Virgin Islands, West Virginia, Washington and Wyoming (as of June 6, 2016). The CARE Act requires hospitals to: (1) record the name of the family caregiver in the medical record, (2) inform the family caregiver when the patient is to be discharged, and (3) provide the family caregiver with education and instruction on the medical tasks that he or she will need to perform for the patient upon return home.[1, 2]

The family caregiver is to be identified by the patient. Because the patient is the source of the information, Health Insurance Portability and Accountability Act concerns are minimal. A family caregiver need not be related to the patient by blood or marriage; a friend, neighbor, partner, or paid caregiver could be identified by the patient as serving in this role. If the patient does not identify a family caregiver (due to the absence of such an individual, concern for potential burden on a loved one, desire for confidentiality, transient or progressive cognitive impairment, or other reasons), this also needs to be documented, though the additional provisions of the CARE Act would not be applicable. As some states have made additions or individual modifications to the CARE Act, the reader is encouraged to learn more about state‐specific differences that might impact implementation.[2, 3]

The impetus for the CARE Act emerges from challenges faced by both family caregivers and healthcare professionals. The 3 care elements included in the Act appear to have considerable face validity for what would constitute good transitional care. To further explore why this is necessary, we need to begin by asking why are these 3 care elements not routine, and why did an advocacy organization resort to a legislative solution to formally recognize and include family caregivers in discharge preparation?

Family caregivers, when able and willing, often play an instrumental role in the care of their loved ones, particularly during the vulnerable time of transitions out of the hospital.[4, 5] They are often the first line of defense for detecting lapses in quality or safety as care is transitioned from the hospital. Family caregivers frequently take on a primary or secondary role in operationalizing and executing the discharge plan. Nearly half of family caregivers perform skilled medical or nursing tasks for their loved ones (eg, wound care, injections, complex medication management, operating specialized medical equipment) often with insufficient assistance or training from healthcare professionals.[6]

Lack of sufficient time might be a major reason why the 3 care elements identified in the CARE Act are not routinely addressed by the discharging team, which may include hospitalists, nurses, pharmacists, social workers, and other clinicians. However, there may be other reasons as well, including a lack of knowledge, confidence, or tools for how to best prepare the patient and family caregiver. This is compounded by the absence of routine feedback loops for gauging the effectiveness of discharge preparation beyond a patient's readmission to the same facility. If hospital‐based clinicians were asked to rank order their daily tasks from greatest sense of professional gratification to lowest, discharge preparation would likely appear toward the bottom of the list.[7, 8]

Meanwhile, hospitalists and hospital clinical leaders are struggling to keep pace with a confluence of new demands that include value‐based purchasing initiatives and population health efforts, to name but a few. Although current Centers for Medicare and Medicaid Services' (CMS) Hospital Conditions of Participation for Discharge Planning do not require recognition or preparation of family caregivers, CMS' newly proposed revisions emphasize better preparation of family caregivers to be active partners upon hospital discharge.[9] Thus, although it might be reflexive to view the CARE Act in isolation as yet 1 more initiative requiring new effort and resources to address, widening the lens may confirm that the contributions of family caregivers are integral and aligned across nearly all efforts aimed at promoting greater value, and in this light could be viewed as complementary rather than competitive.

Innovation or new resources may be needed to implement the CARE Act. In the absence of a step‐by‐step user's guide, hospitals may wish to take advantage of valuable publicly available resources that encourage more effective collaboration between family caregivers and healthcare professionals (Table 1).

Selected Websites That Promote the Role of Family Caregivers in Discharge Preparation.
Organization (URL) Relevant Resources for Implementing the CARE Act
  • NOTE: Abbreviations: BOOST, Better Outcomes by Optimizing Safe Transitions; CARE, Caregiver Advise Record and Enable; FCAT, Family Caregiver Activation in Transitions; RED, Re‐Engineered Discharge.

AARP (www.aarp.org/nolongeralone) Family caregiver video guides to managing medications
Alzheimer's Association (http://www.alz.org/documents/national/topicsheet_hospitaldischarge.pdf) Addresses the unique needs of persons with dementia:
Ensuring that all treating physicians and medical professions are aware of the diagnosis of Alzheimer's or other dementia
If the person with dementia has difficulty communicating, the family caregiver may help medical staff by offering suggestions about what the person may want or need
The family caregiver may alert medical staff of triggers that may cause unpredictable behavior
Considerations for discharge to a residential facility or assisted living
Care Transitions Program (http://caretransitions.org) Provides a wide range of resources for professionals, patients, and family caregivers:
The FCAT tool
Hospital discharge checklist
Tips for managing care at home
Tips for recognizing and responding to red flags
Tips for effective medication management
Institute for Patient‐ and Family‐Centered Care (http://www.ipfcc.org/advance/Advisory_Councils.pdf) Offers practical advice for establishing patient and family advisory councils:
Qualities and skills of patient/family advisors
Recruitment
Development of bylaws
Meeting schedule
National Transitions of Care Coalition (http://www.ntocc.org) Provides a wide variety of tools and resources:
Taking Care of MY Health Care developed as a guide to help patients and family caregivers feel better prepared
My Medicine List helps patients and family caregivers gather important information about medications
Cultural competence tool provides strategies and resources to enhance professionals' capacity to deliver culturally competent services to patients and family caregivers during transitions of care
Next Step in Care (http://www.nextstepincare.org) The most comprehensive site supporting both family caregivers and health professionals; includes:
A toolkit for working with family caregivers
HIPAA considerations for family caregivers
Tips on identifying the family caregiver
Assessment tool for family caregivers' needs
Tips for referring patients and family caregivers to community‐based services

Project BOOST(http://www.hospitalmedicine.org/about_shm/webformz/form_wfz_imptk_boost.aspx?iFormSubmissionKey=21301dd3-5c5f-4a68-a5e7-15fa1d0c01eb)

Extensive toolkit includes:
Self‐assessment questions to promote planning for how to include family
Return on investment calculator that includes patient as well as family satisfaction
Teach back approach applicable to patient and family caregivers
Patient and family caregiver preparedness tool

Project RED(https://www.bu.edu/fammed/projectred/)

Extensive toolkit includes:
Five steps to integrating family caregivers into the discharge plan
Understanding and enhancing the role of family caregivers in RED

Operationalizing the CARE Act may initially appear simple but in practice will not be easy. The first care element focuses on identifying the family caregiver. Next, Step in Care offers a practical guide for how to identify the family caregiver in a busy hospital environment (Table 1). The guide advises health professionals on how to identify the person most likely to assume responsibility for care after discharge by asking a series of questions: Who assists you at home? Who do you call in case of emergency? Who helps with medications or doctor appointments? The guide cautions health professionals not to assume that individuals encountered at the patient's bedside are necessarily the family caregivers. They may be covering for the family caregiver, who has other duties (eg, job, child care).

The second CARE Act element entails informing the family caregiver when the patient will be discharged. At present there is no standardization of this practice. Many hospitals conduct interdisciplinary rounds, during which a discharge date is frequently estimated. A designated member of the inpatient team (eg, primary nurse, social worker, care manager) might be tasked with notifying the family caregiver of this estimated date (either in person, by telephone, or using other approved mode[s] of communication). Ideally, this notification should be conveyed as soon as the inpatient care team can foresee a discharge date, as it would be preferable to give the family caregiver an estimate that turns out to be a day or 2 off and needs to be revised than to inform the family caregiver at the last minute. The white board in the patient's room may serve as a reminder to both the patient and family caregiver as well as to other members of the inpatient care team.

The third CARE Act element could be facilitated with the Family Caregiver Activation in Transitions (FCAT) tool, a self‐efficacy measure of transition specific tasks. The FCAT tool is designed to facilitate more productive interactions and guide the care team in understanding what common transition‐related areas family caregivers would like to feel more prepared for or confident with. The FCAT tool can be administered by a health professional or self‐administered by a family caregiver and takes approximately 2 minutes to complete[10] (Table 1).

Hospital leaders might consider creating an interdisciplinary team charged with facilitating the implementation of the CARE Act. Specifically, this team might develop guidelines and serve as a forum whereby clinicians might share particularly challenging cases. Similarly, for ongoing input and suggestions for how to further improve all aspects of hospital care, including the discharge experience, hospitals are encouraged to form and foster patient and family advisory councils (Table 1).

Finally, when it comes to improving the hospital discharge experience for family caregivers, there is no us and them. Despite our professional advantages, each of has had or will likely have an opportunity to overcome the many gaps in hospital discharge planning, not just as healthcare professionals but also in our roles as adult children, spouses, and parents. In this regard, we are all invested in improving the discharge experience.

Disclosures

Support for this work was provided by the Gordon and Betty Moore Foundation. The sponsor had no role in the preparation, review, or approval of this article. The author reports no conflicts of interest.

Files
References
  1. Ryan E. One caregiver's regret: how the CARE Act could have helped. Available at: http://blog.aarp.org/2016/04/18/one‐caregivers‐regret‐how‐the‐care‐act‐could‐have‐helped. Published April 18, 2016. Accessed June 7, 2016.
  2. Reinhard S, Ryan E. Stepping up to support family caregivers. Available at: http://blog.aarp.org/2016/06/07/stepping‐up‐to‐support‐family‐caregivers. Published June 7, 2016. Accessed June 7, 2016.
  3. Martinez JC. New state laws support millions of Americans who minister to aging relatives and form the backbone of the nation's long‐term care system. Available at: http://www.ncsl.org/research/human‐services/helping‐the‐helpers.aspx. Published February 1, 2015. Accessed June 7, 2016.
  4. Coleman EA, Roman SP. Family caregivers' experiences during transitions out of the hospital. J Healthc Qual. 2015;37:1221.
  5. Gillick MR. The critical role of caregivers in achieving patient‐centered care. JAMA. 2013;310:575576.
  6. Reinhard SC, Levine C, Samis S. Home alone: family caregivers providing complex chronic care, 2012. Available at: http://www.aarp.org/home‐family/caregiving/info‐10‐2012/home‐alone‐family‐caregivers‐providing‐complex‐chronic‐care.html. Accessed June 7, 2016.
  7. Halasyamani L, Kripalani S, Coleman EA, et al. Transition of care for hospitalized elderly patients—development of a discharge checklist for hospitalists. J Hosp Med. 2006;1:354360.
  8. Greysen SR, Schiliro D, Horwitz LI, Curry L, Bradley EH. Out of sight, out of mind: housestaff perceptions of quality‐limiting factors in discharge care at teaching hospitals. J Hosp Med. 2012:7:376381.
  9. Centers for Medicare and Medicaid Services. Proposed revisions to requirements for discharge planning for hospitals, critical access hospitals, and home health agencies. Fed Regist. 2015;80:6812568155.
  10. Coleman EA, Ground KL, Maul A. The Family Caregiver Activation in Transitions tool (FCAT): a new measure of family caregiver self‐efficacy. Jt Comm J Qual Patient Saf. 2015;41:502507.
Article PDF
Issue
Journal of Hospital Medicine - 11(12)
Page Number
883-885
Sections
Files
Files
Article PDF
Article PDF

Under the national leadership of AARP, 42 states and territories have introduced the Caregiver Advise Record and Enable (CARE) Act, 32 have passed it, and the following 30 have enacted it into law: Arkansas, California, Colorado, Connecticut, District of Columbia, Illinois, Indiana, Louisiana, Maine, Maryland, Michigan, Minnesota, Mississippi, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, Utah, Virginia, Virgin Islands, West Virginia, Washington and Wyoming (as of June 6, 2016). The CARE Act requires hospitals to: (1) record the name of the family caregiver in the medical record, (2) inform the family caregiver when the patient is to be discharged, and (3) provide the family caregiver with education and instruction on the medical tasks that he or she will need to perform for the patient upon return home.[1, 2]

The family caregiver is to be identified by the patient. Because the patient is the source of the information, Health Insurance Portability and Accountability Act concerns are minimal. A family caregiver need not be related to the patient by blood or marriage; a friend, neighbor, partner, or paid caregiver could be identified by the patient as serving in this role. If the patient does not identify a family caregiver (due to the absence of such an individual, concern for potential burden on a loved one, desire for confidentiality, transient or progressive cognitive impairment, or other reasons), this also needs to be documented, though the additional provisions of the CARE Act would not be applicable. As some states have made additions or individual modifications to the CARE Act, the reader is encouraged to learn more about state‐specific differences that might impact implementation.[2, 3]

The impetus for the CARE Act emerges from challenges faced by both family caregivers and healthcare professionals. The 3 care elements included in the Act appear to have considerable face validity for what would constitute good transitional care. To further explore why this is necessary, we need to begin by asking why are these 3 care elements not routine, and why did an advocacy organization resort to a legislative solution to formally recognize and include family caregivers in discharge preparation?

Family caregivers, when able and willing, often play an instrumental role in the care of their loved ones, particularly during the vulnerable time of transitions out of the hospital.[4, 5] They are often the first line of defense for detecting lapses in quality or safety as care is transitioned from the hospital. Family caregivers frequently take on a primary or secondary role in operationalizing and executing the discharge plan. Nearly half of family caregivers perform skilled medical or nursing tasks for their loved ones (eg, wound care, injections, complex medication management, operating specialized medical equipment) often with insufficient assistance or training from healthcare professionals.[6]

Lack of sufficient time might be a major reason why the 3 care elements identified in the CARE Act are not routinely addressed by the discharging team, which may include hospitalists, nurses, pharmacists, social workers, and other clinicians. However, there may be other reasons as well, including a lack of knowledge, confidence, or tools for how to best prepare the patient and family caregiver. This is compounded by the absence of routine feedback loops for gauging the effectiveness of discharge preparation beyond a patient's readmission to the same facility. If hospital‐based clinicians were asked to rank order their daily tasks from greatest sense of professional gratification to lowest, discharge preparation would likely appear toward the bottom of the list.[7, 8]

Meanwhile, hospitalists and hospital clinical leaders are struggling to keep pace with a confluence of new demands that include value‐based purchasing initiatives and population health efforts, to name but a few. Although current Centers for Medicare and Medicaid Services' (CMS) Hospital Conditions of Participation for Discharge Planning do not require recognition or preparation of family caregivers, CMS' newly proposed revisions emphasize better preparation of family caregivers to be active partners upon hospital discharge.[9] Thus, although it might be reflexive to view the CARE Act in isolation as yet 1 more initiative requiring new effort and resources to address, widening the lens may confirm that the contributions of family caregivers are integral and aligned across nearly all efforts aimed at promoting greater value, and in this light could be viewed as complementary rather than competitive.

Innovation or new resources may be needed to implement the CARE Act. In the absence of a step‐by‐step user's guide, hospitals may wish to take advantage of valuable publicly available resources that encourage more effective collaboration between family caregivers and healthcare professionals (Table 1).

Selected Websites That Promote the Role of Family Caregivers in Discharge Preparation.
Organization (URL) Relevant Resources for Implementing the CARE Act
  • NOTE: Abbreviations: BOOST, Better Outcomes by Optimizing Safe Transitions; CARE, Caregiver Advise Record and Enable; FCAT, Family Caregiver Activation in Transitions; RED, Re‐Engineered Discharge.

AARP (www.aarp.org/nolongeralone) Family caregiver video guides to managing medications
Alzheimer's Association (http://www.alz.org/documents/national/topicsheet_hospitaldischarge.pdf) Addresses the unique needs of persons with dementia:
Ensuring that all treating physicians and medical professions are aware of the diagnosis of Alzheimer's or other dementia
If the person with dementia has difficulty communicating, the family caregiver may help medical staff by offering suggestions about what the person may want or need
The family caregiver may alert medical staff of triggers that may cause unpredictable behavior
Considerations for discharge to a residential facility or assisted living
Care Transitions Program (http://caretransitions.org) Provides a wide range of resources for professionals, patients, and family caregivers:
The FCAT tool
Hospital discharge checklist
Tips for managing care at home
Tips for recognizing and responding to red flags
Tips for effective medication management
Institute for Patient‐ and Family‐Centered Care (http://www.ipfcc.org/advance/Advisory_Councils.pdf) Offers practical advice for establishing patient and family advisory councils:
Qualities and skills of patient/family advisors
Recruitment
Development of bylaws
Meeting schedule
National Transitions of Care Coalition (http://www.ntocc.org) Provides a wide variety of tools and resources:
Taking Care of MY Health Care developed as a guide to help patients and family caregivers feel better prepared
My Medicine List helps patients and family caregivers gather important information about medications
Cultural competence tool provides strategies and resources to enhance professionals' capacity to deliver culturally competent services to patients and family caregivers during transitions of care
Next Step in Care (http://www.nextstepincare.org) The most comprehensive site supporting both family caregivers and health professionals; includes:
A toolkit for working with family caregivers
HIPAA considerations for family caregivers
Tips on identifying the family caregiver
Assessment tool for family caregivers' needs
Tips for referring patients and family caregivers to community‐based services

Project BOOST(http://www.hospitalmedicine.org/about_shm/webformz/form_wfz_imptk_boost.aspx?iFormSubmissionKey=21301dd3-5c5f-4a68-a5e7-15fa1d0c01eb)

Extensive toolkit includes:
Self‐assessment questions to promote planning for how to include family
Return on investment calculator that includes patient as well as family satisfaction
Teach back approach applicable to patient and family caregivers
Patient and family caregiver preparedness tool

Project RED(https://www.bu.edu/fammed/projectred/)

Extensive toolkit includes:
Five steps to integrating family caregivers into the discharge plan
Understanding and enhancing the role of family caregivers in RED

Operationalizing the CARE Act may initially appear simple but in practice will not be easy. The first care element focuses on identifying the family caregiver. Next, Step in Care offers a practical guide for how to identify the family caregiver in a busy hospital environment (Table 1). The guide advises health professionals on how to identify the person most likely to assume responsibility for care after discharge by asking a series of questions: Who assists you at home? Who do you call in case of emergency? Who helps with medications or doctor appointments? The guide cautions health professionals not to assume that individuals encountered at the patient's bedside are necessarily the family caregivers. They may be covering for the family caregiver, who has other duties (eg, job, child care).

The second CARE Act element entails informing the family caregiver when the patient will be discharged. At present there is no standardization of this practice. Many hospitals conduct interdisciplinary rounds, during which a discharge date is frequently estimated. A designated member of the inpatient team (eg, primary nurse, social worker, care manager) might be tasked with notifying the family caregiver of this estimated date (either in person, by telephone, or using other approved mode[s] of communication). Ideally, this notification should be conveyed as soon as the inpatient care team can foresee a discharge date, as it would be preferable to give the family caregiver an estimate that turns out to be a day or 2 off and needs to be revised than to inform the family caregiver at the last minute. The white board in the patient's room may serve as a reminder to both the patient and family caregiver as well as to other members of the inpatient care team.

The third CARE Act element could be facilitated with the Family Caregiver Activation in Transitions (FCAT) tool, a self‐efficacy measure of transition specific tasks. The FCAT tool is designed to facilitate more productive interactions and guide the care team in understanding what common transition‐related areas family caregivers would like to feel more prepared for or confident with. The FCAT tool can be administered by a health professional or self‐administered by a family caregiver and takes approximately 2 minutes to complete[10] (Table 1).

Hospital leaders might consider creating an interdisciplinary team charged with facilitating the implementation of the CARE Act. Specifically, this team might develop guidelines and serve as a forum whereby clinicians might share particularly challenging cases. Similarly, for ongoing input and suggestions for how to further improve all aspects of hospital care, including the discharge experience, hospitals are encouraged to form and foster patient and family advisory councils (Table 1).

Finally, when it comes to improving the hospital discharge experience for family caregivers, there is no us and them. Despite our professional advantages, each of has had or will likely have an opportunity to overcome the many gaps in hospital discharge planning, not just as healthcare professionals but also in our roles as adult children, spouses, and parents. In this regard, we are all invested in improving the discharge experience.

Disclosures

Support for this work was provided by the Gordon and Betty Moore Foundation. The sponsor had no role in the preparation, review, or approval of this article. The author reports no conflicts of interest.

Under the national leadership of AARP, 42 states and territories have introduced the Caregiver Advise Record and Enable (CARE) Act, 32 have passed it, and the following 30 have enacted it into law: Arkansas, California, Colorado, Connecticut, District of Columbia, Illinois, Indiana, Louisiana, Maine, Maryland, Michigan, Minnesota, Mississippi, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, Utah, Virginia, Virgin Islands, West Virginia, Washington and Wyoming (as of June 6, 2016). The CARE Act requires hospitals to: (1) record the name of the family caregiver in the medical record, (2) inform the family caregiver when the patient is to be discharged, and (3) provide the family caregiver with education and instruction on the medical tasks that he or she will need to perform for the patient upon return home.[1, 2]

The family caregiver is to be identified by the patient. Because the patient is the source of the information, Health Insurance Portability and Accountability Act concerns are minimal. A family caregiver need not be related to the patient by blood or marriage; a friend, neighbor, partner, or paid caregiver could be identified by the patient as serving in this role. If the patient does not identify a family caregiver (due to the absence of such an individual, concern for potential burden on a loved one, desire for confidentiality, transient or progressive cognitive impairment, or other reasons), this also needs to be documented, though the additional provisions of the CARE Act would not be applicable. As some states have made additions or individual modifications to the CARE Act, the reader is encouraged to learn more about state‐specific differences that might impact implementation.[2, 3]

The impetus for the CARE Act emerges from challenges faced by both family caregivers and healthcare professionals. The 3 care elements included in the Act appear to have considerable face validity for what would constitute good transitional care. To further explore why this is necessary, we need to begin by asking why are these 3 care elements not routine, and why did an advocacy organization resort to a legislative solution to formally recognize and include family caregivers in discharge preparation?

Family caregivers, when able and willing, often play an instrumental role in the care of their loved ones, particularly during the vulnerable time of transitions out of the hospital.[4, 5] They are often the first line of defense for detecting lapses in quality or safety as care is transitioned from the hospital. Family caregivers frequently take on a primary or secondary role in operationalizing and executing the discharge plan. Nearly half of family caregivers perform skilled medical or nursing tasks for their loved ones (eg, wound care, injections, complex medication management, operating specialized medical equipment) often with insufficient assistance or training from healthcare professionals.[6]

Lack of sufficient time might be a major reason why the 3 care elements identified in the CARE Act are not routinely addressed by the discharging team, which may include hospitalists, nurses, pharmacists, social workers, and other clinicians. However, there may be other reasons as well, including a lack of knowledge, confidence, or tools for how to best prepare the patient and family caregiver. This is compounded by the absence of routine feedback loops for gauging the effectiveness of discharge preparation beyond a patient's readmission to the same facility. If hospital‐based clinicians were asked to rank order their daily tasks from greatest sense of professional gratification to lowest, discharge preparation would likely appear toward the bottom of the list.[7, 8]

Meanwhile, hospitalists and hospital clinical leaders are struggling to keep pace with a confluence of new demands that include value‐based purchasing initiatives and population health efforts, to name but a few. Although current Centers for Medicare and Medicaid Services' (CMS) Hospital Conditions of Participation for Discharge Planning do not require recognition or preparation of family caregivers, CMS' newly proposed revisions emphasize better preparation of family caregivers to be active partners upon hospital discharge.[9] Thus, although it might be reflexive to view the CARE Act in isolation as yet 1 more initiative requiring new effort and resources to address, widening the lens may confirm that the contributions of family caregivers are integral and aligned across nearly all efforts aimed at promoting greater value, and in this light could be viewed as complementary rather than competitive.

Innovation or new resources may be needed to implement the CARE Act. In the absence of a step‐by‐step user's guide, hospitals may wish to take advantage of valuable publicly available resources that encourage more effective collaboration between family caregivers and healthcare professionals (Table 1).

Selected Websites That Promote the Role of Family Caregivers in Discharge Preparation.
Organization (URL) Relevant Resources for Implementing the CARE Act
  • NOTE: Abbreviations: BOOST, Better Outcomes by Optimizing Safe Transitions; CARE, Caregiver Advise Record and Enable; FCAT, Family Caregiver Activation in Transitions; RED, Re‐Engineered Discharge.

AARP (www.aarp.org/nolongeralone) Family caregiver video guides to managing medications
Alzheimer's Association (http://www.alz.org/documents/national/topicsheet_hospitaldischarge.pdf) Addresses the unique needs of persons with dementia:
Ensuring that all treating physicians and medical professions are aware of the diagnosis of Alzheimer's or other dementia
If the person with dementia has difficulty communicating, the family caregiver may help medical staff by offering suggestions about what the person may want or need
The family caregiver may alert medical staff of triggers that may cause unpredictable behavior
Considerations for discharge to a residential facility or assisted living
Care Transitions Program (http://caretransitions.org) Provides a wide range of resources for professionals, patients, and family caregivers:
The FCAT tool
Hospital discharge checklist
Tips for managing care at home
Tips for recognizing and responding to red flags
Tips for effective medication management
Institute for Patient‐ and Family‐Centered Care (http://www.ipfcc.org/advance/Advisory_Councils.pdf) Offers practical advice for establishing patient and family advisory councils:
Qualities and skills of patient/family advisors
Recruitment
Development of bylaws
Meeting schedule
National Transitions of Care Coalition (http://www.ntocc.org) Provides a wide variety of tools and resources:
Taking Care of MY Health Care developed as a guide to help patients and family caregivers feel better prepared
My Medicine List helps patients and family caregivers gather important information about medications
Cultural competence tool provides strategies and resources to enhance professionals' capacity to deliver culturally competent services to patients and family caregivers during transitions of care
Next Step in Care (http://www.nextstepincare.org) The most comprehensive site supporting both family caregivers and health professionals; includes:
A toolkit for working with family caregivers
HIPAA considerations for family caregivers
Tips on identifying the family caregiver
Assessment tool for family caregivers' needs
Tips for referring patients and family caregivers to community‐based services

Project BOOST(http://www.hospitalmedicine.org/about_shm/webformz/form_wfz_imptk_boost.aspx?iFormSubmissionKey=21301dd3-5c5f-4a68-a5e7-15fa1d0c01eb)

Extensive toolkit includes:
Self‐assessment questions to promote planning for how to include family
Return on investment calculator that includes patient as well as family satisfaction
Teach back approach applicable to patient and family caregivers
Patient and family caregiver preparedness tool

Project RED(https://www.bu.edu/fammed/projectred/)

Extensive toolkit includes:
Five steps to integrating family caregivers into the discharge plan
Understanding and enhancing the role of family caregivers in RED

Operationalizing the CARE Act may initially appear simple but in practice will not be easy. The first care element focuses on identifying the family caregiver. Next, Step in Care offers a practical guide for how to identify the family caregiver in a busy hospital environment (Table 1). The guide advises health professionals on how to identify the person most likely to assume responsibility for care after discharge by asking a series of questions: Who assists you at home? Who do you call in case of emergency? Who helps with medications or doctor appointments? The guide cautions health professionals not to assume that individuals encountered at the patient's bedside are necessarily the family caregivers. They may be covering for the family caregiver, who has other duties (eg, job, child care).

The second CARE Act element entails informing the family caregiver when the patient will be discharged. At present there is no standardization of this practice. Many hospitals conduct interdisciplinary rounds, during which a discharge date is frequently estimated. A designated member of the inpatient team (eg, primary nurse, social worker, care manager) might be tasked with notifying the family caregiver of this estimated date (either in person, by telephone, or using other approved mode[s] of communication). Ideally, this notification should be conveyed as soon as the inpatient care team can foresee a discharge date, as it would be preferable to give the family caregiver an estimate that turns out to be a day or 2 off and needs to be revised than to inform the family caregiver at the last minute. The white board in the patient's room may serve as a reminder to both the patient and family caregiver as well as to other members of the inpatient care team.

The third CARE Act element could be facilitated with the Family Caregiver Activation in Transitions (FCAT) tool, a self‐efficacy measure of transition specific tasks. The FCAT tool is designed to facilitate more productive interactions and guide the care team in understanding what common transition‐related areas family caregivers would like to feel more prepared for or confident with. The FCAT tool can be administered by a health professional or self‐administered by a family caregiver and takes approximately 2 minutes to complete[10] (Table 1).

Hospital leaders might consider creating an interdisciplinary team charged with facilitating the implementation of the CARE Act. Specifically, this team might develop guidelines and serve as a forum whereby clinicians might share particularly challenging cases. Similarly, for ongoing input and suggestions for how to further improve all aspects of hospital care, including the discharge experience, hospitals are encouraged to form and foster patient and family advisory councils (Table 1).

Finally, when it comes to improving the hospital discharge experience for family caregivers, there is no us and them. Despite our professional advantages, each of has had or will likely have an opportunity to overcome the many gaps in hospital discharge planning, not just as healthcare professionals but also in our roles as adult children, spouses, and parents. In this regard, we are all invested in improving the discharge experience.

Disclosures

Support for this work was provided by the Gordon and Betty Moore Foundation. The sponsor had no role in the preparation, review, or approval of this article. The author reports no conflicts of interest.

References
  1. Ryan E. One caregiver's regret: how the CARE Act could have helped. Available at: http://blog.aarp.org/2016/04/18/one‐caregivers‐regret‐how‐the‐care‐act‐could‐have‐helped. Published April 18, 2016. Accessed June 7, 2016.
  2. Reinhard S, Ryan E. Stepping up to support family caregivers. Available at: http://blog.aarp.org/2016/06/07/stepping‐up‐to‐support‐family‐caregivers. Published June 7, 2016. Accessed June 7, 2016.
  3. Martinez JC. New state laws support millions of Americans who minister to aging relatives and form the backbone of the nation's long‐term care system. Available at: http://www.ncsl.org/research/human‐services/helping‐the‐helpers.aspx. Published February 1, 2015. Accessed June 7, 2016.
  4. Coleman EA, Roman SP. Family caregivers' experiences during transitions out of the hospital. J Healthc Qual. 2015;37:1221.
  5. Gillick MR. The critical role of caregivers in achieving patient‐centered care. JAMA. 2013;310:575576.
  6. Reinhard SC, Levine C, Samis S. Home alone: family caregivers providing complex chronic care, 2012. Available at: http://www.aarp.org/home‐family/caregiving/info‐10‐2012/home‐alone‐family‐caregivers‐providing‐complex‐chronic‐care.html. Accessed June 7, 2016.
  7. Halasyamani L, Kripalani S, Coleman EA, et al. Transition of care for hospitalized elderly patients—development of a discharge checklist for hospitalists. J Hosp Med. 2006;1:354360.
  8. Greysen SR, Schiliro D, Horwitz LI, Curry L, Bradley EH. Out of sight, out of mind: housestaff perceptions of quality‐limiting factors in discharge care at teaching hospitals. J Hosp Med. 2012:7:376381.
  9. Centers for Medicare and Medicaid Services. Proposed revisions to requirements for discharge planning for hospitals, critical access hospitals, and home health agencies. Fed Regist. 2015;80:6812568155.
  10. Coleman EA, Ground KL, Maul A. The Family Caregiver Activation in Transitions tool (FCAT): a new measure of family caregiver self‐efficacy. Jt Comm J Qual Patient Saf. 2015;41:502507.
References
  1. Ryan E. One caregiver's regret: how the CARE Act could have helped. Available at: http://blog.aarp.org/2016/04/18/one‐caregivers‐regret‐how‐the‐care‐act‐could‐have‐helped. Published April 18, 2016. Accessed June 7, 2016.
  2. Reinhard S, Ryan E. Stepping up to support family caregivers. Available at: http://blog.aarp.org/2016/06/07/stepping‐up‐to‐support‐family‐caregivers. Published June 7, 2016. Accessed June 7, 2016.
  3. Martinez JC. New state laws support millions of Americans who minister to aging relatives and form the backbone of the nation's long‐term care system. Available at: http://www.ncsl.org/research/human‐services/helping‐the‐helpers.aspx. Published February 1, 2015. Accessed June 7, 2016.
  4. Coleman EA, Roman SP. Family caregivers' experiences during transitions out of the hospital. J Healthc Qual. 2015;37:1221.
  5. Gillick MR. The critical role of caregivers in achieving patient‐centered care. JAMA. 2013;310:575576.
  6. Reinhard SC, Levine C, Samis S. Home alone: family caregivers providing complex chronic care, 2012. Available at: http://www.aarp.org/home‐family/caregiving/info‐10‐2012/home‐alone‐family‐caregivers‐providing‐complex‐chronic‐care.html. Accessed June 7, 2016.
  7. Halasyamani L, Kripalani S, Coleman EA, et al. Transition of care for hospitalized elderly patients—development of a discharge checklist for hospitalists. J Hosp Med. 2006;1:354360.
  8. Greysen SR, Schiliro D, Horwitz LI, Curry L, Bradley EH. Out of sight, out of mind: housestaff perceptions of quality‐limiting factors in discharge care at teaching hospitals. J Hosp Med. 2012:7:376381.
  9. Centers for Medicare and Medicaid Services. Proposed revisions to requirements for discharge planning for hospitals, critical access hospitals, and home health agencies. Fed Regist. 2015;80:6812568155.
  10. Coleman EA, Ground KL, Maul A. The Family Caregiver Activation in Transitions tool (FCAT): a new measure of family caregiver self‐efficacy. Jt Comm J Qual Patient Saf. 2015;41:502507.
Issue
Journal of Hospital Medicine - 11(12)
Issue
Journal of Hospital Medicine - 11(12)
Page Number
883-885
Page Number
883-885
Article Type
Display Headline
Family caregivers as partners in care transitions: The caregiver advise record and enable act
Display Headline
Family caregivers as partners in care transitions: The caregiver advise record and enable act
Sections
Article Source
© 2016 Society of Hospital Medicine
Disallow All Ads
Correspondence Location
Address for correspondence and reprint requests: Eric A. Coleman, MD, University of Colorado Denver Anschutz Medical Campus, 13199 East Montview Blvd., Suite 400, Aurora, CO 80045‐7201; E‐mail: [email protected]
Content Gating
Gated (full article locked unless allowed per User)
Gating Strategy
First Peek Free
Article PDF Media
Media Files

Physicians' Posture at Patients' Bedside

Article Type
Changed
Mon, 01/02/2017 - 19:34
Display Headline
Sitting at patients' bedsides may improve patients' perceptions of physician communication skills

Sitting while interacting with patients is standard in the outpatient setting and encouraged in the inpatient setting as a best practice.[1, 2] Michael W. Kahn defined etiquette‐based medicine as a set of easily taught behaviors that demonstrate respect for the patient; sitting at the bedside is included.[1] A prominent healthcare consulting group also recommends that physicians and nurses sit at the bedside, claiming that the patient will estimate you were in the room 3 times longer.[3] Previous studies suggest patients may perceive physicians who sit at the bedside as more compassionate and as spending more time with them, and may perceive the overall interaction as more positive when the physician sits.[4, 5, 6] Two small studies found that patients perceived the physician as having spent more time with them if he or she sat rather than stood.[5, 6] A study in the emergency department found no effect of posture on patient perception of physician communication skills, and a study of a single attending neurosurgeon found that patients reported a better understanding of their condition when the physician sat.[5, 6] The effect of physician posture on hospitalist physician‐patient communication has not been previously studied. Despite evidence that sitting in the inpatient setting may improve physician‐patient communication, studies suggest that physicians rarely sit at the bedside of inpatients.[7, 8]

We conducted a cluster‐randomized trial of the impact of hospitalist physician posture during morning rounds. We hypothesized that patients whose physician sat rather than stood would perceive that their physician spent more time with them and would rate the physician's communication skills more highly. We also hypothesized that sitting would not prolong the length of the patient‐physician encounter.

PATIENTS AND METHODS

We conducted a cluster‐randomized clinical trial with a crossover component randomizing physicians on the order of sit/stand within a consecutive 7‐day workweek. We enrolled patients being cared for by attending hospitalists on a resident‐uncovered general internal medicine service in an academic tertiary care hospital. We also enrolled the hospitalists and collected demographics and practice information. Wall‐mounted folding chairs (Figure 1) were installed in all rooms on two 28‐bed units for use by physicians. Eligible patients were newly admitted or transferred from the intensive care unit between June 2014 and June 2015, English speaking, and adults who consented to their own medical care. Physicians were randomly assigned to sit or stand during morning rounds for the first 3 days of their workweek. The last 4 days they provided care using the other posture. Blocks of 4 weeks were used to randomize the sit/stand order.

Figure 1
Chair used in the study.

We measured the length of the physician‐patient interaction, asked both the physician and the patient to estimate the length of the interaction, and administered a written survey to the patient with questions about the physician's communication skills. Research assistants timed the interaction from outside the room and entered the room to consent patients and administer the survey after the physician departed. Survey questions were modeled on the physician communication questions from the Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) survey. We aggregated all answers other than the most positive answer because HCAHPS questions are analyzed according to a top box methodology. Adherence to the intervention was measured by asking the physician whether he or she actually sat or stood for each interaction. We administered a survey to physicians to collect demographics and feedback.

We estimated descriptive statistics for physician and patient participants using cross‐tabs and means. To estimate associations, we used logistic and linear regression that employed cluster‐adjusted t statistics and clustered patients within providers. This method optimizes estimation of standard errors (and corresponding confidence intervals and P values) when the number of clusters is small (16 physicians).[9] For our primary analysis, we analyzed as randomized using an intent‐to‐treat approach. In other words, those assigned to the standing group were analyzed in the standing group even if they actually sat (and vice versa). In a sensitivity analysis we used the same methods to analyze the data according actual provider posture as reported by the physician and not as randomized. We calculated the mean and range of the number of patients seen by physicians. We compared estimates of time spent between patients and providers and patients' satisfaction according to provider posture. We complied with the Consolidated Standards of Reporting Trials 2010 guidelines.[10] Our institutional review board approved this project. All participants provided written consent.

RESULTS

All 17 hospitalists attending on the service consented to participate; 1 did not see any patients involved in the study and was removed from the analysis. Sixty‐nine percent were female and 81% had been in practice for 3 years or less at the time of study enrollment; 94% reported standing when assigned to stand and 83% reported sitting when assigned to sit. We found 31% of physicians reported they routinely sat before participating in the study, and 81% said they would sit more after the study; this result approached statistical significance (exact McNemar P = 0.06). Of the 11 physicians who reported not routinely sitting before the study all, 7 cited not having a place to sit as a reason for not sitting. Other rationale provided included being too short to see the patient if seated, believing rounds would take more time if seated, and concerns about contact precautions. Comments in the postintervention survey regarding why providers planned to sit more centered around themes of having chairs available, thinking that sitting improves communication, and thinking that patients prefer providers to sit.

Two hundred eleven patients were assessed for eligibility. Fifty‐two were excluded (27 did not meet inclusion criteria and 25 declined to participate), leaving 159 participating patients. Seven patient‐physician pairs were inadvertently assigned the wrong intervention but were analyzed as randomized. There were no demographic differences between patient groups (Table 1). Physicians participating in the study saw an average of 13 study patients (range, 118) during the study. Mean time spent in the patient's room during rounds was 12:00 minutes for seated physicians and 12:10 for standing physicians (P = 0.84). Regardless of provider posture, patients overestimated the amount of time their physician spent in the room (mean difference 4:10 minutes, P = 0.01). Patients' estimates of the time the physician spent did not vary by posture (16:00 minutes for seated, 16:19 for standing, P = 0.86).

Patient Characteristics
Patients Seen by Seated Physician, N = 66 Patients Seen by Standing Physician, N = 93 P Value
n % n %
Patient age, y
1839 16 25.4 25 27.5 0.59
4059 17 27.0 30 33.0
60+ 30 47.6 36 39.6
Gender
Male 32 49.2 43 46.2 0.71
Female 33 50.8 50 53.8
Ethnicity
Caucasian 54 84.4 67 73.6 0.24
Asian or Pacific Islander 3 4.7 5 5.5
Other 7 10.9 19 20.9

Patients whose physician sat on rounds were statistically significantly more likely to choose the answer always to the questions regarding their physician listening carefully to them (P = 0.02) and explaining things in a way that was easy to understand (P = 0.05, Table 2). There was no difference in the patients' response to questions about the physician interrupting the patient when talking or treating them with courtesy and respect. Nearly all patients chose just right when asked to rate the amount of time their physician had spent with them on rounds (Table 2). The results of our sensitivity analysis that classified physicians according to their actual posture yielded different results; none of the findings in that analysis including questions regarding the physician listening carefully or explaining things in a way that was easy to understand were statistically significant (see Supporting Information, Appendix 1, in the online version of this article).

Patient Perceptions of Physician Communication
Patients Seen by Seated Physician, N = 66 Patients Seen by Standing Physician, N = 93 P Value
n % n %
  • NOTE: All variables missing <5%. *Missing 6.9%.

Patient perception of physician communication on that day's rounds
Today on rounds, how often did this physician.
Explain things in a way that was easy to understand?
Never, sometimes, or usually 7 10.9 22 23.9 0.05
Always 57 89.1 71 76.1
Listen carefully to you?
Never, sometimes, or usually 4 6.1 19 20.4 0.02
Always 62 93.4 74 79.6
Interrupt you when you were talking?
Always, sometimes, or usually 4 6.5 9 10 0.46
Never 58 93.6 81 90
Treat you with courtesy and respect?
Never, sometimes, or usually 0 0 7 7.6 Not estimable
Always 63 100 85 92.4
Please rate the amount of time this physician spent with you today during morning rounds.
Too little 1 1.6 3 3.5 0.41
Just right 63 98.4 84 96.5
Did you have any important questions or concerns about your care that you did not bring up with this doctor today?*
Yes 4 6.6 9 10.3 0.26
No 57 94.4 78 89.7

DISCUSSION

In our study involving general medicine inpatients cared for by academic hospitalists, physicians did not spend more time in the room when seated, and were willing to adopt this practice. Patients perceived that seated compared to standing physicians listened more carefully and explained things in a way that was easy to understand when analyzed using an intent‐to‐treat approach. Patients did not perceive that seated physicians spent more time with them than standing physicians. To our knowledge, this is the first study showing the effects of hospitalist rounding posture on patient experience.

Our finding that patients rated seated physicians more highly on listening carefully and explaining things well indicates that training hospitalists to sit at the bedside may ultimately improve patient satisfaction. Our findings suggest seated interaction may improve satisfaction with communication without increasing time burden on physicians. However, given that these findings were not statistically significant when we analyzed our data according to actual behavior, larger studies should verify the impact of physician posture on patient experience.

Previous studies found that a minority of physicians sit in the inpatient setting, but did not study barriers to sitting while on rounds.[7, 8] A majority of physicians in our study sat when instructed to do so and when chairs were provided, and over 80% of physicians in our study said they planned to continue sitting while on rounds after the study was complete. A lack of chairs may be a major barrier to physicians adopting this facet of etiquette‐based medicine, and institutions wishing to promote this practice should consider providing chairs. Written comments from physician participants suggest physicians who are introduced to this practice enjoy sitting and think it improves physician‐patient communication. Further studies are needed to test our assumption that physicians continue sitting when chairs are provided.

Our work differs from previous studies. Johnson et al. studied interactions in the emergency room with a mean length of 8.6 minutes,[5] and Swayden et al. studied postoperative visits by a single neurosurgeon with a mean length of about 1 minute.[6] One explanation for the lack of a difference in time spent by posture might be that an average visit time of 12 minutes passes a threshold where patients make more accurate estimates of visit length or where factors other than posture more strongly influence perceptions of duration.

Limitations of our study include the relatively small sample size, single location, and limitation to English‐speaking patients able to consent themselves. Reasons for the limited sample size include that chairs were only installed in 2 units, and not all patients on the unit were under the care of participating physicians. Physician subjects were not blinded to their interactions being timed or to the fact that patients were surveyed about their communication skills. It is possible that factors that may have affected patients' responses such as severity of illness, number of consultants involved in their care, or prior experiences in the healthcare system were not equally distributed between our 2 groups. Additionally, our use of questions similar to those used in the HCAHPS instrument is not compliant with Centers for Medicare and Medicaid Services (CMS) policy. We caution others against using questions that might invalidate their hospital's participation in CMS payment programs.

Our study was limited to rounds involving 1 physician; our practice is that in a larger team the presenting member is encouraged to sit and others sit if there are additional chairs. Best practices on a teaching service are unclear and could be the subject of further study. The longer‐term sustainability of the practice of sitting on rounds is unclear. However, our physician subjects reported that they plan to continue to sit after the study, and we have shared the results with physicians in order to provide them with evidence supporting this practice. Not having a place to sit and thinking that sitting increases the amount of time spent on rounds were concerns provided in our preintervention survey, and we believe our study addresses these concerns.

Our study demonstrates the effects of a simple intervention on patient satisfaction without increasing burden on providers. Sitting at the bedside does not impact the amount of time spent with the patient, but may improve the patient's perception of the physician's communication skills and thus impact the patient experience. This simple intervention could improve patient satisfaction at little cost.

Acknowledgements

The authors acknowledge Tom Staiger, MD, UWMC Medical Director, for his assistance with obtaining chairs for this study.

Disclosure: Nothing to report.

Files
References
  1. Kahn M. Etiquette‐based medicine. N Engl J Med. 2008;358(19):19881989.
  2. Sorenson E, Malakouti M, Brown G, Koo J. Enhancing patient satisfaction in dermatology. Am J Clin Dermatol. 2015;16:14.
  3. The Studer Group. Q21:501505.
  4. Johnson RL, Sadosty AT, Weaver AL, Goyal DG. To sit or not to sit? Ann Emerg Med. 2008;51:188193.
  5. Swayden KJ, Anderson KK, Connelly LM, Moran JS, McMahon JK, Arnold PM. Effect of sitting vs. standing on perception of provider time at bedside: a pilot study. Patient Educ Couns. 2012;86(2):166171.
  6. Tackett S, Tad‐y D, Rios R, Kisuule F, Wright S. Appraising the Practice of Etiquette‐Based Medicine in the Inpatient Setting. J Gen Intern Med. 2013;28(7):908913.
  7. Block L, Hutzler L, Habicht R, et al. Do internal medicine interns practice etiquette‐based communication? A critical look at the inpatient encounter. J Hosp Med. 2013; 8:631634.
  8. Esarey J, Menger A. Practical and effective approaches to dealing with clustered data [unpublished manuscript]. Department of Political Science, Rice University, Houston, TX. Available at: http://jee3.web.rice.edu/cluster‐paper.pdf. Accessed February 29, 2016.
  9. Schulz KF, Altman DG, Moher D. Consort 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010;152(11):726732.
Article PDF
Issue
Journal of Hospital Medicine - 11(12)
Page Number
865-868
Sections
Files
Files
Article PDF
Article PDF

Sitting while interacting with patients is standard in the outpatient setting and encouraged in the inpatient setting as a best practice.[1, 2] Michael W. Kahn defined etiquette‐based medicine as a set of easily taught behaviors that demonstrate respect for the patient; sitting at the bedside is included.[1] A prominent healthcare consulting group also recommends that physicians and nurses sit at the bedside, claiming that the patient will estimate you were in the room 3 times longer.[3] Previous studies suggest patients may perceive physicians who sit at the bedside as more compassionate and as spending more time with them, and may perceive the overall interaction as more positive when the physician sits.[4, 5, 6] Two small studies found that patients perceived the physician as having spent more time with them if he or she sat rather than stood.[5, 6] A study in the emergency department found no effect of posture on patient perception of physician communication skills, and a study of a single attending neurosurgeon found that patients reported a better understanding of their condition when the physician sat.[5, 6] The effect of physician posture on hospitalist physician‐patient communication has not been previously studied. Despite evidence that sitting in the inpatient setting may improve physician‐patient communication, studies suggest that physicians rarely sit at the bedside of inpatients.[7, 8]

We conducted a cluster‐randomized trial of the impact of hospitalist physician posture during morning rounds. We hypothesized that patients whose physician sat rather than stood would perceive that their physician spent more time with them and would rate the physician's communication skills more highly. We also hypothesized that sitting would not prolong the length of the patient‐physician encounter.

PATIENTS AND METHODS

We conducted a cluster‐randomized clinical trial with a crossover component randomizing physicians on the order of sit/stand within a consecutive 7‐day workweek. We enrolled patients being cared for by attending hospitalists on a resident‐uncovered general internal medicine service in an academic tertiary care hospital. We also enrolled the hospitalists and collected demographics and practice information. Wall‐mounted folding chairs (Figure 1) were installed in all rooms on two 28‐bed units for use by physicians. Eligible patients were newly admitted or transferred from the intensive care unit between June 2014 and June 2015, English speaking, and adults who consented to their own medical care. Physicians were randomly assigned to sit or stand during morning rounds for the first 3 days of their workweek. The last 4 days they provided care using the other posture. Blocks of 4 weeks were used to randomize the sit/stand order.

Figure 1
Chair used in the study.

We measured the length of the physician‐patient interaction, asked both the physician and the patient to estimate the length of the interaction, and administered a written survey to the patient with questions about the physician's communication skills. Research assistants timed the interaction from outside the room and entered the room to consent patients and administer the survey after the physician departed. Survey questions were modeled on the physician communication questions from the Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) survey. We aggregated all answers other than the most positive answer because HCAHPS questions are analyzed according to a top box methodology. Adherence to the intervention was measured by asking the physician whether he or she actually sat or stood for each interaction. We administered a survey to physicians to collect demographics and feedback.

We estimated descriptive statistics for physician and patient participants using cross‐tabs and means. To estimate associations, we used logistic and linear regression that employed cluster‐adjusted t statistics and clustered patients within providers. This method optimizes estimation of standard errors (and corresponding confidence intervals and P values) when the number of clusters is small (16 physicians).[9] For our primary analysis, we analyzed as randomized using an intent‐to‐treat approach. In other words, those assigned to the standing group were analyzed in the standing group even if they actually sat (and vice versa). In a sensitivity analysis we used the same methods to analyze the data according actual provider posture as reported by the physician and not as randomized. We calculated the mean and range of the number of patients seen by physicians. We compared estimates of time spent between patients and providers and patients' satisfaction according to provider posture. We complied with the Consolidated Standards of Reporting Trials 2010 guidelines.[10] Our institutional review board approved this project. All participants provided written consent.

RESULTS

All 17 hospitalists attending on the service consented to participate; 1 did not see any patients involved in the study and was removed from the analysis. Sixty‐nine percent were female and 81% had been in practice for 3 years or less at the time of study enrollment; 94% reported standing when assigned to stand and 83% reported sitting when assigned to sit. We found 31% of physicians reported they routinely sat before participating in the study, and 81% said they would sit more after the study; this result approached statistical significance (exact McNemar P = 0.06). Of the 11 physicians who reported not routinely sitting before the study all, 7 cited not having a place to sit as a reason for not sitting. Other rationale provided included being too short to see the patient if seated, believing rounds would take more time if seated, and concerns about contact precautions. Comments in the postintervention survey regarding why providers planned to sit more centered around themes of having chairs available, thinking that sitting improves communication, and thinking that patients prefer providers to sit.

Two hundred eleven patients were assessed for eligibility. Fifty‐two were excluded (27 did not meet inclusion criteria and 25 declined to participate), leaving 159 participating patients. Seven patient‐physician pairs were inadvertently assigned the wrong intervention but were analyzed as randomized. There were no demographic differences between patient groups (Table 1). Physicians participating in the study saw an average of 13 study patients (range, 118) during the study. Mean time spent in the patient's room during rounds was 12:00 minutes for seated physicians and 12:10 for standing physicians (P = 0.84). Regardless of provider posture, patients overestimated the amount of time their physician spent in the room (mean difference 4:10 minutes, P = 0.01). Patients' estimates of the time the physician spent did not vary by posture (16:00 minutes for seated, 16:19 for standing, P = 0.86).

Patient Characteristics
Patients Seen by Seated Physician, N = 66 Patients Seen by Standing Physician, N = 93 P Value
n % n %
Patient age, y
1839 16 25.4 25 27.5 0.59
4059 17 27.0 30 33.0
60+ 30 47.6 36 39.6
Gender
Male 32 49.2 43 46.2 0.71
Female 33 50.8 50 53.8
Ethnicity
Caucasian 54 84.4 67 73.6 0.24
Asian or Pacific Islander 3 4.7 5 5.5
Other 7 10.9 19 20.9

Patients whose physician sat on rounds were statistically significantly more likely to choose the answer always to the questions regarding their physician listening carefully to them (P = 0.02) and explaining things in a way that was easy to understand (P = 0.05, Table 2). There was no difference in the patients' response to questions about the physician interrupting the patient when talking or treating them with courtesy and respect. Nearly all patients chose just right when asked to rate the amount of time their physician had spent with them on rounds (Table 2). The results of our sensitivity analysis that classified physicians according to their actual posture yielded different results; none of the findings in that analysis including questions regarding the physician listening carefully or explaining things in a way that was easy to understand were statistically significant (see Supporting Information, Appendix 1, in the online version of this article).

Patient Perceptions of Physician Communication
Patients Seen by Seated Physician, N = 66 Patients Seen by Standing Physician, N = 93 P Value
n % n %
  • NOTE: All variables missing <5%. *Missing 6.9%.

Patient perception of physician communication on that day's rounds
Today on rounds, how often did this physician.
Explain things in a way that was easy to understand?
Never, sometimes, or usually 7 10.9 22 23.9 0.05
Always 57 89.1 71 76.1
Listen carefully to you?
Never, sometimes, or usually 4 6.1 19 20.4 0.02
Always 62 93.4 74 79.6
Interrupt you when you were talking?
Always, sometimes, or usually 4 6.5 9 10 0.46
Never 58 93.6 81 90
Treat you with courtesy and respect?
Never, sometimes, or usually 0 0 7 7.6 Not estimable
Always 63 100 85 92.4
Please rate the amount of time this physician spent with you today during morning rounds.
Too little 1 1.6 3 3.5 0.41
Just right 63 98.4 84 96.5
Did you have any important questions or concerns about your care that you did not bring up with this doctor today?*
Yes 4 6.6 9 10.3 0.26
No 57 94.4 78 89.7

DISCUSSION

In our study involving general medicine inpatients cared for by academic hospitalists, physicians did not spend more time in the room when seated, and were willing to adopt this practice. Patients perceived that seated compared to standing physicians listened more carefully and explained things in a way that was easy to understand when analyzed using an intent‐to‐treat approach. Patients did not perceive that seated physicians spent more time with them than standing physicians. To our knowledge, this is the first study showing the effects of hospitalist rounding posture on patient experience.

Our finding that patients rated seated physicians more highly on listening carefully and explaining things well indicates that training hospitalists to sit at the bedside may ultimately improve patient satisfaction. Our findings suggest seated interaction may improve satisfaction with communication without increasing time burden on physicians. However, given that these findings were not statistically significant when we analyzed our data according to actual behavior, larger studies should verify the impact of physician posture on patient experience.

Previous studies found that a minority of physicians sit in the inpatient setting, but did not study barriers to sitting while on rounds.[7, 8] A majority of physicians in our study sat when instructed to do so and when chairs were provided, and over 80% of physicians in our study said they planned to continue sitting while on rounds after the study was complete. A lack of chairs may be a major barrier to physicians adopting this facet of etiquette‐based medicine, and institutions wishing to promote this practice should consider providing chairs. Written comments from physician participants suggest physicians who are introduced to this practice enjoy sitting and think it improves physician‐patient communication. Further studies are needed to test our assumption that physicians continue sitting when chairs are provided.

Our work differs from previous studies. Johnson et al. studied interactions in the emergency room with a mean length of 8.6 minutes,[5] and Swayden et al. studied postoperative visits by a single neurosurgeon with a mean length of about 1 minute.[6] One explanation for the lack of a difference in time spent by posture might be that an average visit time of 12 minutes passes a threshold where patients make more accurate estimates of visit length or where factors other than posture more strongly influence perceptions of duration.

Limitations of our study include the relatively small sample size, single location, and limitation to English‐speaking patients able to consent themselves. Reasons for the limited sample size include that chairs were only installed in 2 units, and not all patients on the unit were under the care of participating physicians. Physician subjects were not blinded to their interactions being timed or to the fact that patients were surveyed about their communication skills. It is possible that factors that may have affected patients' responses such as severity of illness, number of consultants involved in their care, or prior experiences in the healthcare system were not equally distributed between our 2 groups. Additionally, our use of questions similar to those used in the HCAHPS instrument is not compliant with Centers for Medicare and Medicaid Services (CMS) policy. We caution others against using questions that might invalidate their hospital's participation in CMS payment programs.

Our study was limited to rounds involving 1 physician; our practice is that in a larger team the presenting member is encouraged to sit and others sit if there are additional chairs. Best practices on a teaching service are unclear and could be the subject of further study. The longer‐term sustainability of the practice of sitting on rounds is unclear. However, our physician subjects reported that they plan to continue to sit after the study, and we have shared the results with physicians in order to provide them with evidence supporting this practice. Not having a place to sit and thinking that sitting increases the amount of time spent on rounds were concerns provided in our preintervention survey, and we believe our study addresses these concerns.

Our study demonstrates the effects of a simple intervention on patient satisfaction without increasing burden on providers. Sitting at the bedside does not impact the amount of time spent with the patient, but may improve the patient's perception of the physician's communication skills and thus impact the patient experience. This simple intervention could improve patient satisfaction at little cost.

Acknowledgements

The authors acknowledge Tom Staiger, MD, UWMC Medical Director, for his assistance with obtaining chairs for this study.

Disclosure: Nothing to report.

Sitting while interacting with patients is standard in the outpatient setting and encouraged in the inpatient setting as a best practice.[1, 2] Michael W. Kahn defined etiquette‐based medicine as a set of easily taught behaviors that demonstrate respect for the patient; sitting at the bedside is included.[1] A prominent healthcare consulting group also recommends that physicians and nurses sit at the bedside, claiming that the patient will estimate you were in the room 3 times longer.[3] Previous studies suggest patients may perceive physicians who sit at the bedside as more compassionate and as spending more time with them, and may perceive the overall interaction as more positive when the physician sits.[4, 5, 6] Two small studies found that patients perceived the physician as having spent more time with them if he or she sat rather than stood.[5, 6] A study in the emergency department found no effect of posture on patient perception of physician communication skills, and a study of a single attending neurosurgeon found that patients reported a better understanding of their condition when the physician sat.[5, 6] The effect of physician posture on hospitalist physician‐patient communication has not been previously studied. Despite evidence that sitting in the inpatient setting may improve physician‐patient communication, studies suggest that physicians rarely sit at the bedside of inpatients.[7, 8]

We conducted a cluster‐randomized trial of the impact of hospitalist physician posture during morning rounds. We hypothesized that patients whose physician sat rather than stood would perceive that their physician spent more time with them and would rate the physician's communication skills more highly. We also hypothesized that sitting would not prolong the length of the patient‐physician encounter.

PATIENTS AND METHODS

We conducted a cluster‐randomized clinical trial with a crossover component randomizing physicians on the order of sit/stand within a consecutive 7‐day workweek. We enrolled patients being cared for by attending hospitalists on a resident‐uncovered general internal medicine service in an academic tertiary care hospital. We also enrolled the hospitalists and collected demographics and practice information. Wall‐mounted folding chairs (Figure 1) were installed in all rooms on two 28‐bed units for use by physicians. Eligible patients were newly admitted or transferred from the intensive care unit between June 2014 and June 2015, English speaking, and adults who consented to their own medical care. Physicians were randomly assigned to sit or stand during morning rounds for the first 3 days of their workweek. The last 4 days they provided care using the other posture. Blocks of 4 weeks were used to randomize the sit/stand order.

Figure 1
Chair used in the study.

We measured the length of the physician‐patient interaction, asked both the physician and the patient to estimate the length of the interaction, and administered a written survey to the patient with questions about the physician's communication skills. Research assistants timed the interaction from outside the room and entered the room to consent patients and administer the survey after the physician departed. Survey questions were modeled on the physician communication questions from the Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) survey. We aggregated all answers other than the most positive answer because HCAHPS questions are analyzed according to a top box methodology. Adherence to the intervention was measured by asking the physician whether he or she actually sat or stood for each interaction. We administered a survey to physicians to collect demographics and feedback.

We estimated descriptive statistics for physician and patient participants using cross‐tabs and means. To estimate associations, we used logistic and linear regression that employed cluster‐adjusted t statistics and clustered patients within providers. This method optimizes estimation of standard errors (and corresponding confidence intervals and P values) when the number of clusters is small (16 physicians).[9] For our primary analysis, we analyzed as randomized using an intent‐to‐treat approach. In other words, those assigned to the standing group were analyzed in the standing group even if they actually sat (and vice versa). In a sensitivity analysis we used the same methods to analyze the data according actual provider posture as reported by the physician and not as randomized. We calculated the mean and range of the number of patients seen by physicians. We compared estimates of time spent between patients and providers and patients' satisfaction according to provider posture. We complied with the Consolidated Standards of Reporting Trials 2010 guidelines.[10] Our institutional review board approved this project. All participants provided written consent.

RESULTS

All 17 hospitalists attending on the service consented to participate; 1 did not see any patients involved in the study and was removed from the analysis. Sixty‐nine percent were female and 81% had been in practice for 3 years or less at the time of study enrollment; 94% reported standing when assigned to stand and 83% reported sitting when assigned to sit. We found 31% of physicians reported they routinely sat before participating in the study, and 81% said they would sit more after the study; this result approached statistical significance (exact McNemar P = 0.06). Of the 11 physicians who reported not routinely sitting before the study all, 7 cited not having a place to sit as a reason for not sitting. Other rationale provided included being too short to see the patient if seated, believing rounds would take more time if seated, and concerns about contact precautions. Comments in the postintervention survey regarding why providers planned to sit more centered around themes of having chairs available, thinking that sitting improves communication, and thinking that patients prefer providers to sit.

Two hundred eleven patients were assessed for eligibility. Fifty‐two were excluded (27 did not meet inclusion criteria and 25 declined to participate), leaving 159 participating patients. Seven patient‐physician pairs were inadvertently assigned the wrong intervention but were analyzed as randomized. There were no demographic differences between patient groups (Table 1). Physicians participating in the study saw an average of 13 study patients (range, 118) during the study. Mean time spent in the patient's room during rounds was 12:00 minutes for seated physicians and 12:10 for standing physicians (P = 0.84). Regardless of provider posture, patients overestimated the amount of time their physician spent in the room (mean difference 4:10 minutes, P = 0.01). Patients' estimates of the time the physician spent did not vary by posture (16:00 minutes for seated, 16:19 for standing, P = 0.86).

Patient Characteristics
Patients Seen by Seated Physician, N = 66 Patients Seen by Standing Physician, N = 93 P Value
n % n %
Patient age, y
1839 16 25.4 25 27.5 0.59
4059 17 27.0 30 33.0
60+ 30 47.6 36 39.6
Gender
Male 32 49.2 43 46.2 0.71
Female 33 50.8 50 53.8
Ethnicity
Caucasian 54 84.4 67 73.6 0.24
Asian or Pacific Islander 3 4.7 5 5.5
Other 7 10.9 19 20.9

Patients whose physician sat on rounds were statistically significantly more likely to choose the answer always to the questions regarding their physician listening carefully to them (P = 0.02) and explaining things in a way that was easy to understand (P = 0.05, Table 2). There was no difference in the patients' response to questions about the physician interrupting the patient when talking or treating them with courtesy and respect. Nearly all patients chose just right when asked to rate the amount of time their physician had spent with them on rounds (Table 2). The results of our sensitivity analysis that classified physicians according to their actual posture yielded different results; none of the findings in that analysis including questions regarding the physician listening carefully or explaining things in a way that was easy to understand were statistically significant (see Supporting Information, Appendix 1, in the online version of this article).

Patient Perceptions of Physician Communication
Patients Seen by Seated Physician, N = 66 Patients Seen by Standing Physician, N = 93 P Value
n % n %
  • NOTE: All variables missing <5%. *Missing 6.9%.

Patient perception of physician communication on that day's rounds
Today on rounds, how often did this physician.
Explain things in a way that was easy to understand?
Never, sometimes, or usually 7 10.9 22 23.9 0.05
Always 57 89.1 71 76.1
Listen carefully to you?
Never, sometimes, or usually 4 6.1 19 20.4 0.02
Always 62 93.4 74 79.6
Interrupt you when you were talking?
Always, sometimes, or usually 4 6.5 9 10 0.46
Never 58 93.6 81 90
Treat you with courtesy and respect?
Never, sometimes, or usually 0 0 7 7.6 Not estimable
Always 63 100 85 92.4
Please rate the amount of time this physician spent with you today during morning rounds.
Too little 1 1.6 3 3.5 0.41
Just right 63 98.4 84 96.5
Did you have any important questions or concerns about your care that you did not bring up with this doctor today?*
Yes 4 6.6 9 10.3 0.26
No 57 94.4 78 89.7

DISCUSSION

In our study involving general medicine inpatients cared for by academic hospitalists, physicians did not spend more time in the room when seated, and were willing to adopt this practice. Patients perceived that seated compared to standing physicians listened more carefully and explained things in a way that was easy to understand when analyzed using an intent‐to‐treat approach. Patients did not perceive that seated physicians spent more time with them than standing physicians. To our knowledge, this is the first study showing the effects of hospitalist rounding posture on patient experience.

Our finding that patients rated seated physicians more highly on listening carefully and explaining things well indicates that training hospitalists to sit at the bedside may ultimately improve patient satisfaction. Our findings suggest seated interaction may improve satisfaction with communication without increasing time burden on physicians. However, given that these findings were not statistically significant when we analyzed our data according to actual behavior, larger studies should verify the impact of physician posture on patient experience.

Previous studies found that a minority of physicians sit in the inpatient setting, but did not study barriers to sitting while on rounds.[7, 8] A majority of physicians in our study sat when instructed to do so and when chairs were provided, and over 80% of physicians in our study said they planned to continue sitting while on rounds after the study was complete. A lack of chairs may be a major barrier to physicians adopting this facet of etiquette‐based medicine, and institutions wishing to promote this practice should consider providing chairs. Written comments from physician participants suggest physicians who are introduced to this practice enjoy sitting and think it improves physician‐patient communication. Further studies are needed to test our assumption that physicians continue sitting when chairs are provided.

Our work differs from previous studies. Johnson et al. studied interactions in the emergency room with a mean length of 8.6 minutes,[5] and Swayden et al. studied postoperative visits by a single neurosurgeon with a mean length of about 1 minute.[6] One explanation for the lack of a difference in time spent by posture might be that an average visit time of 12 minutes passes a threshold where patients make more accurate estimates of visit length or where factors other than posture more strongly influence perceptions of duration.

Limitations of our study include the relatively small sample size, single location, and limitation to English‐speaking patients able to consent themselves. Reasons for the limited sample size include that chairs were only installed in 2 units, and not all patients on the unit were under the care of participating physicians. Physician subjects were not blinded to their interactions being timed or to the fact that patients were surveyed about their communication skills. It is possible that factors that may have affected patients' responses such as severity of illness, number of consultants involved in their care, or prior experiences in the healthcare system were not equally distributed between our 2 groups. Additionally, our use of questions similar to those used in the HCAHPS instrument is not compliant with Centers for Medicare and Medicaid Services (CMS) policy. We caution others against using questions that might invalidate their hospital's participation in CMS payment programs.

Our study was limited to rounds involving 1 physician; our practice is that in a larger team the presenting member is encouraged to sit and others sit if there are additional chairs. Best practices on a teaching service are unclear and could be the subject of further study. The longer‐term sustainability of the practice of sitting on rounds is unclear. However, our physician subjects reported that they plan to continue to sit after the study, and we have shared the results with physicians in order to provide them with evidence supporting this practice. Not having a place to sit and thinking that sitting increases the amount of time spent on rounds were concerns provided in our preintervention survey, and we believe our study addresses these concerns.

Our study demonstrates the effects of a simple intervention on patient satisfaction without increasing burden on providers. Sitting at the bedside does not impact the amount of time spent with the patient, but may improve the patient's perception of the physician's communication skills and thus impact the patient experience. This simple intervention could improve patient satisfaction at little cost.

Acknowledgements

The authors acknowledge Tom Staiger, MD, UWMC Medical Director, for his assistance with obtaining chairs for this study.

Disclosure: Nothing to report.

References
  1. Kahn M. Etiquette‐based medicine. N Engl J Med. 2008;358(19):19881989.
  2. Sorenson E, Malakouti M, Brown G, Koo J. Enhancing patient satisfaction in dermatology. Am J Clin Dermatol. 2015;16:14.
  3. The Studer Group. Q21:501505.
  4. Johnson RL, Sadosty AT, Weaver AL, Goyal DG. To sit or not to sit? Ann Emerg Med. 2008;51:188193.
  5. Swayden KJ, Anderson KK, Connelly LM, Moran JS, McMahon JK, Arnold PM. Effect of sitting vs. standing on perception of provider time at bedside: a pilot study. Patient Educ Couns. 2012;86(2):166171.
  6. Tackett S, Tad‐y D, Rios R, Kisuule F, Wright S. Appraising the Practice of Etiquette‐Based Medicine in the Inpatient Setting. J Gen Intern Med. 2013;28(7):908913.
  7. Block L, Hutzler L, Habicht R, et al. Do internal medicine interns practice etiquette‐based communication? A critical look at the inpatient encounter. J Hosp Med. 2013; 8:631634.
  8. Esarey J, Menger A. Practical and effective approaches to dealing with clustered data [unpublished manuscript]. Department of Political Science, Rice University, Houston, TX. Available at: http://jee3.web.rice.edu/cluster‐paper.pdf. Accessed February 29, 2016.
  9. Schulz KF, Altman DG, Moher D. Consort 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010;152(11):726732.
References
  1. Kahn M. Etiquette‐based medicine. N Engl J Med. 2008;358(19):19881989.
  2. Sorenson E, Malakouti M, Brown G, Koo J. Enhancing patient satisfaction in dermatology. Am J Clin Dermatol. 2015;16:14.
  3. The Studer Group. Q21:501505.
  4. Johnson RL, Sadosty AT, Weaver AL, Goyal DG. To sit or not to sit? Ann Emerg Med. 2008;51:188193.
  5. Swayden KJ, Anderson KK, Connelly LM, Moran JS, McMahon JK, Arnold PM. Effect of sitting vs. standing on perception of provider time at bedside: a pilot study. Patient Educ Couns. 2012;86(2):166171.
  6. Tackett S, Tad‐y D, Rios R, Kisuule F, Wright S. Appraising the Practice of Etiquette‐Based Medicine in the Inpatient Setting. J Gen Intern Med. 2013;28(7):908913.
  7. Block L, Hutzler L, Habicht R, et al. Do internal medicine interns practice etiquette‐based communication? A critical look at the inpatient encounter. J Hosp Med. 2013; 8:631634.
  8. Esarey J, Menger A. Practical and effective approaches to dealing with clustered data [unpublished manuscript]. Department of Political Science, Rice University, Houston, TX. Available at: http://jee3.web.rice.edu/cluster‐paper.pdf. Accessed February 29, 2016.
  9. Schulz KF, Altman DG, Moher D. Consort 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010;152(11):726732.
Issue
Journal of Hospital Medicine - 11(12)
Issue
Journal of Hospital Medicine - 11(12)
Page Number
865-868
Page Number
865-868
Article Type
Display Headline
Sitting at patients' bedsides may improve patients' perceptions of physician communication skills
Display Headline
Sitting at patients' bedsides may improve patients' perceptions of physician communication skills
Sections
Article Source
© 2016 Society of Hospital Medicine
Disallow All Ads
Correspondence Location
Address for correspondence and reprint requests: Susan E. Merel, MD, 1959 NE Pacific Street, Box 356429, Seattle, WA 98195‐6429; Telephone: 206‐616‐4088; Fax: 206‐221‐8732; E‐mail: [email protected]
Content Gating
Gated (full article locked unless allowed per User)
Gating Strategy
First Peek Free
Article PDF Media
Media Files

Covert Observation of Hand Hygiene

Article Type
Changed
Mon, 01/02/2017 - 19:34
Display Headline
Do physicians clean their hands? Insights from a covert observational study

Hand hygiene (HH) is believed to be one of the single most important interventions to prevent healthcare‐associated infection, yet physicians are notorious for their poor compliance.[1, 2, 3] At our 800‐bed acute care academic hospital, we implemented a multifaceted HH program[4] in 2007, which was associated with improved HH compliance rates from 43% to 87%. Despite this improvement, HH compliance among physicians remained suboptimal, with rates below 60% in some patient areas. A targeted campaign focused on recruitment of physician champions, resulted in some improvement, but physician compliance has consistently remained below performance of nurses (70%75% for physicians vs 85%90% for nurses).

Our experience parallels the results seen in multinational surveys demonstrating consistently lower physician HH compliance.[5] Given the multiple improvement efforts directed at physicians and the apparent ceiling observed in HH performance, we wanted to confirm whether physicians are truly recalcitrant to cleaning their hands, or whether lower compliance among physicians reflected a differential in the Hawthorne effect inherent to direct observation methods. Specifically, we wondered if nurses tend to recognize auditors more readily than physicians and therefore show higher apparent HH compliance when auditors are present. We also wanted to verify whether the behavior of attending physicians influenced compliance of their physician trainees. To test these hypotheses, we trained 2 clinical observers to covertly measure HH compliance of nurses and physicians on 3 different clinical services.

METHODS

Between May 27, 2015 and July 31, 2015, 2 student observers joined clinical rotations on physician and nursing teams, respectively. Healthcare teams were unaware that the student observers were measuring HH compliance during their clinical rotation. Students rotated in the emergency department, general medical and surgical wards for no more than 1 week at a time to increase exposure to different providers and minimize risk of exposing the covert observation.

Prior to the study period, the students underwent training and validation with a hospital HH auditor at another clinical setting offsite to avoid any recognition of these students by healthcare providers as observers of HH at the main hospital. Training with the auditors occurred until interobserver agreement between all HH opportunities reached 100% agreement for 2 consecutive observation days.

During their rotations, students covertly recorded HH compliance based on moments of hand hygiene[4] and also noted location, presence, and compliance of the attending physician, team size during patient encounter, and isolation requirements. Both students measured HH compliance of nurses and physicians around them. Although students spent the majority of their time with their assigned physician or nurse teams, they did not limit their observations to these individuals only, but recorded compliance of any nurse or physician on the ward as long as they were within sight during an HH opportunity. To limit clustering of observations of the same healthcare worker, up to a maximum of 2 observations per healthcare worker per day was recorded.

We compared covertly measured HH compliance with data from overt observation by hospital auditors during the same time period. Differences in proportion of HH compliance were compared with hospital audits during the same period with a 2 test. Difference between differences in overtly and covertly measured HH compliance for nurses and physicians was compared using Breslow day test.

The study was approved by the hospital's research ethics board. Although deception was used in this study,[2, 6] all data were collected for quality improvement purposes, and the aggregate results were disclosed to hospital staff following the study.

RESULTS

Covertly observed HH compliance was 50.0% (799/1597) compared with 83.7% (2769/3309) recorded by hospital auditors during the same time period (P < 0.0002) (Table 1). There was no significant difference in the compliance measured by each student (50.1%, 473/928 vs 48.7%, 326/669) (P = 0.3), and their results were combined for the rest of the analysis. Compliance before contact with the patient or patient environment was 43.1% (344/798), 74.3% (26/35) before clean/aseptic procedures, 34.8% (8/23) after potential body fluid exposure, and 56.8% (483/851) after contact with the patient or patient environment. Healthcare providers examining patients with isolation precautions were found to have a HH compliance of 74.8% (101/135) compared to 47.0% (385/820) when isolation precautions were not required (P < 0.0002).

Hand Hygiene Compliance Across Clinical Services and Professional Groupings as Measured by Covert Observers and Hospital Auditors During the Study Period
Covert Observers, Compliance (95% CI) Hospital Auditors, Compliance (95% CI) Difference
  • NOTE: Abbreviations: CI, confidence interval. *When attending physicians cleaned their hands. When attending physicians did not clean their hands.

Overall hand hygiene compliance 50.0% (47.6‐52.5) 83.7% (82.4‐84.9) 33.7%
Service
Medicine 58.9% (55.3‐62.5) 85.0% (82.7‐87.3) 26.1%
Surgery 45.7% (41.6‐49.8) 91.0% (87.5‐93.7) 45.3%
Emergency 43.9% (38.9‐49.9) 73.8% (68.9‐78.2) 29.9%
Nurses 45.1% (41.5‐48.7) 85.8% (83.3‐87.9) 40.7%
Physicians
Overall compliance 54.2% (50.9‐57.1) 73.2% (67.3‐78.4) 19.0%
Trainee compliance* 79.5% (73.6‐84.3)
Trainee compliance 18.9% (13.3‐26.1)

Hospital auditor data showed that surgery and medicine had similarly high rates of compliance (91.0% and 85.0%, respectively), whereas the emergency department had a notably lower rate of 73.8%. Covert observation confirmed a lower rate in the emergency department (43.9%), but showed a higher compliance on general medicine than on surgery (58.9% vs 45.7%; P = 0.02). The difference in physician compliance between hospital auditors and covert observers was 19.0% (73.2%, 175/239 vs. 54.2%, 469/865); for nurses this difference was much higher at 40.7% (85.8%, 754/879 vs. 45.1%, 330/732) (P < 0.0001) (Table 1).

In terms of physician compliance, primary teams tended to have lower HH compliance of 50.4% (323/641) compared with consulting services at 57.0% (158/277) (P = 0.06). Team rounds of 3 members were associated with higher compliance compared with encounters involving <3 members (62.1%, 282/454 vs. 42.0%, 128/308) (P < 0.0002). Presence of attending physician did not affect trainee HH compliance (55.5%, 201/362 when attending present vs. 56.8%, 133/234 when attending absent; P = 0.79). However, trainee HH compliance improved markedly when attending staff cleaned their hands and decreased markedly when they did not (79.5%, 174/219 vs. 18.9%, 27/143; P < 0.0002).

DISCUSSION

We introduced covert HH observers at our hospital to determine whether differences in Hawthorne effect accounted for measured disparity between physician HH compliance, and to gain further insights into the barriers and enablers of physician HH compliance. We discovered that performance differences between physicians and nurses decreased when neither group was aware that HH was being measured, suggesting that healthcare professions are differentially affected by the Hawthorne effect. This difference may be explained by the continuity of nurses on the ward that makes them more aware of visitors like HH auditors,[7] compared with physicians who rotate periodically on the ward.

Although hospital auditors play a central role in HH education through in‐the‐moment feedback, use of these data to benchmark performance can lead to inappropriate inferences about HH compliance. Prior studies using automated HH surveillance have suggested that the magnitude of the Hawthorne effect varies based on baseline HH rates,[8] whereas our study suggests a differential Hawthorne effect between professions and clinical services. If we relied only on auditor data, we would have continued to believe that only physicians in our organization had poor HH compliance, and we would not be aware of the global nature of the HH problem.

Our results are similar to that of Pan et al., who used covert medical students to measure HH and found compliance of 44.1% compared with 94.1% by unit auditors.[2] Because their study involved an active feedback intervention, the differential in Hawthorne effect between professions could not be reliably assessed. However, they observed a progressive increase in nurse HH compliance using covert observation methods, suggesting improvement in HH performance independent of observer bias.[7]

Covert observation in our study also provided important insights regarding barriers and enablers of HH compliance. Self‐preservation behaviors were common among both nurses and physicians, as HH compliance was consistently higher after patient contact compared to before or when seeing patients who required additional precautions. This finding confirms that the perceived risk of transmission seems to be a powerful motivating factor for HH.[9] Larger groups of trainees were more likely to clean their hands, likely due to peer effects.[10] The strong impact of role modeling on HH was also noted as previously suggested in the literature,[3, 6] but our study captures the magnitude of this effect. Whether or not the attending physician cleaned their hands during rounds either positively or negatively influenced HH compliance of the rest of the physician team (80% when compliant vs 20% when noncompliant).

Our study has several important limitations. The differential Hawthorne effect seen at our center may not reflect other institutions that have numerous HH auditors or high staff turnover resulting in lower ability to recognize auditors. We cannot exclude the possibility of Hawthorne effect using covert methods that could have affected nurse and physician performance differently, but frequent rotation of the students helped maintain covertness of observations. Finally, due to the nature of the covert student observers, a longer observation time frame could not be sustained.

Our experience using covert HH auditors suggests that traditional HH audits not only overstate HH performance overall, but can lead to inaccurate inferences regarding HH performance due to relative differences in Hawthorne effect. The answer to the question regarding whether physicians clean their hands appears to be that they do just as often as nurses, but that all healthcare workers have tremendous room for improvement. We suggest that future improvement efforts will rely on more accurate HH monitoring systems and strong attending physician leadership to set an example for trainees.

Disclosures

This study was jointly funded by the Centre for Quality Improvement and Patient Safety of the University of Toronto in collaboration with Sunnybrook Health Sciences Centre. All authors report no conflicts of interest relevant to this article.

Files
References
  1. World Health Organization. WHO guidelines on hand hygiene in health care. Available at: http://whqlibdoc.who.int/publications/2009/9789241597906_eng.pdf. Accessed April 4th, 2015.
  2. Pan SC, Tien KL, Hung IC, et al. Compliance of health care workers with hand hygiene practices: independent advantages of overt and covert observers. PLoS One. 2013;8:e53746.
  3. Squires JE, Linklater S, Grimshaw JM, et al. Understanding practice: factors that influence physician hand hygiene compliance. Infect Control Hosp Epidemiol. 2014;35:15111520.
  4. (JCYH) Just Clean Your Hands. Ontario Agency for Health Promotion and Protection. Available at: http://www.publichealthontario.ca/en/BrowseByTopic/InfectiousDiseases/JustCleanYourHands/Pages/Just‐Clean‐Your‐Hands.aspx. Accessed August 4, 2015.
  5. Allegranzi B, Gayet‐Ageron A, Damani N, et al. Global implementation of WHO's multimodal strategy for improvement of hand hygiene: a quasi‐experimental study. Lancet Infect Dis. 2013;13:843851.
  6. Schneider J, Moromisato D, Zemetra B, et al. Hand hygiene adherence is influenced by the behavior of role models. Pediatr Crit Care Med. 2009;10:360363.
  7. Srigley JA, Furness CD, Baker GR, Gardam M. Quantification of the Hawthorne effect in hand hygiene compliance monitoring using an electronic monitoring system: a retrospective cohort study. BMJ Qual Saf. 2014;23:974980.
  8. Kohli E, Ptak J, Smith R, et al. Variability in the Hawthorne effect with regard to hand hygiene performance in high‐ and low‐performing inpatient care units. Infect Control Hosp Epidemiol. 2009;30:222225.
  9. Borg MA, Benbachir M, Cookson BD, et al. Self‐protection as a driver for hand hygiene among healthcare workers. Infect Control. 2009;30:578580.
  10. Monsalve MN, Pemmaraju SV, Thomas GW et al. Do peer effects improve hand hygiene adherence among healthcare workers? Infect Control Hosp Epidemiol. 2014;35:12771285.
Article PDF
Issue
Journal of Hospital Medicine - 11(12)
Page Number
862-864
Sections
Files
Files
Article PDF
Article PDF

Hand hygiene (HH) is believed to be one of the single most important interventions to prevent healthcare‐associated infection, yet physicians are notorious for their poor compliance.[1, 2, 3] At our 800‐bed acute care academic hospital, we implemented a multifaceted HH program[4] in 2007, which was associated with improved HH compliance rates from 43% to 87%. Despite this improvement, HH compliance among physicians remained suboptimal, with rates below 60% in some patient areas. A targeted campaign focused on recruitment of physician champions, resulted in some improvement, but physician compliance has consistently remained below performance of nurses (70%75% for physicians vs 85%90% for nurses).

Our experience parallels the results seen in multinational surveys demonstrating consistently lower physician HH compliance.[5] Given the multiple improvement efforts directed at physicians and the apparent ceiling observed in HH performance, we wanted to confirm whether physicians are truly recalcitrant to cleaning their hands, or whether lower compliance among physicians reflected a differential in the Hawthorne effect inherent to direct observation methods. Specifically, we wondered if nurses tend to recognize auditors more readily than physicians and therefore show higher apparent HH compliance when auditors are present. We also wanted to verify whether the behavior of attending physicians influenced compliance of their physician trainees. To test these hypotheses, we trained 2 clinical observers to covertly measure HH compliance of nurses and physicians on 3 different clinical services.

METHODS

Between May 27, 2015 and July 31, 2015, 2 student observers joined clinical rotations on physician and nursing teams, respectively. Healthcare teams were unaware that the student observers were measuring HH compliance during their clinical rotation. Students rotated in the emergency department, general medical and surgical wards for no more than 1 week at a time to increase exposure to different providers and minimize risk of exposing the covert observation.

Prior to the study period, the students underwent training and validation with a hospital HH auditor at another clinical setting offsite to avoid any recognition of these students by healthcare providers as observers of HH at the main hospital. Training with the auditors occurred until interobserver agreement between all HH opportunities reached 100% agreement for 2 consecutive observation days.

During their rotations, students covertly recorded HH compliance based on moments of hand hygiene[4] and also noted location, presence, and compliance of the attending physician, team size during patient encounter, and isolation requirements. Both students measured HH compliance of nurses and physicians around them. Although students spent the majority of their time with their assigned physician or nurse teams, they did not limit their observations to these individuals only, but recorded compliance of any nurse or physician on the ward as long as they were within sight during an HH opportunity. To limit clustering of observations of the same healthcare worker, up to a maximum of 2 observations per healthcare worker per day was recorded.

We compared covertly measured HH compliance with data from overt observation by hospital auditors during the same time period. Differences in proportion of HH compliance were compared with hospital audits during the same period with a 2 test. Difference between differences in overtly and covertly measured HH compliance for nurses and physicians was compared using Breslow day test.

The study was approved by the hospital's research ethics board. Although deception was used in this study,[2, 6] all data were collected for quality improvement purposes, and the aggregate results were disclosed to hospital staff following the study.

RESULTS

Covertly observed HH compliance was 50.0% (799/1597) compared with 83.7% (2769/3309) recorded by hospital auditors during the same time period (P < 0.0002) (Table 1). There was no significant difference in the compliance measured by each student (50.1%, 473/928 vs 48.7%, 326/669) (P = 0.3), and their results were combined for the rest of the analysis. Compliance before contact with the patient or patient environment was 43.1% (344/798), 74.3% (26/35) before clean/aseptic procedures, 34.8% (8/23) after potential body fluid exposure, and 56.8% (483/851) after contact with the patient or patient environment. Healthcare providers examining patients with isolation precautions were found to have a HH compliance of 74.8% (101/135) compared to 47.0% (385/820) when isolation precautions were not required (P < 0.0002).

Hand Hygiene Compliance Across Clinical Services and Professional Groupings as Measured by Covert Observers and Hospital Auditors During the Study Period
Covert Observers, Compliance (95% CI) Hospital Auditors, Compliance (95% CI) Difference
  • NOTE: Abbreviations: CI, confidence interval. *When attending physicians cleaned their hands. When attending physicians did not clean their hands.

Overall hand hygiene compliance 50.0% (47.6‐52.5) 83.7% (82.4‐84.9) 33.7%
Service
Medicine 58.9% (55.3‐62.5) 85.0% (82.7‐87.3) 26.1%
Surgery 45.7% (41.6‐49.8) 91.0% (87.5‐93.7) 45.3%
Emergency 43.9% (38.9‐49.9) 73.8% (68.9‐78.2) 29.9%
Nurses 45.1% (41.5‐48.7) 85.8% (83.3‐87.9) 40.7%
Physicians
Overall compliance 54.2% (50.9‐57.1) 73.2% (67.3‐78.4) 19.0%
Trainee compliance* 79.5% (73.6‐84.3)
Trainee compliance 18.9% (13.3‐26.1)

Hospital auditor data showed that surgery and medicine had similarly high rates of compliance (91.0% and 85.0%, respectively), whereas the emergency department had a notably lower rate of 73.8%. Covert observation confirmed a lower rate in the emergency department (43.9%), but showed a higher compliance on general medicine than on surgery (58.9% vs 45.7%; P = 0.02). The difference in physician compliance between hospital auditors and covert observers was 19.0% (73.2%, 175/239 vs. 54.2%, 469/865); for nurses this difference was much higher at 40.7% (85.8%, 754/879 vs. 45.1%, 330/732) (P < 0.0001) (Table 1).

In terms of physician compliance, primary teams tended to have lower HH compliance of 50.4% (323/641) compared with consulting services at 57.0% (158/277) (P = 0.06). Team rounds of 3 members were associated with higher compliance compared with encounters involving <3 members (62.1%, 282/454 vs. 42.0%, 128/308) (P < 0.0002). Presence of attending physician did not affect trainee HH compliance (55.5%, 201/362 when attending present vs. 56.8%, 133/234 when attending absent; P = 0.79). However, trainee HH compliance improved markedly when attending staff cleaned their hands and decreased markedly when they did not (79.5%, 174/219 vs. 18.9%, 27/143; P < 0.0002).

DISCUSSION

We introduced covert HH observers at our hospital to determine whether differences in Hawthorne effect accounted for measured disparity between physician HH compliance, and to gain further insights into the barriers and enablers of physician HH compliance. We discovered that performance differences between physicians and nurses decreased when neither group was aware that HH was being measured, suggesting that healthcare professions are differentially affected by the Hawthorne effect. This difference may be explained by the continuity of nurses on the ward that makes them more aware of visitors like HH auditors,[7] compared with physicians who rotate periodically on the ward.

Although hospital auditors play a central role in HH education through in‐the‐moment feedback, use of these data to benchmark performance can lead to inappropriate inferences about HH compliance. Prior studies using automated HH surveillance have suggested that the magnitude of the Hawthorne effect varies based on baseline HH rates,[8] whereas our study suggests a differential Hawthorne effect between professions and clinical services. If we relied only on auditor data, we would have continued to believe that only physicians in our organization had poor HH compliance, and we would not be aware of the global nature of the HH problem.

Our results are similar to that of Pan et al., who used covert medical students to measure HH and found compliance of 44.1% compared with 94.1% by unit auditors.[2] Because their study involved an active feedback intervention, the differential in Hawthorne effect between professions could not be reliably assessed. However, they observed a progressive increase in nurse HH compliance using covert observation methods, suggesting improvement in HH performance independent of observer bias.[7]

Covert observation in our study also provided important insights regarding barriers and enablers of HH compliance. Self‐preservation behaviors were common among both nurses and physicians, as HH compliance was consistently higher after patient contact compared to before or when seeing patients who required additional precautions. This finding confirms that the perceived risk of transmission seems to be a powerful motivating factor for HH.[9] Larger groups of trainees were more likely to clean their hands, likely due to peer effects.[10] The strong impact of role modeling on HH was also noted as previously suggested in the literature,[3, 6] but our study captures the magnitude of this effect. Whether or not the attending physician cleaned their hands during rounds either positively or negatively influenced HH compliance of the rest of the physician team (80% when compliant vs 20% when noncompliant).

Our study has several important limitations. The differential Hawthorne effect seen at our center may not reflect other institutions that have numerous HH auditors or high staff turnover resulting in lower ability to recognize auditors. We cannot exclude the possibility of Hawthorne effect using covert methods that could have affected nurse and physician performance differently, but frequent rotation of the students helped maintain covertness of observations. Finally, due to the nature of the covert student observers, a longer observation time frame could not be sustained.

Our experience using covert HH auditors suggests that traditional HH audits not only overstate HH performance overall, but can lead to inaccurate inferences regarding HH performance due to relative differences in Hawthorne effect. The answer to the question regarding whether physicians clean their hands appears to be that they do just as often as nurses, but that all healthcare workers have tremendous room for improvement. We suggest that future improvement efforts will rely on more accurate HH monitoring systems and strong attending physician leadership to set an example for trainees.

Disclosures

This study was jointly funded by the Centre for Quality Improvement and Patient Safety of the University of Toronto in collaboration with Sunnybrook Health Sciences Centre. All authors report no conflicts of interest relevant to this article.

Hand hygiene (HH) is believed to be one of the single most important interventions to prevent healthcare‐associated infection, yet physicians are notorious for their poor compliance.[1, 2, 3] At our 800‐bed acute care academic hospital, we implemented a multifaceted HH program[4] in 2007, which was associated with improved HH compliance rates from 43% to 87%. Despite this improvement, HH compliance among physicians remained suboptimal, with rates below 60% in some patient areas. A targeted campaign focused on recruitment of physician champions, resulted in some improvement, but physician compliance has consistently remained below performance of nurses (70%75% for physicians vs 85%90% for nurses).

Our experience parallels the results seen in multinational surveys demonstrating consistently lower physician HH compliance.[5] Given the multiple improvement efforts directed at physicians and the apparent ceiling observed in HH performance, we wanted to confirm whether physicians are truly recalcitrant to cleaning their hands, or whether lower compliance among physicians reflected a differential in the Hawthorne effect inherent to direct observation methods. Specifically, we wondered if nurses tend to recognize auditors more readily than physicians and therefore show higher apparent HH compliance when auditors are present. We also wanted to verify whether the behavior of attending physicians influenced compliance of their physician trainees. To test these hypotheses, we trained 2 clinical observers to covertly measure HH compliance of nurses and physicians on 3 different clinical services.

METHODS

Between May 27, 2015 and July 31, 2015, 2 student observers joined clinical rotations on physician and nursing teams, respectively. Healthcare teams were unaware that the student observers were measuring HH compliance during their clinical rotation. Students rotated in the emergency department, general medical and surgical wards for no more than 1 week at a time to increase exposure to different providers and minimize risk of exposing the covert observation.

Prior to the study period, the students underwent training and validation with a hospital HH auditor at another clinical setting offsite to avoid any recognition of these students by healthcare providers as observers of HH at the main hospital. Training with the auditors occurred until interobserver agreement between all HH opportunities reached 100% agreement for 2 consecutive observation days.

During their rotations, students covertly recorded HH compliance based on moments of hand hygiene[4] and also noted location, presence, and compliance of the attending physician, team size during patient encounter, and isolation requirements. Both students measured HH compliance of nurses and physicians around them. Although students spent the majority of their time with their assigned physician or nurse teams, they did not limit their observations to these individuals only, but recorded compliance of any nurse or physician on the ward as long as they were within sight during an HH opportunity. To limit clustering of observations of the same healthcare worker, up to a maximum of 2 observations per healthcare worker per day was recorded.

We compared covertly measured HH compliance with data from overt observation by hospital auditors during the same time period. Differences in proportion of HH compliance were compared with hospital audits during the same period with a 2 test. Difference between differences in overtly and covertly measured HH compliance for nurses and physicians was compared using Breslow day test.

The study was approved by the hospital's research ethics board. Although deception was used in this study,[2, 6] all data were collected for quality improvement purposes, and the aggregate results were disclosed to hospital staff following the study.

RESULTS

Covertly observed HH compliance was 50.0% (799/1597) compared with 83.7% (2769/3309) recorded by hospital auditors during the same time period (P < 0.0002) (Table 1). There was no significant difference in the compliance measured by each student (50.1%, 473/928 vs 48.7%, 326/669) (P = 0.3), and their results were combined for the rest of the analysis. Compliance before contact with the patient or patient environment was 43.1% (344/798), 74.3% (26/35) before clean/aseptic procedures, 34.8% (8/23) after potential body fluid exposure, and 56.8% (483/851) after contact with the patient or patient environment. Healthcare providers examining patients with isolation precautions were found to have a HH compliance of 74.8% (101/135) compared to 47.0% (385/820) when isolation precautions were not required (P < 0.0002).

Hand Hygiene Compliance Across Clinical Services and Professional Groupings as Measured by Covert Observers and Hospital Auditors During the Study Period
Covert Observers, Compliance (95% CI) Hospital Auditors, Compliance (95% CI) Difference
  • NOTE: Abbreviations: CI, confidence interval. *When attending physicians cleaned their hands. When attending physicians did not clean their hands.

Overall hand hygiene compliance 50.0% (47.6‐52.5) 83.7% (82.4‐84.9) 33.7%
Service
Medicine 58.9% (55.3‐62.5) 85.0% (82.7‐87.3) 26.1%
Surgery 45.7% (41.6‐49.8) 91.0% (87.5‐93.7) 45.3%
Emergency 43.9% (38.9‐49.9) 73.8% (68.9‐78.2) 29.9%
Nurses 45.1% (41.5‐48.7) 85.8% (83.3‐87.9) 40.7%
Physicians
Overall compliance 54.2% (50.9‐57.1) 73.2% (67.3‐78.4) 19.0%
Trainee compliance* 79.5% (73.6‐84.3)
Trainee compliance 18.9% (13.3‐26.1)

Hospital auditor data showed that surgery and medicine had similarly high rates of compliance (91.0% and 85.0%, respectively), whereas the emergency department had a notably lower rate of 73.8%. Covert observation confirmed a lower rate in the emergency department (43.9%), but showed a higher compliance on general medicine than on surgery (58.9% vs 45.7%; P = 0.02). The difference in physician compliance between hospital auditors and covert observers was 19.0% (73.2%, 175/239 vs. 54.2%, 469/865); for nurses this difference was much higher at 40.7% (85.8%, 754/879 vs. 45.1%, 330/732) (P < 0.0001) (Table 1).

In terms of physician compliance, primary teams tended to have lower HH compliance of 50.4% (323/641) compared with consulting services at 57.0% (158/277) (P = 0.06). Team rounds of 3 members were associated with higher compliance compared with encounters involving <3 members (62.1%, 282/454 vs. 42.0%, 128/308) (P < 0.0002). Presence of attending physician did not affect trainee HH compliance (55.5%, 201/362 when attending present vs. 56.8%, 133/234 when attending absent; P = 0.79). However, trainee HH compliance improved markedly when attending staff cleaned their hands and decreased markedly when they did not (79.5%, 174/219 vs. 18.9%, 27/143; P < 0.0002).

DISCUSSION

We introduced covert HH observers at our hospital to determine whether differences in Hawthorne effect accounted for measured disparity between physician HH compliance, and to gain further insights into the barriers and enablers of physician HH compliance. We discovered that performance differences between physicians and nurses decreased when neither group was aware that HH was being measured, suggesting that healthcare professions are differentially affected by the Hawthorne effect. This difference may be explained by the continuity of nurses on the ward that makes them more aware of visitors like HH auditors,[7] compared with physicians who rotate periodically on the ward.

Although hospital auditors play a central role in HH education through in‐the‐moment feedback, use of these data to benchmark performance can lead to inappropriate inferences about HH compliance. Prior studies using automated HH surveillance have suggested that the magnitude of the Hawthorne effect varies based on baseline HH rates,[8] whereas our study suggests a differential Hawthorne effect between professions and clinical services. If we relied only on auditor data, we would have continued to believe that only physicians in our organization had poor HH compliance, and we would not be aware of the global nature of the HH problem.

Our results are similar to that of Pan et al., who used covert medical students to measure HH and found compliance of 44.1% compared with 94.1% by unit auditors.[2] Because their study involved an active feedback intervention, the differential in Hawthorne effect between professions could not be reliably assessed. However, they observed a progressive increase in nurse HH compliance using covert observation methods, suggesting improvement in HH performance independent of observer bias.[7]

Covert observation in our study also provided important insights regarding barriers and enablers of HH compliance. Self‐preservation behaviors were common among both nurses and physicians, as HH compliance was consistently higher after patient contact compared to before or when seeing patients who required additional precautions. This finding confirms that the perceived risk of transmission seems to be a powerful motivating factor for HH.[9] Larger groups of trainees were more likely to clean their hands, likely due to peer effects.[10] The strong impact of role modeling on HH was also noted as previously suggested in the literature,[3, 6] but our study captures the magnitude of this effect. Whether or not the attending physician cleaned their hands during rounds either positively or negatively influenced HH compliance of the rest of the physician team (80% when compliant vs 20% when noncompliant).

Our study has several important limitations. The differential Hawthorne effect seen at our center may not reflect other institutions that have numerous HH auditors or high staff turnover resulting in lower ability to recognize auditors. We cannot exclude the possibility of Hawthorne effect using covert methods that could have affected nurse and physician performance differently, but frequent rotation of the students helped maintain covertness of observations. Finally, due to the nature of the covert student observers, a longer observation time frame could not be sustained.

Our experience using covert HH auditors suggests that traditional HH audits not only overstate HH performance overall, but can lead to inaccurate inferences regarding HH performance due to relative differences in Hawthorne effect. The answer to the question regarding whether physicians clean their hands appears to be that they do just as often as nurses, but that all healthcare workers have tremendous room for improvement. We suggest that future improvement efforts will rely on more accurate HH monitoring systems and strong attending physician leadership to set an example for trainees.

Disclosures

This study was jointly funded by the Centre for Quality Improvement and Patient Safety of the University of Toronto in collaboration with Sunnybrook Health Sciences Centre. All authors report no conflicts of interest relevant to this article.

References
  1. World Health Organization. WHO guidelines on hand hygiene in health care. Available at: http://whqlibdoc.who.int/publications/2009/9789241597906_eng.pdf. Accessed April 4th, 2015.
  2. Pan SC, Tien KL, Hung IC, et al. Compliance of health care workers with hand hygiene practices: independent advantages of overt and covert observers. PLoS One. 2013;8:e53746.
  3. Squires JE, Linklater S, Grimshaw JM, et al. Understanding practice: factors that influence physician hand hygiene compliance. Infect Control Hosp Epidemiol. 2014;35:15111520.
  4. (JCYH) Just Clean Your Hands. Ontario Agency for Health Promotion and Protection. Available at: http://www.publichealthontario.ca/en/BrowseByTopic/InfectiousDiseases/JustCleanYourHands/Pages/Just‐Clean‐Your‐Hands.aspx. Accessed August 4, 2015.
  5. Allegranzi B, Gayet‐Ageron A, Damani N, et al. Global implementation of WHO's multimodal strategy for improvement of hand hygiene: a quasi‐experimental study. Lancet Infect Dis. 2013;13:843851.
  6. Schneider J, Moromisato D, Zemetra B, et al. Hand hygiene adherence is influenced by the behavior of role models. Pediatr Crit Care Med. 2009;10:360363.
  7. Srigley JA, Furness CD, Baker GR, Gardam M. Quantification of the Hawthorne effect in hand hygiene compliance monitoring using an electronic monitoring system: a retrospective cohort study. BMJ Qual Saf. 2014;23:974980.
  8. Kohli E, Ptak J, Smith R, et al. Variability in the Hawthorne effect with regard to hand hygiene performance in high‐ and low‐performing inpatient care units. Infect Control Hosp Epidemiol. 2009;30:222225.
  9. Borg MA, Benbachir M, Cookson BD, et al. Self‐protection as a driver for hand hygiene among healthcare workers. Infect Control. 2009;30:578580.
  10. Monsalve MN, Pemmaraju SV, Thomas GW et al. Do peer effects improve hand hygiene adherence among healthcare workers? Infect Control Hosp Epidemiol. 2014;35:12771285.
References
  1. World Health Organization. WHO guidelines on hand hygiene in health care. Available at: http://whqlibdoc.who.int/publications/2009/9789241597906_eng.pdf. Accessed April 4th, 2015.
  2. Pan SC, Tien KL, Hung IC, et al. Compliance of health care workers with hand hygiene practices: independent advantages of overt and covert observers. PLoS One. 2013;8:e53746.
  3. Squires JE, Linklater S, Grimshaw JM, et al. Understanding practice: factors that influence physician hand hygiene compliance. Infect Control Hosp Epidemiol. 2014;35:15111520.
  4. (JCYH) Just Clean Your Hands. Ontario Agency for Health Promotion and Protection. Available at: http://www.publichealthontario.ca/en/BrowseByTopic/InfectiousDiseases/JustCleanYourHands/Pages/Just‐Clean‐Your‐Hands.aspx. Accessed August 4, 2015.
  5. Allegranzi B, Gayet‐Ageron A, Damani N, et al. Global implementation of WHO's multimodal strategy for improvement of hand hygiene: a quasi‐experimental study. Lancet Infect Dis. 2013;13:843851.
  6. Schneider J, Moromisato D, Zemetra B, et al. Hand hygiene adherence is influenced by the behavior of role models. Pediatr Crit Care Med. 2009;10:360363.
  7. Srigley JA, Furness CD, Baker GR, Gardam M. Quantification of the Hawthorne effect in hand hygiene compliance monitoring using an electronic monitoring system: a retrospective cohort study. BMJ Qual Saf. 2014;23:974980.
  8. Kohli E, Ptak J, Smith R, et al. Variability in the Hawthorne effect with regard to hand hygiene performance in high‐ and low‐performing inpatient care units. Infect Control Hosp Epidemiol. 2009;30:222225.
  9. Borg MA, Benbachir M, Cookson BD, et al. Self‐protection as a driver for hand hygiene among healthcare workers. Infect Control. 2009;30:578580.
  10. Monsalve MN, Pemmaraju SV, Thomas GW et al. Do peer effects improve hand hygiene adherence among healthcare workers? Infect Control Hosp Epidemiol. 2014;35:12771285.
Issue
Journal of Hospital Medicine - 11(12)
Issue
Journal of Hospital Medicine - 11(12)
Page Number
862-864
Page Number
862-864
Article Type
Display Headline
Do physicians clean their hands? Insights from a covert observational study
Display Headline
Do physicians clean their hands? Insights from a covert observational study
Sections
Article Source
© 2016 Society of Hospital Medicine
Disallow All Ads
Correspondence Location
Address for correspondence and reprint requests: Jerome A. Leis, MD, Sunnybrook Health Sciences Centre, H463, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5 Canada; Telephone: 416‐480‐6100 x89352; Fax: 416‐480‐6769; E‐mail: [email protected]
Content Gating
Gated (full article locked unless allowed per User)
Gating Strategy
First Peek Free
Article PDF Media
Media Files

LOS in Children With Medical Complexity

Article Type
Changed
Mon, 01/02/2017 - 19:34
Display Headline
Long length of hospital stay in children with medical complexity

Children with medical complexity (CMC) have complex and chronic health conditions that often involve multiple organ systems and severely affect cognitive and physical functioning. Although the prevalence of CMC is low (1% of all children), they account for nearly one‐fifth of all pediatric admissions and one‐half of all hospital days and charges in the United States.[1] Over the last decade, CMC have had a particularly large and increasing impact in tertiary‐care children's hospitals.[1, 2] The Institute of Medicine has identified CMC as a priority population for a revised healthcare system.[3]

Medical homes, hospitals, health plans, states, federal agencies, and others are striving to reduce excessive hospital use in CMC because of its high cost.[4, 5, 6] Containing length of stay (LOS)an increasingly used indicator of the time sensitiveness and efficiency of hospital careis a common aim across these initiatives. CMC have longer hospitalizations than children without medical complexity. Speculated reasons for this are that CMC tend to have (1) higher severity of acute illnesses (eg, pneumonia, cellulitis), (2) prolonged recovery time in the hospital, and (3) higher risk of adverse events in the hospital. Moreover, hospital clinicians caring for CMC often find it difficult to determine discharge readiness, given that many CMC do not return to a completely healthy baseline.[7]

Little is known about long LOS in CMC, including which CMC have the highest risk of experiencing such stays and which stays might have the greatest opportunity to be shortened. Patient characteristics associated with prolonged length of stay have been studied extensively for many pediatric conditions (eg, asthma).[8, 9, 10, 11, 12, 13, 14] However, most of these studies excluded CMC. Therefore, the objectives of this study were to examine (1) the prevalence of long LOS in CMC, (2) patient characteristics associated with long LOS, and (3) hospital‐to‐hospital variation in prevalence of long LOS hospitalizations.

METHODS

Study Design and Data Source

This study is a multicenter, retrospective cohort analysis of the Pediatric Health Information System (PHIS). PHIS is an administrative database of 44 not for profit, tertiary care pediatric hospitals affiliated with the Children's Hospital Association (CHA) (Overland Park, KS). PHIS contains data regarding patient demographics, diagnoses, and procedures (with International Classification of Diseases, 9th Revision, Clinical Modification [ICD‐9‐CM] codes), All‐Patient Refined Diagnostic Related Groups version 30 (APR‐DRGs) (3M Health Information Systems, Salt Lake City, UT), and service lines that aggregate the APR‐DRGs into 38 distinct groups. Data quality and reliability are assured through CHA and participating hospitals. In accordance with the policies of the Cincinnati Children's Hospital Medical Center Institutional Review Board, this study of deidentified data was not considered human subjects research.

Study Population

Inclusion Criteria

Children discharged following an observation or inpatient admission from a hospital participating in the PHIS database between January 1, 2013 and December 31, 2014 were eligible for inclusion if they were considered medically complex. Medical complexity was defined using Clinical Risk Groups (CRGs) version 1.8, developed by 3M Health Information Systems and the National Association of Children's Hospitals and Related Institutions. CRGs were used to assign each hospitalized patient to 1 of 9 mutually exclusive chronicity groups according to the presence, type, and severity of chronic conditions.[15, 16, 17, 18] Each patient's CRG designation was based on 2 years of previous hospital encounters.

As defined in prior studies and definitional frameworks of CMC,[1] patients belonging to CRG group 6 (significant chronic disease in 2 organ systems), CRG group 7 (dominant chronic disease in 3 organ systems), and CRG group 9 (catastrophic condition) were considered medically complex.[17, 19] Patients with malignancies (CRG group 8) were not included for analysis because they are a unique population with anticipated, long hospital stays. Patients with CRG group 5, representing those with chronic conditions affecting a single body system, were also not included because most do not have attributes consistent with medical complexity.

Exclusion Criteria

We used the APR‐DRG system, which leverages ICD‐9‐CM codes to identify the health problem most responsible for the hospitalization, to refine the study cohort. We excluded hospitalizations that were classified by the APR‐DRG system as neonatal, as we did not wish to focus on LOS in the neonatal intensive care unit (ICU) or for birth admissions. Similarly, hospitalizations for chemotherapy (APR‐DRG 693) or malignancy (identified with previously used ICD‐9‐CM codes)[20] were also excluded because long LOS is anticipated. We also excluded hospitalizations for medical rehabilitation (APR‐DRG 860).

Outcome Measures

The primary outcome measure was long LOS, defined as LOS 10 days. The cut point of LOS 10 days represents the 90th percentile of LOS for all children, with and without medical complexity, hospitalized during 2013 to 2014. LOS 10 days has previously been used as a threshold of long LOS.[21] For hospitalizations involving transfer at admission from another acute care facility, LOS was measured from the date of transfer. We also assessed hospitals' cost attributable to long LOS admissions.

Patient Demographics and Clinical Characteristics

We measured demographic characteristics including age, gender, race/ethnicity, insurance type, and distance traveled (the linear distance between the centroid of the patient's home ZIP code and the centroid of the hospital's ZIP code). Clinical characteristics included CRG classification, complex chronic condition (CCC), and dependence on medical technology. CCCs are defined as any medical condition that can be reasonably expected to last at least 12 months (unless death intervenes) and to involve either several different organ systems or 1 system severely enough to require specialty pediatric care and probably some period of hospitalization in a tertiary care center.[20] Medical technology included devices used to optimize the health and functioning of the child (eg, gastrostomy, tracheostomy, cerebrospinal fluid shunt).[22]

Hospitalization Characteristics

Characteristics of the hospitalization included transfer from an outside facility, ICU admission, surgical procedure (using surgical APR‐DRGs), and discharge disposition (home, skilled nursing facility, home health services, death, other). Cost of the hospitalization was estimated in the PHIS from charges using hospital and year‐specific ratios of cost to charge.

Statistical Analysis

Continuous data (eg, distance from hospital to home residence) were described with median and interquartile ranges (IQR) because they were not normally distributed. Categorical data (eg, type of chronic condition) were described with counts and frequencies. In bivariate analyses, demographic, clinical, and hospitalization characteristics were stratified by LOS (long LOS vs LOS <10 days), and compared using 2 statistics or Wilcoxon rank sum tests as appropriate.

We modeled the likelihood of experiencing a long LOS using generalized linear mixed effects models with a random hospital intercept and discharge‐level fixed effects for age, gender, payor, CCC type, ICU utilization, transfer status, a medical/surgical admission indicator derived from the APR‐DRG, and CRG assigned to each hospitalization. To examine hospital‐to‐hospital variability, we generated hospital risk‐adjusted rates of long LOS from these models. Similar models and hospital risk‐adjusted rates were built for a post hoc correlational analysis of 30‐day all cause readmission, where hospitals' rates and percent of long LOS were compared with a Pearson correlation coefficient. Also, for our multivariable models, we performed a sensitivity analysis using an alternative definition of long LOS as 4 days (the 75th percentile of LOS for all children, with and without medical complexity, hospitalized during 20132014). All analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC), and P values <0.05 were considered statistically significant.

RESULTS

Study Population

There were 954,018 hospitalizations of 217,163 CMC at 44 children's hospitals included for analysis. Forty‐seven percent of hospitalizations were for females, 49.4% for non‐Hispanic whites, and 61.1% for children with government insurance. Fifteen percent (n = 142,082) had a long LOS of 10 days. The median (IQR) LOS of hospitalizations <10 days versus 10 days were 2 (IQR, 14) and 16 days (IQR, 1226), respectively. Long LOS hospitalizations accounted for 61.1% (3.7 million) hospital days and 61.8% ($13.7 billion) of total hospitalization costs for all CMC in the cohort (Table 1).

Demographic, Clinical, and Hospitalization Characteristics of Hospitalized Children With Medical Complexity by Length of Stay*
Characteristic Overall (n = 954,018) Length of Stay
<10 Days (n = 811,936) 10 Days (n = 142,082)
  • NOTE: Abbreviations: IQR, interquartile range. *All comparisons were significant at the P < 0.001 level.

Age at admission, y, %
<1 14.6 12.7 25.7
14 27.1 27.9 22.4
59 20.1 21.0 14.9
1018 33.6 34.0 31.7
18+ 4.6 4.4 5.4
Gender, %
Female 47.0 46.9 47.5
Race/ethnicity, %
Non‐Hispanic white 49.4 49.4 49.4
Non‐Hispanic black 23.1 23.8 19.3
Hispanic 18.2 17.8 20.4
Asian 2.0 1.9 2.3
Other 7.4 7.1 8.6
Complex chronic condition, %
Any 79.5 77.3 91.8
Technology assistance 37.1 34.1 54.2
Gastrointestinal 30.0 27.2 45.9
Neuromuscular 28.2 27.7 30.9
Cardiovascular 16.8 14.5 29.9
Respiratory 14.1 11.5 29.4
Congenital/genetic defect 17.2 16.7 20.2
Metabolic 9.9 8.9 15.4
Renal 10.1 9.5 13.8
Hematology/emmmunodeficiency 11.7 12.0 10.0
Neonatal 3.8 3.1 7.7
Transplantation 4.5 4.2 6.7
Clinical risk group, %
Chronic condition in 2 systems 68.4 71.2 53.9
Catastrophic chronic condition 31.4 28.8 46.1
Distance from hospital to home residence in miles, median [IQR] 16.2 [7.440.4] 15.8 [7.338.7] 19.1 [8.552.6]
Transferred from outside hospital (%) 6.5 5.3 13.6
Admitted for surgery, % 23.4 20.7 38.7
Use of intensive care, % 19.6 14.9 46.5
Discharge disposition, %
Home 91.2 92.9 81.4
Home healthcare 4.5 3.5 9.9
Other 2.9 2.6 4.5
Postacute care facility 1.1 0.8 3.1
Died 0.4 0.3 1.1
Payor, %
Government 61.1 60.6 63.5
Private 33.2 33.6 30.9
Other 5.7 5.7 5.7
Hospital resource use
Median length of stay [IQR] 3 [16] 2 [14] 16 [1226]
Median hospital cost [IQR] $8,144 [$4,122$18,447] $6,689 [$3,685$12,395] $49,207 [$29,444$95,738]
Total hospital cost, $, billions $22.2 $8.5 $13.7

Demographics and Clinical Characteristics of Children With and Without Long LOS

Compared with hospitalized CMC with LOS <10 days, a higher percentage of hospitalizations with LOS 10 days were CMC age <1 year (25.7% vs 12.7%, P < 0.001) and Hispanic (20.4% vs 17.8%, P < 0.001). CMC hospitalizations with a long LOS had a higher percentage of any CCC (91.8% vs 77.3%, P < 0.001); the most common CCCs were gastrointestinal (45.9%), neuromuscular (30.9%), and cardiovascular (29.9%). Hospitalizations of CMC with a long LOS had a higher percentage of a catastrophic chronic condition (46.1% vs 28.8%, P < 0.001) and technology dependence (46.1% vs 28.8%, P < 0.001) (Table 1).

Hospitalization Characteristics of Children With and Without Long LOS

Compared with hospitalizations of CMC with LOS <10 days, hospitalizations of CMC with a long LOS more often involved transfer in from another hospital at admission (13.6% vs 5.3%, P < 0.001). CMC hospital stays with a long LOS more often involved surgery (38.7% vs 20.7%, P < 0.001) and use of intensive care (46.5% vs 14.9%; P < 0.001). A higher percentage of CMC with long LOS were discharged with home health services (9.9% vs 3.5%; P < 0.001) (Table 1).

The most common admitting diagnoses and CCCs for hospitalizations of CMC with long LOS are presented in Table 2. The two most prevalent APR‐DRGs in CMC hospitalizations lasting 10 days or longer were cystic fibrosis (10.7%) and respiratory system disease with ventilator support (5.5%). The two most common chronic condition characteristics represented among long CMC hospitalizations were gastrointestinal devices (eg, gastrostomy tube) (39.7%) and heart and great vessel malformations (eg, tetralogy of Fallot) (12.8%). The 5 most common CCC subcategories, as listed in Table 2, account for nearly 100% of the patients with long LOS hospitalizations.

Most Common Reasons for Admission and Specific Complex Chronic Conditions for Hospitalized Children With Medical Complexity Who Had Length of Stay 10 Days
  • NOTE: *Reason for admission identified using All‐Patient Refined Diagnosis‐Related Groups. Complex chronic conditions identified using Feudtner and colleagues set of International Classification of Diseases, 9th Revision, Clinical Modification codes. Gastrointestinal devices include gastrostomy, gastrojejunostomy, colostomy. Respiratory devices include tracheostomy, noninvasive positive pressure, ventilator.

Most common reason for admission*
Cystic fibrosis 10.7%
Respiratory system diagnosis with ventilator support 96+ hours 5.5%
Malfunction, reaction, and complication of cardiac or vascular device or procedure 2.8%
Craniotomy except for trauma 2.6%
Major small and large bowel procedures 2.3%
Most common complex chronic condition
Gastrointestinal devices 39.7%
Heart and great vessel malformations 12.8%
Cystic fibrosis 12.5%
Dysrhythmias 11.0%
Respiratory devices 10.7%

Multivariable Analysis of Characteristics Associated With Long LOS

In multivariable analysis, the highest likelihood of long LOS was experienced by children who received care in the ICU (odds ratio [OR]: 3.5, 95% confidence interval [CI]: 3.43.5), who had a respiratory CCC (OR: 2.7, 95% CI: 2.62.7), and who were transferred from another acute care hospital at admission (OR: 2.1, 95% CI: 2.0, 2.1). The likelihood of long LOS was also higher in children <1 year of age (OR: 1.2, 95% CI: 1.21.3), and Hispanic children (OR: 1.1, 95% CI 1.0‐1.10) (Table 3). Similar multivariable findings were observed in sensitivity analysis using the 75th percentile of LOS (4 days) as the model outcome.

Multivariable Analysis of the Likelihood of Long Length of Stay 10 Days
Characteristic Odds Ratio (95% CI) of LOS 10 Days P Value
  • NOTE: Abbreviations: CI, confidence interval; LOS, length of stay.

Use of intensive care 3.5 (3.4‐3.5) <0.001
Transfer from another acute‐care hospital 2.1 (2.0‐2.1) <0.001
Procedure/surgery 1.8 (1.8‐1.9) <0.001
Complex chronic condition
Respiratory 2.7 (2.6‐2.7) <0.001
Gastrointestinal 1.8 (1.8‐1.8) <0.001
Metabolic 1.7 (1.7‐1.7) <0.001
Cardiovascular 1.6 (1.5‐1.6) <0.001
Neonatal 1.5 (1.5‐1.5) <0.001
Renal 1.4 (1.4‐1.4) <0.001
Transplant 1.4 (1.4‐1.4) <0.001
Hematology and immunodeficiency 1.3 (1.3‐1.3) <0.001
Technology assistance 1.1 (1.1, 1.1) <0.001
Neuromuscular 0.9 (0.9‐0.9) <0.001
Congenital or genetic defect 0.8 (0.8‐0.8) <0.001
Age at admission, y
<1 1.2 (1.2‐1.3) <0.001
14 0.5 (0.5‐0.5) <0.001
59 0.6 (0.6‐0.6) <0.001
1018 0.9 (0.9‐0.9) <0.001
18+ Reference
Male 0.9 (0.9‐0.9) <0.001
Race/ethnicity
Non‐Hispanic black 0.9 (0.9‐0.9) <0.001
Hispanic 1.1 (1.0‐1.1) <0.001
Asian 1.0 (1.0‐1.1) 0.3
Other 1.1 (1.1‐1.1) <0.001
Non‐Hispanic white Reference
Payor
Private 0.9 (0.8 0.9) <0.001
Other 1.0 (1.0‐1.0) 0.4
Government Reference
Season
Spring 1.0 (1.0 1.0) <0.001
Summer 0.9 (0.9‐0.9) <0.001
Fall 1.0 (0.9‐1.0) <0.001
Winter Reference

Variation in the Prevalence of Long LOS Across Children's Hospitals

After controlling for demographic, clinical, and hospital characteristics associated with long LOS, there was significant (P < 0.001) variation in the prevalence of long LOS for CMC across children's hospitals in the cohort (range, 10.3%21.8%) (Figure 1). Twelve (27%) hospitals had a significantly (P < 0.001) higher prevalence of long LOS for their hospitalized CMC, compared to the mean. Eighteen (41%) had a significantly (P < 0.001) lower prevalence of long LOS for their hospitalized CMC. There was also significant variation across hospitals with respect to cost, with 49.7% to 73.7% of all hospital costs of CMC attributed to long LOS hospitalizations. Finally, there was indirect correlation with the prevalence of LOS across hospitals and the hospitals' 30‐day readmission rate ( = 0.3; P = 0.04). As the prevalence of long LOS increased, the readmission rate decreased.

Figure 1
Variation in the Prevalence and Cost of Long Length of Stay ≥10 days for Children with Medical Complexity Across Children's Hospitals. Presented from the left y‐axis are the adjusted percentages (with 95% confidence interval)—shown as circles and whiskers—of total admissions for complex chronic condition (CMC) with length of stay (LOS) ≥10 days across 44 freestanding children's hospitals. The percentages are adjusted for demographic, clinical, and hospitalization characteristics associated with the likelihood of CMC experiencing LOS ≥10 days. The dashed line indicates the mean percentage (15%) across all hospitals. Also presented on the right y‐axis are the percentages—shown as gray bars—of all hospital charges attributable to hospitalizations ≥10 days among CMC across children's hospitals.

DISCUSSION

The main findings from this study suggest that a small percentage of CMC experiencing long LOS account for the majority of hospital bed days and cost of all hospitalized CMC in children's hospitals. The likelihood of long LOS varies significantly by CMC's age, race/ethnicity, and payor as well as by type and number of chronic conditions. Among CMC with long LOS, the use of gastrointestinal devices such as gastrostomy tubes, as well as congenital heart disease, were highly prevalent. In multivariable analysis, the characteristics most strongly associated with LOS 10 days were use of the ICU, respiratory complex chronic condition, and transfer from another medical facility at admission. After adjusting for these factors, there was significant variation in the prevalence of LOS 10 days for CMC across children's hospitals.

Although it is well known that CMC as a whole have a major impact on resource use in children's hospitals, this study reveals that 15% of hospitalizations of CMC account for 62% of all hospital costs of CMC. That is, a small fraction of hospitalizations of CMC is largely responsible for the significant financial impact of hospital resource use. To date, most clinical efforts and policies striving to reduce hospital use in CMC have focused on avoiding readmissions or index hospital admissions entirely, rather than improving the efficiency of hospital care after admission occurs.[23, 24, 25, 26] In the adult population, the impact of long LOS on hospital costs has been recognized, and several Medicare incentive programs have focused on in‐hospital timeliness and efficiency. As a result, LOS in Medicare beneficiaries has decreased dramatically over the past 2 decades.[27, 28, 29, 30] Optimizing the efficiency of hospital care for CMC may be an important goal to pursue, especially with precedent set in the adult literature.

Perhaps the substantial variation across hospitals in the prevalence of long LOS in CMC indicates opportunity to improve the efficiency of their inpatient care. This variation was not due to differences across hospitals' case mix of CMC. Further investigation is needed to determine how much of it is due to differences in quality of care. Clinical practice guidelines for hospital treatment of common illnesses usually exclude CMC. In our clinical experience across 9 children's hospitals, we have experienced varying approaches to setting discharge goals (ie, parameters on how healthy the child needs to be to ensure a successful hospital discharge) for CMC.[31] When the goals are absent or not clearly articulated, they can contribute to a prolonged hospitalization. Some families of CMC report significant issues when working with pediatric hospital staff to assess their child's discharge readiness.[7, 32, 33] In addition, there is significant variation across states and regions in access to and quality of post‐discharge health services (eg, home nursing, postacute care, durable medical equipment).[34, 35] In some areas, many CMC are not actively involved with their primary care physician.[5] These issues might also influence the ability of some children's hospitals to efficiently discharge CMC to a safe and supportive post‐discharge environment. Further examination of hospital outliersthose with the lowest and highest percentage of CMC hospitalizations with long LOSmay reveal opportunities to identify and spread best practices.

The demographic and clinical factors associated with long LOS in the present study, including age, ICU use, and transfer from another hospital, might help hospitals target which CMC have the greatest risk for experiencing long LOS. We found that infants age <1 year had longer LOS when compared with older children. Similar to our findings, younger‐aged children hospitalized with bronchiolitis have longer LOS.[36] Certainly, infants with medical complexity, in general, are a high‐acuity population with the potential for rapid clinical deterioration during an acute illness. Prolonged hospitalization for treatment and stabilization may be expected for many of them. Additional investigation is warranted to examine ICU use in CMC, and whether ICU admission or duration can be safely prevented or abbreviated. Opportunities to assess the quality of transfers into children's hospitals of CMC admitted to outside hospitals may be necessary. A study of pediatric burn patients reported that patients initially stabilized at a facility that was not a burn center and subsequently transferred to a burn center had a longer LOS than patients solely treated at a designated burn center.[37] Furthermore, events during transport itself may adversely impact the stability of an already fragile patient. Interventions to optimize the quality of care provided by transport teams have resulted in decreased LOS at the receiving hospital.[38]

This study's findings should be considered in the context of several limitations. Absent a gold‐standard definition of long LOS, we used the distribution of LOS across patients to inform our methods; LOS at the 90th percentile was selected as long. Although our sensitivity analysis using LOS at the 75th percentile produced similar findings, other cut points in LOS might be associated with different results. The study is not positioned to determine how much of the reported LOS was excessive, unnecessary, or preventable. The study findings may not generalize to types of hospitals not contained in PHIS (eg, nonchildren's hospitals and community hospitals). We did not focus on the impact of a new diagnosis (eg, new chronic illness) or acute in‐hospital event (eg, nosocomial infection) on prolonged LOS; future studies should investigate these clinical events with LOS.

PHIS does not contain information regarding characteristics that could influence LOS, including the children's social and familial attributes, transportation availability, home equipment needs, and local availability of postacute care facilities. Moreover, PHIS does not contain information about the hospital discharge procedures, process, or personnel across hospitals, which could influence LOS. Future studies on prolonged LOS should consider assessing this information. Because of the large sample size of hospitalizations included, the statistical power for the analyses was strong, rendering it possible that some findings that were statistically significant might have modest clinical significance (eg, relationship of Hispanic ethnicity with prolonged LOS). We could not determine why a positive correlation was not observed between hospitals' long LOS prevalence and their percentage of cost associated with long LOS; future studies should investigate the reasons for this finding.

Despite these limitations, the findings of the present study highlight the significance of long LOS in hospitalized CMC. These long hospitalizations account for a significant proportion of all hospital costs for this important population of children. The prevalence of long LOS for CMC varies considerably across children's hospitals, even after accounting for the case mix. Efforts to curtail hospital resource use and costs for CMC may benefit from focus on long LOS.

Files
References
  1. Berry JG, Hall M, Hall DE, et al. Inpatient growth and resource use in 28 children's hospitals: a longitudinal, multi‐institutional study. JAMA Pediatr. 2013;167(2):170177.
  2. Simon TD, Berry J, Feudtner C, et al. Children with complex chronic conditions in inpatient hospital settings in the united states. Pediatrics. 2010;126(4):647655.
  3. Clancy CM, Andresen EM. Meeting the health care needs of persons with disabilities. Milbank Q. 2002;80(2):381391.
  4. Mosquera RA, Avritscher EBC, Samuels CL, et al. Effect of an enhanced medical home on serious illness and cost of care among high‐risk children with chronic illness: a randomized clinical trial. JAMA. 2014;312(24):26402648.
  5. Berry JG, Hall M, Neff J, et al. Children with medical complexity and Medicaid: spending and cost savings. Health Aff Proj Hope. 2014;33(12):21992206.
  6. Children's Hospital Association. CARE Award. Available at: https://www.childrenshospitals.org/Programs‐and‐Services/Quality‐Improvement‐and‐Measurement/CARE‐Award. Accessed December 18, 2015.
  7. Berry JG, Ziniel SI, Freeman L, et al. Hospital readmission and parent perceptions of their child's hospital discharge. Int J Qual Health Care. 2013;25(5):573581.
  8. Fendler W, Baranowska‐Jazwiecka A, Hogendorf A, et al. Weekend matters: Friday and Saturday admissions are associated with prolonged hospitalization of children. Clin Pediatr (Phila). 2013;52(9):875878.
  9. Goudie A, Dynan L, Brady PW, Rettiganti M. Attributable cost and length of stay for central line‐associated bloodstream infections. Pediatrics. 2014;133(6):e1525e1532.
  10. Graves N, Weinhold D, Tong E, et al. Effect of healthcare‐acquired infection on length of hospital stay and cost. Infect Control Hosp Epidemiol. 2007;28(3):280292.
  11. Hassan F, Lewis TC, Davis MM, Gebremariam A, Dombkowski K. Hospital utilization and costs among children with influenza, 2003. Am J Prev Med. 2009;36(4):292296.
  12. Kronman MP, Hall M, Slonim AD, Shah SS. Charges and lengths of stay attributable to adverse patient‐care events using pediatric‐specific quality indicators: a multicenter study of freestanding children's hospitals. Pediatrics. 2008;121(6):e1653e1659.
  13. Leyenaar JK, Lagu T, Shieh M‐S, Pekow PS, Lindenauer PK. Variation in resource utilization for the management of uncomplicated community‐acquired pneumonia across community and children's hospitals. J Pediatr. 2014;165(3):585591.
  14. Leyenaar JK, Shieh M‐S, Lagu T, Pekow PS, Lindenauer PK. Variation and outcomes associated with direct hospital admission among children with pneumonia in the United States. JAMA Pediatr. 2014;168(9):829836.
  15. Hughes JS, Averill RF, Eisenhandler J, et al. Clinical Risk Groups (CRGs): a classification system for risk‐adjusted capitation‐based payment and health care management. Med Care. 2004;42(1):8190.
  16. Neff JM, Clifton H, Park KJ, et al. Identifying children with lifelong chronic conditions for care coordination by using hospital discharge data. Acad Pediatr. 2010;10(6):417423.
  17. Neff JM, Sharp VL, Muldoon J, Graham J, Myers K. Profile of medical charges for children by health status group and severity level in a Washington State Health Plan. Health Serv Res. 2004;39(1):7389.
  18. Neff JM, Sharp VL, Popalisky J, Fitzgibbon T. Using medical billing data to evaluate chronically ill children over time. J Ambulatory Care Manage. 2006;29(4):283290.
  19. O'Mahony L, O'Mahony DS, Simon TD, Neff J, Klein EJ, Quan L. Medical complexity and pediatric emergency department and inpatient utilization. Pediatrics. 2013;131(2):e559e565.
  20. Feudtner C, Feinstein JA, Zhong W, Hall M, Dai D. Pediatric complex chronic conditions classification system version 2: updated for ICD‐10 and complex medical technology dependence and transplantation. BMC Pediatr. 2014;14:199.
  21. Weissman C. Analyzing intensive care unit length of stay data: problems and possible solutions. Crit Care Med. 1997;25(9):15941600.
  22. Berry JG, Hall DE, Kuo DZ, et al. Hospital utilization and characteristics of patients experiencing recurrent readmissions within children's hospitals. JAMA. 2011;305(7):682690.
  23. Hudson SM. Hospital readmissions and repeat emergency department visits among children with medical complexity: an integrative review. J Pediatr Nurs. 2013;28(4):316339.
  24. Jurgens V, Spaeder MC, Pavuluri P, Waldman Z. Hospital readmission in children with complex chronic conditions discharged from subacute care. Hosp Pediatr. 2014;4(3):153158.
  25. Coller RJ, Nelson BB, Sklansky DJ, et al. Preventing hospitalizations in children with medical complexity: a systematic review. Pediatrics. 2014;134(6):e1628e1647.
  26. Kun SS, Edwards JD, Ward SLD, Keens TG. Hospital readmissions for newly discharged pediatric home mechanical ventilation patients. Pediatr Pulmonol. 2012;47(4):409414.
  27. Cram P, Lu X, Kaboli PJ, et al. Clinical characteristics and outcomes of Medicare patients undergoing total hip arthroplasty, 1991–2008. JAMA. 2011;305(15):15601567.
  28. Bueno H, Ross JS, Wang Y, et al. Trends in length of stay and short‐term outcomes among Medicare patients hospitalized for heart failure, 1993–2006. JAMA. 2010;303(21):21412147.
  29. U.S. Department of Health and Human Services. CMS Statistics 2013. Available at: https://www.cms.gov/Research‐Statistics‐Data‐and‐Systems/Statistics‐Trends‐and‐Reports/CMS‐Statistics‐Reference‐Booklet/Downloads/CMS_Stats_2013_final.pdf. Published August 2013. Accessed October 6, 2015.
  30. Centers for Medicare and Medicaid Services. Evaluation of the premier hospital quality incentive demonstration. Available at: https://www.cms.gov/Research‐Statistics‐Data‐and‐Systems/Statistics‐Trends‐and‐Reports/Reports/downloads/Premier_ExecSum_2010.pdf. Published March 3, 2009. Accessed September 18, 2015.
  31. Berry JG, Blaine K, Rogers J, et al. A framework of pediatric hospital discharge care informed by legislation, research, and practice. JAMA Pediatr. 2014;168(10):955962; quiz 965–966.
  32. Brittan M, Albright K, Cifuentes M, Jimenez‐Zambrano A, Kempe A. Parent and provider perspectives on pediatric readmissions: what can we learn about readiness for discharge? Hosp Pediatr. 2015;5(11):559565.
  33. Berry JG, Gay JC. Preventing readmissions in children: how do we do that? Hosp Pediatr. 2015;5(11):602604.
  34. O'Brien JE, Berry J, Dumas H. Pediatric post‐acute hospital care: striving for identity and value. Hosp Pediatr. 2015;5(10):548551.
  35. Berry JG, Hall M, Dumas H, et al. Pediatric hospital discharges to home health and postacute facility care: a national study. JAMA Pediatr. 2016;170(4):326333.
  36. Corneli HM, Zorc JJ, Holubkov R, et al. Bronchiolitis: clinical characteristics associated with hospitalization and length of stay. Pediatr Emerg Care. 2012;28(2):99103.
  37. Myers J, Smith M, Woods C, Espinosa C, Lehna C. The effect of transfers between health care facilities on costs and length of stay for pediatric burn patients. J Burn Care Res. 2015;36(1):178183.
  38. Stroud MH, Sanders RC, Moss MM, et al. Goal‐directed resuscitative interventions during pediatric interfacility transport. Crit Care Med. 2015;43(8):16921698.
Article PDF
Issue
Journal of Hospital Medicine - 11(11)
Page Number
750-756
Sections
Files
Files
Article PDF
Article PDF

Children with medical complexity (CMC) have complex and chronic health conditions that often involve multiple organ systems and severely affect cognitive and physical functioning. Although the prevalence of CMC is low (1% of all children), they account for nearly one‐fifth of all pediatric admissions and one‐half of all hospital days and charges in the United States.[1] Over the last decade, CMC have had a particularly large and increasing impact in tertiary‐care children's hospitals.[1, 2] The Institute of Medicine has identified CMC as a priority population for a revised healthcare system.[3]

Medical homes, hospitals, health plans, states, federal agencies, and others are striving to reduce excessive hospital use in CMC because of its high cost.[4, 5, 6] Containing length of stay (LOS)an increasingly used indicator of the time sensitiveness and efficiency of hospital careis a common aim across these initiatives. CMC have longer hospitalizations than children without medical complexity. Speculated reasons for this are that CMC tend to have (1) higher severity of acute illnesses (eg, pneumonia, cellulitis), (2) prolonged recovery time in the hospital, and (3) higher risk of adverse events in the hospital. Moreover, hospital clinicians caring for CMC often find it difficult to determine discharge readiness, given that many CMC do not return to a completely healthy baseline.[7]

Little is known about long LOS in CMC, including which CMC have the highest risk of experiencing such stays and which stays might have the greatest opportunity to be shortened. Patient characteristics associated with prolonged length of stay have been studied extensively for many pediatric conditions (eg, asthma).[8, 9, 10, 11, 12, 13, 14] However, most of these studies excluded CMC. Therefore, the objectives of this study were to examine (1) the prevalence of long LOS in CMC, (2) patient characteristics associated with long LOS, and (3) hospital‐to‐hospital variation in prevalence of long LOS hospitalizations.

METHODS

Study Design and Data Source

This study is a multicenter, retrospective cohort analysis of the Pediatric Health Information System (PHIS). PHIS is an administrative database of 44 not for profit, tertiary care pediatric hospitals affiliated with the Children's Hospital Association (CHA) (Overland Park, KS). PHIS contains data regarding patient demographics, diagnoses, and procedures (with International Classification of Diseases, 9th Revision, Clinical Modification [ICD‐9‐CM] codes), All‐Patient Refined Diagnostic Related Groups version 30 (APR‐DRGs) (3M Health Information Systems, Salt Lake City, UT), and service lines that aggregate the APR‐DRGs into 38 distinct groups. Data quality and reliability are assured through CHA and participating hospitals. In accordance with the policies of the Cincinnati Children's Hospital Medical Center Institutional Review Board, this study of deidentified data was not considered human subjects research.

Study Population

Inclusion Criteria

Children discharged following an observation or inpatient admission from a hospital participating in the PHIS database between January 1, 2013 and December 31, 2014 were eligible for inclusion if they were considered medically complex. Medical complexity was defined using Clinical Risk Groups (CRGs) version 1.8, developed by 3M Health Information Systems and the National Association of Children's Hospitals and Related Institutions. CRGs were used to assign each hospitalized patient to 1 of 9 mutually exclusive chronicity groups according to the presence, type, and severity of chronic conditions.[15, 16, 17, 18] Each patient's CRG designation was based on 2 years of previous hospital encounters.

As defined in prior studies and definitional frameworks of CMC,[1] patients belonging to CRG group 6 (significant chronic disease in 2 organ systems), CRG group 7 (dominant chronic disease in 3 organ systems), and CRG group 9 (catastrophic condition) were considered medically complex.[17, 19] Patients with malignancies (CRG group 8) were not included for analysis because they are a unique population with anticipated, long hospital stays. Patients with CRG group 5, representing those with chronic conditions affecting a single body system, were also not included because most do not have attributes consistent with medical complexity.

Exclusion Criteria

We used the APR‐DRG system, which leverages ICD‐9‐CM codes to identify the health problem most responsible for the hospitalization, to refine the study cohort. We excluded hospitalizations that were classified by the APR‐DRG system as neonatal, as we did not wish to focus on LOS in the neonatal intensive care unit (ICU) or for birth admissions. Similarly, hospitalizations for chemotherapy (APR‐DRG 693) or malignancy (identified with previously used ICD‐9‐CM codes)[20] were also excluded because long LOS is anticipated. We also excluded hospitalizations for medical rehabilitation (APR‐DRG 860).

Outcome Measures

The primary outcome measure was long LOS, defined as LOS 10 days. The cut point of LOS 10 days represents the 90th percentile of LOS for all children, with and without medical complexity, hospitalized during 2013 to 2014. LOS 10 days has previously been used as a threshold of long LOS.[21] For hospitalizations involving transfer at admission from another acute care facility, LOS was measured from the date of transfer. We also assessed hospitals' cost attributable to long LOS admissions.

Patient Demographics and Clinical Characteristics

We measured demographic characteristics including age, gender, race/ethnicity, insurance type, and distance traveled (the linear distance between the centroid of the patient's home ZIP code and the centroid of the hospital's ZIP code). Clinical characteristics included CRG classification, complex chronic condition (CCC), and dependence on medical technology. CCCs are defined as any medical condition that can be reasonably expected to last at least 12 months (unless death intervenes) and to involve either several different organ systems or 1 system severely enough to require specialty pediatric care and probably some period of hospitalization in a tertiary care center.[20] Medical technology included devices used to optimize the health and functioning of the child (eg, gastrostomy, tracheostomy, cerebrospinal fluid shunt).[22]

Hospitalization Characteristics

Characteristics of the hospitalization included transfer from an outside facility, ICU admission, surgical procedure (using surgical APR‐DRGs), and discharge disposition (home, skilled nursing facility, home health services, death, other). Cost of the hospitalization was estimated in the PHIS from charges using hospital and year‐specific ratios of cost to charge.

Statistical Analysis

Continuous data (eg, distance from hospital to home residence) were described with median and interquartile ranges (IQR) because they were not normally distributed. Categorical data (eg, type of chronic condition) were described with counts and frequencies. In bivariate analyses, demographic, clinical, and hospitalization characteristics were stratified by LOS (long LOS vs LOS <10 days), and compared using 2 statistics or Wilcoxon rank sum tests as appropriate.

We modeled the likelihood of experiencing a long LOS using generalized linear mixed effects models with a random hospital intercept and discharge‐level fixed effects for age, gender, payor, CCC type, ICU utilization, transfer status, a medical/surgical admission indicator derived from the APR‐DRG, and CRG assigned to each hospitalization. To examine hospital‐to‐hospital variability, we generated hospital risk‐adjusted rates of long LOS from these models. Similar models and hospital risk‐adjusted rates were built for a post hoc correlational analysis of 30‐day all cause readmission, where hospitals' rates and percent of long LOS were compared with a Pearson correlation coefficient. Also, for our multivariable models, we performed a sensitivity analysis using an alternative definition of long LOS as 4 days (the 75th percentile of LOS for all children, with and without medical complexity, hospitalized during 20132014). All analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC), and P values <0.05 were considered statistically significant.

RESULTS

Study Population

There were 954,018 hospitalizations of 217,163 CMC at 44 children's hospitals included for analysis. Forty‐seven percent of hospitalizations were for females, 49.4% for non‐Hispanic whites, and 61.1% for children with government insurance. Fifteen percent (n = 142,082) had a long LOS of 10 days. The median (IQR) LOS of hospitalizations <10 days versus 10 days were 2 (IQR, 14) and 16 days (IQR, 1226), respectively. Long LOS hospitalizations accounted for 61.1% (3.7 million) hospital days and 61.8% ($13.7 billion) of total hospitalization costs for all CMC in the cohort (Table 1).

Demographic, Clinical, and Hospitalization Characteristics of Hospitalized Children With Medical Complexity by Length of Stay*
Characteristic Overall (n = 954,018) Length of Stay
<10 Days (n = 811,936) 10 Days (n = 142,082)
  • NOTE: Abbreviations: IQR, interquartile range. *All comparisons were significant at the P < 0.001 level.

Age at admission, y, %
<1 14.6 12.7 25.7
14 27.1 27.9 22.4
59 20.1 21.0 14.9
1018 33.6 34.0 31.7
18+ 4.6 4.4 5.4
Gender, %
Female 47.0 46.9 47.5
Race/ethnicity, %
Non‐Hispanic white 49.4 49.4 49.4
Non‐Hispanic black 23.1 23.8 19.3
Hispanic 18.2 17.8 20.4
Asian 2.0 1.9 2.3
Other 7.4 7.1 8.6
Complex chronic condition, %
Any 79.5 77.3 91.8
Technology assistance 37.1 34.1 54.2
Gastrointestinal 30.0 27.2 45.9
Neuromuscular 28.2 27.7 30.9
Cardiovascular 16.8 14.5 29.9
Respiratory 14.1 11.5 29.4
Congenital/genetic defect 17.2 16.7 20.2
Metabolic 9.9 8.9 15.4
Renal 10.1 9.5 13.8
Hematology/emmmunodeficiency 11.7 12.0 10.0
Neonatal 3.8 3.1 7.7
Transplantation 4.5 4.2 6.7
Clinical risk group, %
Chronic condition in 2 systems 68.4 71.2 53.9
Catastrophic chronic condition 31.4 28.8 46.1
Distance from hospital to home residence in miles, median [IQR] 16.2 [7.440.4] 15.8 [7.338.7] 19.1 [8.552.6]
Transferred from outside hospital (%) 6.5 5.3 13.6
Admitted for surgery, % 23.4 20.7 38.7
Use of intensive care, % 19.6 14.9 46.5
Discharge disposition, %
Home 91.2 92.9 81.4
Home healthcare 4.5 3.5 9.9
Other 2.9 2.6 4.5
Postacute care facility 1.1 0.8 3.1
Died 0.4 0.3 1.1
Payor, %
Government 61.1 60.6 63.5
Private 33.2 33.6 30.9
Other 5.7 5.7 5.7
Hospital resource use
Median length of stay [IQR] 3 [16] 2 [14] 16 [1226]
Median hospital cost [IQR] $8,144 [$4,122$18,447] $6,689 [$3,685$12,395] $49,207 [$29,444$95,738]
Total hospital cost, $, billions $22.2 $8.5 $13.7

Demographics and Clinical Characteristics of Children With and Without Long LOS

Compared with hospitalized CMC with LOS <10 days, a higher percentage of hospitalizations with LOS 10 days were CMC age <1 year (25.7% vs 12.7%, P < 0.001) and Hispanic (20.4% vs 17.8%, P < 0.001). CMC hospitalizations with a long LOS had a higher percentage of any CCC (91.8% vs 77.3%, P < 0.001); the most common CCCs were gastrointestinal (45.9%), neuromuscular (30.9%), and cardiovascular (29.9%). Hospitalizations of CMC with a long LOS had a higher percentage of a catastrophic chronic condition (46.1% vs 28.8%, P < 0.001) and technology dependence (46.1% vs 28.8%, P < 0.001) (Table 1).

Hospitalization Characteristics of Children With and Without Long LOS

Compared with hospitalizations of CMC with LOS <10 days, hospitalizations of CMC with a long LOS more often involved transfer in from another hospital at admission (13.6% vs 5.3%, P < 0.001). CMC hospital stays with a long LOS more often involved surgery (38.7% vs 20.7%, P < 0.001) and use of intensive care (46.5% vs 14.9%; P < 0.001). A higher percentage of CMC with long LOS were discharged with home health services (9.9% vs 3.5%; P < 0.001) (Table 1).

The most common admitting diagnoses and CCCs for hospitalizations of CMC with long LOS are presented in Table 2. The two most prevalent APR‐DRGs in CMC hospitalizations lasting 10 days or longer were cystic fibrosis (10.7%) and respiratory system disease with ventilator support (5.5%). The two most common chronic condition characteristics represented among long CMC hospitalizations were gastrointestinal devices (eg, gastrostomy tube) (39.7%) and heart and great vessel malformations (eg, tetralogy of Fallot) (12.8%). The 5 most common CCC subcategories, as listed in Table 2, account for nearly 100% of the patients with long LOS hospitalizations.

Most Common Reasons for Admission and Specific Complex Chronic Conditions for Hospitalized Children With Medical Complexity Who Had Length of Stay 10 Days
  • NOTE: *Reason for admission identified using All‐Patient Refined Diagnosis‐Related Groups. Complex chronic conditions identified using Feudtner and colleagues set of International Classification of Diseases, 9th Revision, Clinical Modification codes. Gastrointestinal devices include gastrostomy, gastrojejunostomy, colostomy. Respiratory devices include tracheostomy, noninvasive positive pressure, ventilator.

Most common reason for admission*
Cystic fibrosis 10.7%
Respiratory system diagnosis with ventilator support 96+ hours 5.5%
Malfunction, reaction, and complication of cardiac or vascular device or procedure 2.8%
Craniotomy except for trauma 2.6%
Major small and large bowel procedures 2.3%
Most common complex chronic condition
Gastrointestinal devices 39.7%
Heart and great vessel malformations 12.8%
Cystic fibrosis 12.5%
Dysrhythmias 11.0%
Respiratory devices 10.7%

Multivariable Analysis of Characteristics Associated With Long LOS

In multivariable analysis, the highest likelihood of long LOS was experienced by children who received care in the ICU (odds ratio [OR]: 3.5, 95% confidence interval [CI]: 3.43.5), who had a respiratory CCC (OR: 2.7, 95% CI: 2.62.7), and who were transferred from another acute care hospital at admission (OR: 2.1, 95% CI: 2.0, 2.1). The likelihood of long LOS was also higher in children <1 year of age (OR: 1.2, 95% CI: 1.21.3), and Hispanic children (OR: 1.1, 95% CI 1.0‐1.10) (Table 3). Similar multivariable findings were observed in sensitivity analysis using the 75th percentile of LOS (4 days) as the model outcome.

Multivariable Analysis of the Likelihood of Long Length of Stay 10 Days
Characteristic Odds Ratio (95% CI) of LOS 10 Days P Value
  • NOTE: Abbreviations: CI, confidence interval; LOS, length of stay.

Use of intensive care 3.5 (3.4‐3.5) <0.001
Transfer from another acute‐care hospital 2.1 (2.0‐2.1) <0.001
Procedure/surgery 1.8 (1.8‐1.9) <0.001
Complex chronic condition
Respiratory 2.7 (2.6‐2.7) <0.001
Gastrointestinal 1.8 (1.8‐1.8) <0.001
Metabolic 1.7 (1.7‐1.7) <0.001
Cardiovascular 1.6 (1.5‐1.6) <0.001
Neonatal 1.5 (1.5‐1.5) <0.001
Renal 1.4 (1.4‐1.4) <0.001
Transplant 1.4 (1.4‐1.4) <0.001
Hematology and immunodeficiency 1.3 (1.3‐1.3) <0.001
Technology assistance 1.1 (1.1, 1.1) <0.001
Neuromuscular 0.9 (0.9‐0.9) <0.001
Congenital or genetic defect 0.8 (0.8‐0.8) <0.001
Age at admission, y
<1 1.2 (1.2‐1.3) <0.001
14 0.5 (0.5‐0.5) <0.001
59 0.6 (0.6‐0.6) <0.001
1018 0.9 (0.9‐0.9) <0.001
18+ Reference
Male 0.9 (0.9‐0.9) <0.001
Race/ethnicity
Non‐Hispanic black 0.9 (0.9‐0.9) <0.001
Hispanic 1.1 (1.0‐1.1) <0.001
Asian 1.0 (1.0‐1.1) 0.3
Other 1.1 (1.1‐1.1) <0.001
Non‐Hispanic white Reference
Payor
Private 0.9 (0.8 0.9) <0.001
Other 1.0 (1.0‐1.0) 0.4
Government Reference
Season
Spring 1.0 (1.0 1.0) <0.001
Summer 0.9 (0.9‐0.9) <0.001
Fall 1.0 (0.9‐1.0) <0.001
Winter Reference

Variation in the Prevalence of Long LOS Across Children's Hospitals

After controlling for demographic, clinical, and hospital characteristics associated with long LOS, there was significant (P < 0.001) variation in the prevalence of long LOS for CMC across children's hospitals in the cohort (range, 10.3%21.8%) (Figure 1). Twelve (27%) hospitals had a significantly (P < 0.001) higher prevalence of long LOS for their hospitalized CMC, compared to the mean. Eighteen (41%) had a significantly (P < 0.001) lower prevalence of long LOS for their hospitalized CMC. There was also significant variation across hospitals with respect to cost, with 49.7% to 73.7% of all hospital costs of CMC attributed to long LOS hospitalizations. Finally, there was indirect correlation with the prevalence of LOS across hospitals and the hospitals' 30‐day readmission rate ( = 0.3; P = 0.04). As the prevalence of long LOS increased, the readmission rate decreased.

Figure 1
Variation in the Prevalence and Cost of Long Length of Stay ≥10 days for Children with Medical Complexity Across Children's Hospitals. Presented from the left y‐axis are the adjusted percentages (with 95% confidence interval)—shown as circles and whiskers—of total admissions for complex chronic condition (CMC) with length of stay (LOS) ≥10 days across 44 freestanding children's hospitals. The percentages are adjusted for demographic, clinical, and hospitalization characteristics associated with the likelihood of CMC experiencing LOS ≥10 days. The dashed line indicates the mean percentage (15%) across all hospitals. Also presented on the right y‐axis are the percentages—shown as gray bars—of all hospital charges attributable to hospitalizations ≥10 days among CMC across children's hospitals.

DISCUSSION

The main findings from this study suggest that a small percentage of CMC experiencing long LOS account for the majority of hospital bed days and cost of all hospitalized CMC in children's hospitals. The likelihood of long LOS varies significantly by CMC's age, race/ethnicity, and payor as well as by type and number of chronic conditions. Among CMC with long LOS, the use of gastrointestinal devices such as gastrostomy tubes, as well as congenital heart disease, were highly prevalent. In multivariable analysis, the characteristics most strongly associated with LOS 10 days were use of the ICU, respiratory complex chronic condition, and transfer from another medical facility at admission. After adjusting for these factors, there was significant variation in the prevalence of LOS 10 days for CMC across children's hospitals.

Although it is well known that CMC as a whole have a major impact on resource use in children's hospitals, this study reveals that 15% of hospitalizations of CMC account for 62% of all hospital costs of CMC. That is, a small fraction of hospitalizations of CMC is largely responsible for the significant financial impact of hospital resource use. To date, most clinical efforts and policies striving to reduce hospital use in CMC have focused on avoiding readmissions or index hospital admissions entirely, rather than improving the efficiency of hospital care after admission occurs.[23, 24, 25, 26] In the adult population, the impact of long LOS on hospital costs has been recognized, and several Medicare incentive programs have focused on in‐hospital timeliness and efficiency. As a result, LOS in Medicare beneficiaries has decreased dramatically over the past 2 decades.[27, 28, 29, 30] Optimizing the efficiency of hospital care for CMC may be an important goal to pursue, especially with precedent set in the adult literature.

Perhaps the substantial variation across hospitals in the prevalence of long LOS in CMC indicates opportunity to improve the efficiency of their inpatient care. This variation was not due to differences across hospitals' case mix of CMC. Further investigation is needed to determine how much of it is due to differences in quality of care. Clinical practice guidelines for hospital treatment of common illnesses usually exclude CMC. In our clinical experience across 9 children's hospitals, we have experienced varying approaches to setting discharge goals (ie, parameters on how healthy the child needs to be to ensure a successful hospital discharge) for CMC.[31] When the goals are absent or not clearly articulated, they can contribute to a prolonged hospitalization. Some families of CMC report significant issues when working with pediatric hospital staff to assess their child's discharge readiness.[7, 32, 33] In addition, there is significant variation across states and regions in access to and quality of post‐discharge health services (eg, home nursing, postacute care, durable medical equipment).[34, 35] In some areas, many CMC are not actively involved with their primary care physician.[5] These issues might also influence the ability of some children's hospitals to efficiently discharge CMC to a safe and supportive post‐discharge environment. Further examination of hospital outliersthose with the lowest and highest percentage of CMC hospitalizations with long LOSmay reveal opportunities to identify and spread best practices.

The demographic and clinical factors associated with long LOS in the present study, including age, ICU use, and transfer from another hospital, might help hospitals target which CMC have the greatest risk for experiencing long LOS. We found that infants age <1 year had longer LOS when compared with older children. Similar to our findings, younger‐aged children hospitalized with bronchiolitis have longer LOS.[36] Certainly, infants with medical complexity, in general, are a high‐acuity population with the potential for rapid clinical deterioration during an acute illness. Prolonged hospitalization for treatment and stabilization may be expected for many of them. Additional investigation is warranted to examine ICU use in CMC, and whether ICU admission or duration can be safely prevented or abbreviated. Opportunities to assess the quality of transfers into children's hospitals of CMC admitted to outside hospitals may be necessary. A study of pediatric burn patients reported that patients initially stabilized at a facility that was not a burn center and subsequently transferred to a burn center had a longer LOS than patients solely treated at a designated burn center.[37] Furthermore, events during transport itself may adversely impact the stability of an already fragile patient. Interventions to optimize the quality of care provided by transport teams have resulted in decreased LOS at the receiving hospital.[38]

This study's findings should be considered in the context of several limitations. Absent a gold‐standard definition of long LOS, we used the distribution of LOS across patients to inform our methods; LOS at the 90th percentile was selected as long. Although our sensitivity analysis using LOS at the 75th percentile produced similar findings, other cut points in LOS might be associated with different results. The study is not positioned to determine how much of the reported LOS was excessive, unnecessary, or preventable. The study findings may not generalize to types of hospitals not contained in PHIS (eg, nonchildren's hospitals and community hospitals). We did not focus on the impact of a new diagnosis (eg, new chronic illness) or acute in‐hospital event (eg, nosocomial infection) on prolonged LOS; future studies should investigate these clinical events with LOS.

PHIS does not contain information regarding characteristics that could influence LOS, including the children's social and familial attributes, transportation availability, home equipment needs, and local availability of postacute care facilities. Moreover, PHIS does not contain information about the hospital discharge procedures, process, or personnel across hospitals, which could influence LOS. Future studies on prolonged LOS should consider assessing this information. Because of the large sample size of hospitalizations included, the statistical power for the analyses was strong, rendering it possible that some findings that were statistically significant might have modest clinical significance (eg, relationship of Hispanic ethnicity with prolonged LOS). We could not determine why a positive correlation was not observed between hospitals' long LOS prevalence and their percentage of cost associated with long LOS; future studies should investigate the reasons for this finding.

Despite these limitations, the findings of the present study highlight the significance of long LOS in hospitalized CMC. These long hospitalizations account for a significant proportion of all hospital costs for this important population of children. The prevalence of long LOS for CMC varies considerably across children's hospitals, even after accounting for the case mix. Efforts to curtail hospital resource use and costs for CMC may benefit from focus on long LOS.

Children with medical complexity (CMC) have complex and chronic health conditions that often involve multiple organ systems and severely affect cognitive and physical functioning. Although the prevalence of CMC is low (1% of all children), they account for nearly one‐fifth of all pediatric admissions and one‐half of all hospital days and charges in the United States.[1] Over the last decade, CMC have had a particularly large and increasing impact in tertiary‐care children's hospitals.[1, 2] The Institute of Medicine has identified CMC as a priority population for a revised healthcare system.[3]

Medical homes, hospitals, health plans, states, federal agencies, and others are striving to reduce excessive hospital use in CMC because of its high cost.[4, 5, 6] Containing length of stay (LOS)an increasingly used indicator of the time sensitiveness and efficiency of hospital careis a common aim across these initiatives. CMC have longer hospitalizations than children without medical complexity. Speculated reasons for this are that CMC tend to have (1) higher severity of acute illnesses (eg, pneumonia, cellulitis), (2) prolonged recovery time in the hospital, and (3) higher risk of adverse events in the hospital. Moreover, hospital clinicians caring for CMC often find it difficult to determine discharge readiness, given that many CMC do not return to a completely healthy baseline.[7]

Little is known about long LOS in CMC, including which CMC have the highest risk of experiencing such stays and which stays might have the greatest opportunity to be shortened. Patient characteristics associated with prolonged length of stay have been studied extensively for many pediatric conditions (eg, asthma).[8, 9, 10, 11, 12, 13, 14] However, most of these studies excluded CMC. Therefore, the objectives of this study were to examine (1) the prevalence of long LOS in CMC, (2) patient characteristics associated with long LOS, and (3) hospital‐to‐hospital variation in prevalence of long LOS hospitalizations.

METHODS

Study Design and Data Source

This study is a multicenter, retrospective cohort analysis of the Pediatric Health Information System (PHIS). PHIS is an administrative database of 44 not for profit, tertiary care pediatric hospitals affiliated with the Children's Hospital Association (CHA) (Overland Park, KS). PHIS contains data regarding patient demographics, diagnoses, and procedures (with International Classification of Diseases, 9th Revision, Clinical Modification [ICD‐9‐CM] codes), All‐Patient Refined Diagnostic Related Groups version 30 (APR‐DRGs) (3M Health Information Systems, Salt Lake City, UT), and service lines that aggregate the APR‐DRGs into 38 distinct groups. Data quality and reliability are assured through CHA and participating hospitals. In accordance with the policies of the Cincinnati Children's Hospital Medical Center Institutional Review Board, this study of deidentified data was not considered human subjects research.

Study Population

Inclusion Criteria

Children discharged following an observation or inpatient admission from a hospital participating in the PHIS database between January 1, 2013 and December 31, 2014 were eligible for inclusion if they were considered medically complex. Medical complexity was defined using Clinical Risk Groups (CRGs) version 1.8, developed by 3M Health Information Systems and the National Association of Children's Hospitals and Related Institutions. CRGs were used to assign each hospitalized patient to 1 of 9 mutually exclusive chronicity groups according to the presence, type, and severity of chronic conditions.[15, 16, 17, 18] Each patient's CRG designation was based on 2 years of previous hospital encounters.

As defined in prior studies and definitional frameworks of CMC,[1] patients belonging to CRG group 6 (significant chronic disease in 2 organ systems), CRG group 7 (dominant chronic disease in 3 organ systems), and CRG group 9 (catastrophic condition) were considered medically complex.[17, 19] Patients with malignancies (CRG group 8) were not included for analysis because they are a unique population with anticipated, long hospital stays. Patients with CRG group 5, representing those with chronic conditions affecting a single body system, were also not included because most do not have attributes consistent with medical complexity.

Exclusion Criteria

We used the APR‐DRG system, which leverages ICD‐9‐CM codes to identify the health problem most responsible for the hospitalization, to refine the study cohort. We excluded hospitalizations that were classified by the APR‐DRG system as neonatal, as we did not wish to focus on LOS in the neonatal intensive care unit (ICU) or for birth admissions. Similarly, hospitalizations for chemotherapy (APR‐DRG 693) or malignancy (identified with previously used ICD‐9‐CM codes)[20] were also excluded because long LOS is anticipated. We also excluded hospitalizations for medical rehabilitation (APR‐DRG 860).

Outcome Measures

The primary outcome measure was long LOS, defined as LOS 10 days. The cut point of LOS 10 days represents the 90th percentile of LOS for all children, with and without medical complexity, hospitalized during 2013 to 2014. LOS 10 days has previously been used as a threshold of long LOS.[21] For hospitalizations involving transfer at admission from another acute care facility, LOS was measured from the date of transfer. We also assessed hospitals' cost attributable to long LOS admissions.

Patient Demographics and Clinical Characteristics

We measured demographic characteristics including age, gender, race/ethnicity, insurance type, and distance traveled (the linear distance between the centroid of the patient's home ZIP code and the centroid of the hospital's ZIP code). Clinical characteristics included CRG classification, complex chronic condition (CCC), and dependence on medical technology. CCCs are defined as any medical condition that can be reasonably expected to last at least 12 months (unless death intervenes) and to involve either several different organ systems or 1 system severely enough to require specialty pediatric care and probably some period of hospitalization in a tertiary care center.[20] Medical technology included devices used to optimize the health and functioning of the child (eg, gastrostomy, tracheostomy, cerebrospinal fluid shunt).[22]

Hospitalization Characteristics

Characteristics of the hospitalization included transfer from an outside facility, ICU admission, surgical procedure (using surgical APR‐DRGs), and discharge disposition (home, skilled nursing facility, home health services, death, other). Cost of the hospitalization was estimated in the PHIS from charges using hospital and year‐specific ratios of cost to charge.

Statistical Analysis

Continuous data (eg, distance from hospital to home residence) were described with median and interquartile ranges (IQR) because they were not normally distributed. Categorical data (eg, type of chronic condition) were described with counts and frequencies. In bivariate analyses, demographic, clinical, and hospitalization characteristics were stratified by LOS (long LOS vs LOS <10 days), and compared using 2 statistics or Wilcoxon rank sum tests as appropriate.

We modeled the likelihood of experiencing a long LOS using generalized linear mixed effects models with a random hospital intercept and discharge‐level fixed effects for age, gender, payor, CCC type, ICU utilization, transfer status, a medical/surgical admission indicator derived from the APR‐DRG, and CRG assigned to each hospitalization. To examine hospital‐to‐hospital variability, we generated hospital risk‐adjusted rates of long LOS from these models. Similar models and hospital risk‐adjusted rates were built for a post hoc correlational analysis of 30‐day all cause readmission, where hospitals' rates and percent of long LOS were compared with a Pearson correlation coefficient. Also, for our multivariable models, we performed a sensitivity analysis using an alternative definition of long LOS as 4 days (the 75th percentile of LOS for all children, with and without medical complexity, hospitalized during 20132014). All analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC), and P values <0.05 were considered statistically significant.

RESULTS

Study Population

There were 954,018 hospitalizations of 217,163 CMC at 44 children's hospitals included for analysis. Forty‐seven percent of hospitalizations were for females, 49.4% for non‐Hispanic whites, and 61.1% for children with government insurance. Fifteen percent (n = 142,082) had a long LOS of 10 days. The median (IQR) LOS of hospitalizations <10 days versus 10 days were 2 (IQR, 14) and 16 days (IQR, 1226), respectively. Long LOS hospitalizations accounted for 61.1% (3.7 million) hospital days and 61.8% ($13.7 billion) of total hospitalization costs for all CMC in the cohort (Table 1).

Demographic, Clinical, and Hospitalization Characteristics of Hospitalized Children With Medical Complexity by Length of Stay*
Characteristic Overall (n = 954,018) Length of Stay
<10 Days (n = 811,936) 10 Days (n = 142,082)
  • NOTE: Abbreviations: IQR, interquartile range. *All comparisons were significant at the P < 0.001 level.

Age at admission, y, %
<1 14.6 12.7 25.7
14 27.1 27.9 22.4
59 20.1 21.0 14.9
1018 33.6 34.0 31.7
18+ 4.6 4.4 5.4
Gender, %
Female 47.0 46.9 47.5
Race/ethnicity, %
Non‐Hispanic white 49.4 49.4 49.4
Non‐Hispanic black 23.1 23.8 19.3
Hispanic 18.2 17.8 20.4
Asian 2.0 1.9 2.3
Other 7.4 7.1 8.6
Complex chronic condition, %
Any 79.5 77.3 91.8
Technology assistance 37.1 34.1 54.2
Gastrointestinal 30.0 27.2 45.9
Neuromuscular 28.2 27.7 30.9
Cardiovascular 16.8 14.5 29.9
Respiratory 14.1 11.5 29.4
Congenital/genetic defect 17.2 16.7 20.2
Metabolic 9.9 8.9 15.4
Renal 10.1 9.5 13.8
Hematology/emmmunodeficiency 11.7 12.0 10.0
Neonatal 3.8 3.1 7.7
Transplantation 4.5 4.2 6.7
Clinical risk group, %
Chronic condition in 2 systems 68.4 71.2 53.9
Catastrophic chronic condition 31.4 28.8 46.1
Distance from hospital to home residence in miles, median [IQR] 16.2 [7.440.4] 15.8 [7.338.7] 19.1 [8.552.6]
Transferred from outside hospital (%) 6.5 5.3 13.6
Admitted for surgery, % 23.4 20.7 38.7
Use of intensive care, % 19.6 14.9 46.5
Discharge disposition, %
Home 91.2 92.9 81.4
Home healthcare 4.5 3.5 9.9
Other 2.9 2.6 4.5
Postacute care facility 1.1 0.8 3.1
Died 0.4 0.3 1.1
Payor, %
Government 61.1 60.6 63.5
Private 33.2 33.6 30.9
Other 5.7 5.7 5.7
Hospital resource use
Median length of stay [IQR] 3 [16] 2 [14] 16 [1226]
Median hospital cost [IQR] $8,144 [$4,122$18,447] $6,689 [$3,685$12,395] $49,207 [$29,444$95,738]
Total hospital cost, $, billions $22.2 $8.5 $13.7

Demographics and Clinical Characteristics of Children With and Without Long LOS

Compared with hospitalized CMC with LOS <10 days, a higher percentage of hospitalizations with LOS 10 days were CMC age <1 year (25.7% vs 12.7%, P < 0.001) and Hispanic (20.4% vs 17.8%, P < 0.001). CMC hospitalizations with a long LOS had a higher percentage of any CCC (91.8% vs 77.3%, P < 0.001); the most common CCCs were gastrointestinal (45.9%), neuromuscular (30.9%), and cardiovascular (29.9%). Hospitalizations of CMC with a long LOS had a higher percentage of a catastrophic chronic condition (46.1% vs 28.8%, P < 0.001) and technology dependence (46.1% vs 28.8%, P < 0.001) (Table 1).

Hospitalization Characteristics of Children With and Without Long LOS

Compared with hospitalizations of CMC with LOS <10 days, hospitalizations of CMC with a long LOS more often involved transfer in from another hospital at admission (13.6% vs 5.3%, P < 0.001). CMC hospital stays with a long LOS more often involved surgery (38.7% vs 20.7%, P < 0.001) and use of intensive care (46.5% vs 14.9%; P < 0.001). A higher percentage of CMC with long LOS were discharged with home health services (9.9% vs 3.5%; P < 0.001) (Table 1).

The most common admitting diagnoses and CCCs for hospitalizations of CMC with long LOS are presented in Table 2. The two most prevalent APR‐DRGs in CMC hospitalizations lasting 10 days or longer were cystic fibrosis (10.7%) and respiratory system disease with ventilator support (5.5%). The two most common chronic condition characteristics represented among long CMC hospitalizations were gastrointestinal devices (eg, gastrostomy tube) (39.7%) and heart and great vessel malformations (eg, tetralogy of Fallot) (12.8%). The 5 most common CCC subcategories, as listed in Table 2, account for nearly 100% of the patients with long LOS hospitalizations.

Most Common Reasons for Admission and Specific Complex Chronic Conditions for Hospitalized Children With Medical Complexity Who Had Length of Stay 10 Days
  • NOTE: *Reason for admission identified using All‐Patient Refined Diagnosis‐Related Groups. Complex chronic conditions identified using Feudtner and colleagues set of International Classification of Diseases, 9th Revision, Clinical Modification codes. Gastrointestinal devices include gastrostomy, gastrojejunostomy, colostomy. Respiratory devices include tracheostomy, noninvasive positive pressure, ventilator.

Most common reason for admission*
Cystic fibrosis 10.7%
Respiratory system diagnosis with ventilator support 96+ hours 5.5%
Malfunction, reaction, and complication of cardiac or vascular device or procedure 2.8%
Craniotomy except for trauma 2.6%
Major small and large bowel procedures 2.3%
Most common complex chronic condition
Gastrointestinal devices 39.7%
Heart and great vessel malformations 12.8%
Cystic fibrosis 12.5%
Dysrhythmias 11.0%
Respiratory devices 10.7%

Multivariable Analysis of Characteristics Associated With Long LOS

In multivariable analysis, the highest likelihood of long LOS was experienced by children who received care in the ICU (odds ratio [OR]: 3.5, 95% confidence interval [CI]: 3.43.5), who had a respiratory CCC (OR: 2.7, 95% CI: 2.62.7), and who were transferred from another acute care hospital at admission (OR: 2.1, 95% CI: 2.0, 2.1). The likelihood of long LOS was also higher in children <1 year of age (OR: 1.2, 95% CI: 1.21.3), and Hispanic children (OR: 1.1, 95% CI 1.0‐1.10) (Table 3). Similar multivariable findings were observed in sensitivity analysis using the 75th percentile of LOS (4 days) as the model outcome.

Multivariable Analysis of the Likelihood of Long Length of Stay 10 Days
Characteristic Odds Ratio (95% CI) of LOS 10 Days P Value
  • NOTE: Abbreviations: CI, confidence interval; LOS, length of stay.

Use of intensive care 3.5 (3.4‐3.5) <0.001
Transfer from another acute‐care hospital 2.1 (2.0‐2.1) <0.001
Procedure/surgery 1.8 (1.8‐1.9) <0.001
Complex chronic condition
Respiratory 2.7 (2.6‐2.7) <0.001
Gastrointestinal 1.8 (1.8‐1.8) <0.001
Metabolic 1.7 (1.7‐1.7) <0.001
Cardiovascular 1.6 (1.5‐1.6) <0.001
Neonatal 1.5 (1.5‐1.5) <0.001
Renal 1.4 (1.4‐1.4) <0.001
Transplant 1.4 (1.4‐1.4) <0.001
Hematology and immunodeficiency 1.3 (1.3‐1.3) <0.001
Technology assistance 1.1 (1.1, 1.1) <0.001
Neuromuscular 0.9 (0.9‐0.9) <0.001
Congenital or genetic defect 0.8 (0.8‐0.8) <0.001
Age at admission, y
<1 1.2 (1.2‐1.3) <0.001
14 0.5 (0.5‐0.5) <0.001
59 0.6 (0.6‐0.6) <0.001
1018 0.9 (0.9‐0.9) <0.001
18+ Reference
Male 0.9 (0.9‐0.9) <0.001
Race/ethnicity
Non‐Hispanic black 0.9 (0.9‐0.9) <0.001
Hispanic 1.1 (1.0‐1.1) <0.001
Asian 1.0 (1.0‐1.1) 0.3
Other 1.1 (1.1‐1.1) <0.001
Non‐Hispanic white Reference
Payor
Private 0.9 (0.8 0.9) <0.001
Other 1.0 (1.0‐1.0) 0.4
Government Reference
Season
Spring 1.0 (1.0 1.0) <0.001
Summer 0.9 (0.9‐0.9) <0.001
Fall 1.0 (0.9‐1.0) <0.001
Winter Reference

Variation in the Prevalence of Long LOS Across Children's Hospitals

After controlling for demographic, clinical, and hospital characteristics associated with long LOS, there was significant (P < 0.001) variation in the prevalence of long LOS for CMC across children's hospitals in the cohort (range, 10.3%21.8%) (Figure 1). Twelve (27%) hospitals had a significantly (P < 0.001) higher prevalence of long LOS for their hospitalized CMC, compared to the mean. Eighteen (41%) had a significantly (P < 0.001) lower prevalence of long LOS for their hospitalized CMC. There was also significant variation across hospitals with respect to cost, with 49.7% to 73.7% of all hospital costs of CMC attributed to long LOS hospitalizations. Finally, there was indirect correlation with the prevalence of LOS across hospitals and the hospitals' 30‐day readmission rate ( = 0.3; P = 0.04). As the prevalence of long LOS increased, the readmission rate decreased.

Figure 1
Variation in the Prevalence and Cost of Long Length of Stay ≥10 days for Children with Medical Complexity Across Children's Hospitals. Presented from the left y‐axis are the adjusted percentages (with 95% confidence interval)—shown as circles and whiskers—of total admissions for complex chronic condition (CMC) with length of stay (LOS) ≥10 days across 44 freestanding children's hospitals. The percentages are adjusted for demographic, clinical, and hospitalization characteristics associated with the likelihood of CMC experiencing LOS ≥10 days. The dashed line indicates the mean percentage (15%) across all hospitals. Also presented on the right y‐axis are the percentages—shown as gray bars—of all hospital charges attributable to hospitalizations ≥10 days among CMC across children's hospitals.

DISCUSSION

The main findings from this study suggest that a small percentage of CMC experiencing long LOS account for the majority of hospital bed days and cost of all hospitalized CMC in children's hospitals. The likelihood of long LOS varies significantly by CMC's age, race/ethnicity, and payor as well as by type and number of chronic conditions. Among CMC with long LOS, the use of gastrointestinal devices such as gastrostomy tubes, as well as congenital heart disease, were highly prevalent. In multivariable analysis, the characteristics most strongly associated with LOS 10 days were use of the ICU, respiratory complex chronic condition, and transfer from another medical facility at admission. After adjusting for these factors, there was significant variation in the prevalence of LOS 10 days for CMC across children's hospitals.

Although it is well known that CMC as a whole have a major impact on resource use in children's hospitals, this study reveals that 15% of hospitalizations of CMC account for 62% of all hospital costs of CMC. That is, a small fraction of hospitalizations of CMC is largely responsible for the significant financial impact of hospital resource use. To date, most clinical efforts and policies striving to reduce hospital use in CMC have focused on avoiding readmissions or index hospital admissions entirely, rather than improving the efficiency of hospital care after admission occurs.[23, 24, 25, 26] In the adult population, the impact of long LOS on hospital costs has been recognized, and several Medicare incentive programs have focused on in‐hospital timeliness and efficiency. As a result, LOS in Medicare beneficiaries has decreased dramatically over the past 2 decades.[27, 28, 29, 30] Optimizing the efficiency of hospital care for CMC may be an important goal to pursue, especially with precedent set in the adult literature.

Perhaps the substantial variation across hospitals in the prevalence of long LOS in CMC indicates opportunity to improve the efficiency of their inpatient care. This variation was not due to differences across hospitals' case mix of CMC. Further investigation is needed to determine how much of it is due to differences in quality of care. Clinical practice guidelines for hospital treatment of common illnesses usually exclude CMC. In our clinical experience across 9 children's hospitals, we have experienced varying approaches to setting discharge goals (ie, parameters on how healthy the child needs to be to ensure a successful hospital discharge) for CMC.[31] When the goals are absent or not clearly articulated, they can contribute to a prolonged hospitalization. Some families of CMC report significant issues when working with pediatric hospital staff to assess their child's discharge readiness.[7, 32, 33] In addition, there is significant variation across states and regions in access to and quality of post‐discharge health services (eg, home nursing, postacute care, durable medical equipment).[34, 35] In some areas, many CMC are not actively involved with their primary care physician.[5] These issues might also influence the ability of some children's hospitals to efficiently discharge CMC to a safe and supportive post‐discharge environment. Further examination of hospital outliersthose with the lowest and highest percentage of CMC hospitalizations with long LOSmay reveal opportunities to identify and spread best practices.

The demographic and clinical factors associated with long LOS in the present study, including age, ICU use, and transfer from another hospital, might help hospitals target which CMC have the greatest risk for experiencing long LOS. We found that infants age <1 year had longer LOS when compared with older children. Similar to our findings, younger‐aged children hospitalized with bronchiolitis have longer LOS.[36] Certainly, infants with medical complexity, in general, are a high‐acuity population with the potential for rapid clinical deterioration during an acute illness. Prolonged hospitalization for treatment and stabilization may be expected for many of them. Additional investigation is warranted to examine ICU use in CMC, and whether ICU admission or duration can be safely prevented or abbreviated. Opportunities to assess the quality of transfers into children's hospitals of CMC admitted to outside hospitals may be necessary. A study of pediatric burn patients reported that patients initially stabilized at a facility that was not a burn center and subsequently transferred to a burn center had a longer LOS than patients solely treated at a designated burn center.[37] Furthermore, events during transport itself may adversely impact the stability of an already fragile patient. Interventions to optimize the quality of care provided by transport teams have resulted in decreased LOS at the receiving hospital.[38]

This study's findings should be considered in the context of several limitations. Absent a gold‐standard definition of long LOS, we used the distribution of LOS across patients to inform our methods; LOS at the 90th percentile was selected as long. Although our sensitivity analysis using LOS at the 75th percentile produced similar findings, other cut points in LOS might be associated with different results. The study is not positioned to determine how much of the reported LOS was excessive, unnecessary, or preventable. The study findings may not generalize to types of hospitals not contained in PHIS (eg, nonchildren's hospitals and community hospitals). We did not focus on the impact of a new diagnosis (eg, new chronic illness) or acute in‐hospital event (eg, nosocomial infection) on prolonged LOS; future studies should investigate these clinical events with LOS.

PHIS does not contain information regarding characteristics that could influence LOS, including the children's social and familial attributes, transportation availability, home equipment needs, and local availability of postacute care facilities. Moreover, PHIS does not contain information about the hospital discharge procedures, process, or personnel across hospitals, which could influence LOS. Future studies on prolonged LOS should consider assessing this information. Because of the large sample size of hospitalizations included, the statistical power for the analyses was strong, rendering it possible that some findings that were statistically significant might have modest clinical significance (eg, relationship of Hispanic ethnicity with prolonged LOS). We could not determine why a positive correlation was not observed between hospitals' long LOS prevalence and their percentage of cost associated with long LOS; future studies should investigate the reasons for this finding.

Despite these limitations, the findings of the present study highlight the significance of long LOS in hospitalized CMC. These long hospitalizations account for a significant proportion of all hospital costs for this important population of children. The prevalence of long LOS for CMC varies considerably across children's hospitals, even after accounting for the case mix. Efforts to curtail hospital resource use and costs for CMC may benefit from focus on long LOS.

References
  1. Berry JG, Hall M, Hall DE, et al. Inpatient growth and resource use in 28 children's hospitals: a longitudinal, multi‐institutional study. JAMA Pediatr. 2013;167(2):170177.
  2. Simon TD, Berry J, Feudtner C, et al. Children with complex chronic conditions in inpatient hospital settings in the united states. Pediatrics. 2010;126(4):647655.
  3. Clancy CM, Andresen EM. Meeting the health care needs of persons with disabilities. Milbank Q. 2002;80(2):381391.
  4. Mosquera RA, Avritscher EBC, Samuels CL, et al. Effect of an enhanced medical home on serious illness and cost of care among high‐risk children with chronic illness: a randomized clinical trial. JAMA. 2014;312(24):26402648.
  5. Berry JG, Hall M, Neff J, et al. Children with medical complexity and Medicaid: spending and cost savings. Health Aff Proj Hope. 2014;33(12):21992206.
  6. Children's Hospital Association. CARE Award. Available at: https://www.childrenshospitals.org/Programs‐and‐Services/Quality‐Improvement‐and‐Measurement/CARE‐Award. Accessed December 18, 2015.
  7. Berry JG, Ziniel SI, Freeman L, et al. Hospital readmission and parent perceptions of their child's hospital discharge. Int J Qual Health Care. 2013;25(5):573581.
  8. Fendler W, Baranowska‐Jazwiecka A, Hogendorf A, et al. Weekend matters: Friday and Saturday admissions are associated with prolonged hospitalization of children. Clin Pediatr (Phila). 2013;52(9):875878.
  9. Goudie A, Dynan L, Brady PW, Rettiganti M. Attributable cost and length of stay for central line‐associated bloodstream infections. Pediatrics. 2014;133(6):e1525e1532.
  10. Graves N, Weinhold D, Tong E, et al. Effect of healthcare‐acquired infection on length of hospital stay and cost. Infect Control Hosp Epidemiol. 2007;28(3):280292.
  11. Hassan F, Lewis TC, Davis MM, Gebremariam A, Dombkowski K. Hospital utilization and costs among children with influenza, 2003. Am J Prev Med. 2009;36(4):292296.
  12. Kronman MP, Hall M, Slonim AD, Shah SS. Charges and lengths of stay attributable to adverse patient‐care events using pediatric‐specific quality indicators: a multicenter study of freestanding children's hospitals. Pediatrics. 2008;121(6):e1653e1659.
  13. Leyenaar JK, Lagu T, Shieh M‐S, Pekow PS, Lindenauer PK. Variation in resource utilization for the management of uncomplicated community‐acquired pneumonia across community and children's hospitals. J Pediatr. 2014;165(3):585591.
  14. Leyenaar JK, Shieh M‐S, Lagu T, Pekow PS, Lindenauer PK. Variation and outcomes associated with direct hospital admission among children with pneumonia in the United States. JAMA Pediatr. 2014;168(9):829836.
  15. Hughes JS, Averill RF, Eisenhandler J, et al. Clinical Risk Groups (CRGs): a classification system for risk‐adjusted capitation‐based payment and health care management. Med Care. 2004;42(1):8190.
  16. Neff JM, Clifton H, Park KJ, et al. Identifying children with lifelong chronic conditions for care coordination by using hospital discharge data. Acad Pediatr. 2010;10(6):417423.
  17. Neff JM, Sharp VL, Muldoon J, Graham J, Myers K. Profile of medical charges for children by health status group and severity level in a Washington State Health Plan. Health Serv Res. 2004;39(1):7389.
  18. Neff JM, Sharp VL, Popalisky J, Fitzgibbon T. Using medical billing data to evaluate chronically ill children over time. J Ambulatory Care Manage. 2006;29(4):283290.
  19. O'Mahony L, O'Mahony DS, Simon TD, Neff J, Klein EJ, Quan L. Medical complexity and pediatric emergency department and inpatient utilization. Pediatrics. 2013;131(2):e559e565.
  20. Feudtner C, Feinstein JA, Zhong W, Hall M, Dai D. Pediatric complex chronic conditions classification system version 2: updated for ICD‐10 and complex medical technology dependence and transplantation. BMC Pediatr. 2014;14:199.
  21. Weissman C. Analyzing intensive care unit length of stay data: problems and possible solutions. Crit Care Med. 1997;25(9):15941600.
  22. Berry JG, Hall DE, Kuo DZ, et al. Hospital utilization and characteristics of patients experiencing recurrent readmissions within children's hospitals. JAMA. 2011;305(7):682690.
  23. Hudson SM. Hospital readmissions and repeat emergency department visits among children with medical complexity: an integrative review. J Pediatr Nurs. 2013;28(4):316339.
  24. Jurgens V, Spaeder MC, Pavuluri P, Waldman Z. Hospital readmission in children with complex chronic conditions discharged from subacute care. Hosp Pediatr. 2014;4(3):153158.
  25. Coller RJ, Nelson BB, Sklansky DJ, et al. Preventing hospitalizations in children with medical complexity: a systematic review. Pediatrics. 2014;134(6):e1628e1647.
  26. Kun SS, Edwards JD, Ward SLD, Keens TG. Hospital readmissions for newly discharged pediatric home mechanical ventilation patients. Pediatr Pulmonol. 2012;47(4):409414.
  27. Cram P, Lu X, Kaboli PJ, et al. Clinical characteristics and outcomes of Medicare patients undergoing total hip arthroplasty, 1991–2008. JAMA. 2011;305(15):15601567.
  28. Bueno H, Ross JS, Wang Y, et al. Trends in length of stay and short‐term outcomes among Medicare patients hospitalized for heart failure, 1993–2006. JAMA. 2010;303(21):21412147.
  29. U.S. Department of Health and Human Services. CMS Statistics 2013. Available at: https://www.cms.gov/Research‐Statistics‐Data‐and‐Systems/Statistics‐Trends‐and‐Reports/CMS‐Statistics‐Reference‐Booklet/Downloads/CMS_Stats_2013_final.pdf. Published August 2013. Accessed October 6, 2015.
  30. Centers for Medicare and Medicaid Services. Evaluation of the premier hospital quality incentive demonstration. Available at: https://www.cms.gov/Research‐Statistics‐Data‐and‐Systems/Statistics‐Trends‐and‐Reports/Reports/downloads/Premier_ExecSum_2010.pdf. Published March 3, 2009. Accessed September 18, 2015.
  31. Berry JG, Blaine K, Rogers J, et al. A framework of pediatric hospital discharge care informed by legislation, research, and practice. JAMA Pediatr. 2014;168(10):955962; quiz 965–966.
  32. Brittan M, Albright K, Cifuentes M, Jimenez‐Zambrano A, Kempe A. Parent and provider perspectives on pediatric readmissions: what can we learn about readiness for discharge? Hosp Pediatr. 2015;5(11):559565.
  33. Berry JG, Gay JC. Preventing readmissions in children: how do we do that? Hosp Pediatr. 2015;5(11):602604.
  34. O'Brien JE, Berry J, Dumas H. Pediatric post‐acute hospital care: striving for identity and value. Hosp Pediatr. 2015;5(10):548551.
  35. Berry JG, Hall M, Dumas H, et al. Pediatric hospital discharges to home health and postacute facility care: a national study. JAMA Pediatr. 2016;170(4):326333.
  36. Corneli HM, Zorc JJ, Holubkov R, et al. Bronchiolitis: clinical characteristics associated with hospitalization and length of stay. Pediatr Emerg Care. 2012;28(2):99103.
  37. Myers J, Smith M, Woods C, Espinosa C, Lehna C. The effect of transfers between health care facilities on costs and length of stay for pediatric burn patients. J Burn Care Res. 2015;36(1):178183.
  38. Stroud MH, Sanders RC, Moss MM, et al. Goal‐directed resuscitative interventions during pediatric interfacility transport. Crit Care Med. 2015;43(8):16921698.
References
  1. Berry JG, Hall M, Hall DE, et al. Inpatient growth and resource use in 28 children's hospitals: a longitudinal, multi‐institutional study. JAMA Pediatr. 2013;167(2):170177.
  2. Simon TD, Berry J, Feudtner C, et al. Children with complex chronic conditions in inpatient hospital settings in the united states. Pediatrics. 2010;126(4):647655.
  3. Clancy CM, Andresen EM. Meeting the health care needs of persons with disabilities. Milbank Q. 2002;80(2):381391.
  4. Mosquera RA, Avritscher EBC, Samuels CL, et al. Effect of an enhanced medical home on serious illness and cost of care among high‐risk children with chronic illness: a randomized clinical trial. JAMA. 2014;312(24):26402648.
  5. Berry JG, Hall M, Neff J, et al. Children with medical complexity and Medicaid: spending and cost savings. Health Aff Proj Hope. 2014;33(12):21992206.
  6. Children's Hospital Association. CARE Award. Available at: https://www.childrenshospitals.org/Programs‐and‐Services/Quality‐Improvement‐and‐Measurement/CARE‐Award. Accessed December 18, 2015.
  7. Berry JG, Ziniel SI, Freeman L, et al. Hospital readmission and parent perceptions of their child's hospital discharge. Int J Qual Health Care. 2013;25(5):573581.
  8. Fendler W, Baranowska‐Jazwiecka A, Hogendorf A, et al. Weekend matters: Friday and Saturday admissions are associated with prolonged hospitalization of children. Clin Pediatr (Phila). 2013;52(9):875878.
  9. Goudie A, Dynan L, Brady PW, Rettiganti M. Attributable cost and length of stay for central line‐associated bloodstream infections. Pediatrics. 2014;133(6):e1525e1532.
  10. Graves N, Weinhold D, Tong E, et al. Effect of healthcare‐acquired infection on length of hospital stay and cost. Infect Control Hosp Epidemiol. 2007;28(3):280292.
  11. Hassan F, Lewis TC, Davis MM, Gebremariam A, Dombkowski K. Hospital utilization and costs among children with influenza, 2003. Am J Prev Med. 2009;36(4):292296.
  12. Kronman MP, Hall M, Slonim AD, Shah SS. Charges and lengths of stay attributable to adverse patient‐care events using pediatric‐specific quality indicators: a multicenter study of freestanding children's hospitals. Pediatrics. 2008;121(6):e1653e1659.
  13. Leyenaar JK, Lagu T, Shieh M‐S, Pekow PS, Lindenauer PK. Variation in resource utilization for the management of uncomplicated community‐acquired pneumonia across community and children's hospitals. J Pediatr. 2014;165(3):585591.
  14. Leyenaar JK, Shieh M‐S, Lagu T, Pekow PS, Lindenauer PK. Variation and outcomes associated with direct hospital admission among children with pneumonia in the United States. JAMA Pediatr. 2014;168(9):829836.
  15. Hughes JS, Averill RF, Eisenhandler J, et al. Clinical Risk Groups (CRGs): a classification system for risk‐adjusted capitation‐based payment and health care management. Med Care. 2004;42(1):8190.
  16. Neff JM, Clifton H, Park KJ, et al. Identifying children with lifelong chronic conditions for care coordination by using hospital discharge data. Acad Pediatr. 2010;10(6):417423.
  17. Neff JM, Sharp VL, Muldoon J, Graham J, Myers K. Profile of medical charges for children by health status group and severity level in a Washington State Health Plan. Health Serv Res. 2004;39(1):7389.
  18. Neff JM, Sharp VL, Popalisky J, Fitzgibbon T. Using medical billing data to evaluate chronically ill children over time. J Ambulatory Care Manage. 2006;29(4):283290.
  19. O'Mahony L, O'Mahony DS, Simon TD, Neff J, Klein EJ, Quan L. Medical complexity and pediatric emergency department and inpatient utilization. Pediatrics. 2013;131(2):e559e565.
  20. Feudtner C, Feinstein JA, Zhong W, Hall M, Dai D. Pediatric complex chronic conditions classification system version 2: updated for ICD‐10 and complex medical technology dependence and transplantation. BMC Pediatr. 2014;14:199.
  21. Weissman C. Analyzing intensive care unit length of stay data: problems and possible solutions. Crit Care Med. 1997;25(9):15941600.
  22. Berry JG, Hall DE, Kuo DZ, et al. Hospital utilization and characteristics of patients experiencing recurrent readmissions within children's hospitals. JAMA. 2011;305(7):682690.
  23. Hudson SM. Hospital readmissions and repeat emergency department visits among children with medical complexity: an integrative review. J Pediatr Nurs. 2013;28(4):316339.
  24. Jurgens V, Spaeder MC, Pavuluri P, Waldman Z. Hospital readmission in children with complex chronic conditions discharged from subacute care. Hosp Pediatr. 2014;4(3):153158.
  25. Coller RJ, Nelson BB, Sklansky DJ, et al. Preventing hospitalizations in children with medical complexity: a systematic review. Pediatrics. 2014;134(6):e1628e1647.
  26. Kun SS, Edwards JD, Ward SLD, Keens TG. Hospital readmissions for newly discharged pediatric home mechanical ventilation patients. Pediatr Pulmonol. 2012;47(4):409414.
  27. Cram P, Lu X, Kaboli PJ, et al. Clinical characteristics and outcomes of Medicare patients undergoing total hip arthroplasty, 1991–2008. JAMA. 2011;305(15):15601567.
  28. Bueno H, Ross JS, Wang Y, et al. Trends in length of stay and short‐term outcomes among Medicare patients hospitalized for heart failure, 1993–2006. JAMA. 2010;303(21):21412147.
  29. U.S. Department of Health and Human Services. CMS Statistics 2013. Available at: https://www.cms.gov/Research‐Statistics‐Data‐and‐Systems/Statistics‐Trends‐and‐Reports/CMS‐Statistics‐Reference‐Booklet/Downloads/CMS_Stats_2013_final.pdf. Published August 2013. Accessed October 6, 2015.
  30. Centers for Medicare and Medicaid Services. Evaluation of the premier hospital quality incentive demonstration. Available at: https://www.cms.gov/Research‐Statistics‐Data‐and‐Systems/Statistics‐Trends‐and‐Reports/Reports/downloads/Premier_ExecSum_2010.pdf. Published March 3, 2009. Accessed September 18, 2015.
  31. Berry JG, Blaine K, Rogers J, et al. A framework of pediatric hospital discharge care informed by legislation, research, and practice. JAMA Pediatr. 2014;168(10):955962; quiz 965–966.
  32. Brittan M, Albright K, Cifuentes M, Jimenez‐Zambrano A, Kempe A. Parent and provider perspectives on pediatric readmissions: what can we learn about readiness for discharge? Hosp Pediatr. 2015;5(11):559565.
  33. Berry JG, Gay JC. Preventing readmissions in children: how do we do that? Hosp Pediatr. 2015;5(11):602604.
  34. O'Brien JE, Berry J, Dumas H. Pediatric post‐acute hospital care: striving for identity and value. Hosp Pediatr. 2015;5(10):548551.
  35. Berry JG, Hall M, Dumas H, et al. Pediatric hospital discharges to home health and postacute facility care: a national study. JAMA Pediatr. 2016;170(4):326333.
  36. Corneli HM, Zorc JJ, Holubkov R, et al. Bronchiolitis: clinical characteristics associated with hospitalization and length of stay. Pediatr Emerg Care. 2012;28(2):99103.
  37. Myers J, Smith M, Woods C, Espinosa C, Lehna C. The effect of transfers between health care facilities on costs and length of stay for pediatric burn patients. J Burn Care Res. 2015;36(1):178183.
  38. Stroud MH, Sanders RC, Moss MM, et al. Goal‐directed resuscitative interventions during pediatric interfacility transport. Crit Care Med. 2015;43(8):16921698.
Issue
Journal of Hospital Medicine - 11(11)
Issue
Journal of Hospital Medicine - 11(11)
Page Number
750-756
Page Number
750-756
Article Type
Display Headline
Long length of hospital stay in children with medical complexity
Display Headline
Long length of hospital stay in children with medical complexity
Sections
Article Source
© 2016 Society of Hospital Medicine
Disallow All Ads
Correspondence Location
Address for correspondence and reprint requests: Jessica Gold, MD, Division of Pediatric Hospital Medicine, Lucile Packard Children's Hospital and Stanford University School of Medicine, 300 Pasteur Drive, MC 5776, Stanford, CA 94305; Telephone: 650‐736‐4423; Fax: (650) 736‐6690 E‐mail: [email protected]
Content Gating
Gated (full article locked unless allowed per User)
Gating Strategy
First Peek Free
Article PDF Media
Media Files